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The Saccharomyces cerevisiae alpha-factor receptor, Ste2p, belongs to the G protein-
coupled receptors (GPCRs), a class of integral membrane proteins that are characterized by 
seven-transmembrane (TM) domains.  Ste2p-alpha-factor pair has been used extensively as a 
paradigm for investigating GPCRs structure and function.  Upon binding of alpha-factor to 
Ste2p, a signal is transduced via an associated guanine-nucleotide binding protein, Gpa1p, 
initiating a cascade of events similar to those for mammalian GPCRs signal transduction.  
GPCRs are essential in many physiological processes associated with human diseases. Many 
aspects of structure and function are highly conserved across GPCRs, irrespective of primary 
amino acid sequence.  This dissertation investigated the interactions of Ste2p with alpha-factor 
and Gpa1p.  An overview of GPCRs in general with specific emphasis on Ste2p interactions with 
alpha-factor and Gpa1p are discussed in part I.  Cross-linking studies of alpha-factor analogs 
containing 3,4-dihydroxylphenylalanine (DOPA) at positions 1 and 13 indicated that Trp1 and 
Tyr13 of α-factor are in close proximity to Lys269 and Cys59 of Ste2p, respectively when alpha-
factor is bound to Ste2p.  An alpha-factor synergist lacking the last two amino acids required for 
binding could only inhibit the cross-linking of DOPA at position 1 suggesting that the alpha-
factor synergist interacts with the N-terminus of alpha-factor (described in part II).  Part III 
describes the first report of an unnatural amino acid, p-benzoyl-L-phenylalanine (Bpa), 
replacement in a GPCR expressed in its native environment, and the use these receptors to 
photocapture a peptide ligand.  Many of the Bpa-substituted Ste2p receptors exhibited biological 
activity and two of them, Phe55-Bpa and Tyr193-Bpa, were able to selectively capture alpha-
factor in the ligand binding site after photoactivation; indicating that these residues may be in 
direct contact or in close proximity to alpha-factor when bound to Ste2p.  Part IV reports for the 
 
 vii
first time the involvement of the third intracellular loop (IL3) in Ste2p homo-dimer formation, 
and also conformational changes at the cytoplasmic ends of TM5-TM6 of Ste2p induced by 
alpha-factor binding.  Conformational changes in the C-terminus of Gpa1p occurring during 
Ste2p and Gpa1p activation are also discussed for the first time in part V.  Variants of Ste2p-
Gpa1p fusion proteins that displayed activities similar to Ste2p and Gpa1p are described in part 
VI.  The final part of this dissertation discusses the overall conclusions and contains suggestions 
for future studies.  The results obtained during this study should provide very important 
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G Protein-coupled Receptors: An overview 
G-protein-coupled receptors (GPCRs) are the largest but the most diverse group of cell 
surface proteins present in fungi, plants, and the animal kingdom.  They are characterized by the 
presence of seven membrane spanning α-helical segments separated by alternating intracellular 
and extracellular loop regions (1).  They are essential for communication between the internal 
and external environments of cells. Although they share a common structure they can be 
activated by very diverse extracellular signals such as light, peptides, proteins, lipids, organic 
odorants, taste molecules, nucleotides or nucleosides (1-7). Despite the diverse ligands for 
GPCRs they all perform a similar function: coupling the binding of ligands to the activation of 
specific heterotrimeric guanine nucleotide-binding proteins (G proteins) leading to the 
modulation of downstream effector proteins.  Thus, they are called G protein-coupled receptors 
(GPCRs). However, individual group of GPCRs have unique combinations of signal-
transduction activities involving multiple G-protein subtypes, as well as G-protein-independent 
signaling pathways and regulatory processes (8-10).  These signal-transductions are involved in a 
large number of physiological functions (see Figure 1). 
 Ligand binding to a GPCR initiates a cascade of intracellular events, including changes in 
levels of second messengers, ionic conductance, and other signaling activity.  The activated 
GPCR induces a conformational change in the associated heteromeric G proteins.  This change 
initiates activation of the alpha (α) subunit of G protein leading to release of GDP followed by 





Figure 1: The role of GPCRs in pathophysiology.  A large variety of large peptide hormones 
are secreted that mediate multiple physiological functions at various target sites via the 
activations of their GPCRs.  Mutations and/or defects in expression of both ligands and GPCRs 
can result in multiple acute and chronic diseases.  Figure taken from Chapter et al., (7).  
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Both the GTP bound Gα-subunit and the released Gβγ-dimer can mediate the stimulation or 
inhibition of a diverse collection of effectors (6, 11, 12).  For example, the binding of adrenaline 
or noradrenaline to β2AR, the human GPCR for adrenergic agents, during sympathetic 
neurotransmission leads to the activation of Gα proteins, the stimulation of adenylyl cyclase, the 
accumulation of cyclic AMP (cAMP), and the phosphorylation of proteins involved in muscle-
cell contraction (11, 12).  Due to their involvement in physiological functions GPCRs are 
potential drug targets for many human diseases and are targets for approximately 50-60% of the 
human drugs currently marketed with annual sales revenue of about 44 billion US dollars(4, 5, 
7).  The human genome encodes about 1000 different GPCRs, however the marketed drugs 
currently target only about 50 GPCRs (4).  There is no doubt that the field of GPCR research, 
drug discovery and development will continue to be very critical in the years ahead. 
 
GPCRs Classification: 
GPCRs are classified by several systems based on characteristics, such as how their ligand binds, 
and other criteria like physiological and structural features. The most commonly used 
classification systems divide GPCRs into clans A, B, C, D, E, and F, and subclans (families) that 
cover all GPCRs in both vertebrates and invertebrates (13, 14). A GPCR ‘Clan’ consists of 
receptors whose protein sequences share greater than 20% sequence identity in their 
transmembrane regions, and are thought to have evolved from a common ancestor, whereas 
families within a clan share obvious common biochemical properties (see Table 1). Examples of 
invertebrate GPCRs are bacterial opsin receptors in clan A, and archaebacterial opsins in clan F.  
Clans D and E (fungal pheromone receptors) contain the STE2 and the STE3 receptors 
respectively (14-16).  These clans will be discussed in detail in the next chapter. 
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Table 1: Sequence-based groupings within the G protein-coupled receptors. 
 
 
Table adapted from Flower D. R.(14) 
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GPCRs in vertebrates are classified into clans and families on the basis of their sequence 
and structural similarity.  These are the rhodopsin (clan A), secretin (clan B), glutamate (clan C), 
and adhesion Frizzled/Taste2 receptor families (16).  The most diverse is found among the 
rhodopsin family members that are characterized by conserved sequence motifs.  Most of these 
members have the NSxxNPxxY motif in transmembrane (TM) 7 and the DRY motif or D(E)-R-
Y(F) at the border between TM3 and intracellular loop (IL) 2 that are essential for receptor 
activities (17-19).  The ligands for most of the rhodopsin receptors bind within a pocket between 
the TM regions (20).  The rhodopsin family is further divided into two categories, α- and β-
groups.  This α-group consists of the prostaglandin, amine, opsin, and melatonin receptors.  The 
β-group group is composed of about 36 classes of peptide binding receptors, such as the growth 
hormone secretagogues, chemokine, thyrotropin releasing hormone, hypocretin, neuropeptide, 
cholecystokinin, neurotensin, and gonadotropin-releasing hormone receptors.  The rhodopsin 
family has been studied and characterized more than any of the other GPCRs families (16). 
The secretin family, also termed “secretin-like receptor” has an N terminus between 60 
and 80 amino acids long, and it contains conserved cyteines bridges that are important for 
binding of the ligand to these receptors.  These receptors bind rather large peptides that share 
high amino acid identity compared to the rhodopsin family (14, 16).  The family of glutamate 
receptors consists of the ion-sensing, and some taste receptors.  Several of these receptors found 
in human are also ion channels.  The ligand recognition region is found in the N terminus and is 
280 to 580 amino acids long.  Some of them are believed to have N termini that form two distinct 
lobes separated by a cavity in which the ligand binds (16).  The adhesion family consists of 
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receptors with GPCR-like transmembrane-spanning regions fused together with domains of 
adhesion-like motifs in the N terminus.   
The N termini are about 200 to 280 amino acids long, rich in glycosylation sites and 
proline residues that are important for cell adhesion (21-24).  The Frizzled/Taste2 receptor 
family is divided into two groups, the frizzled and TAS2 (taste2) receptors. They have consensus 
sequence of IFL SFLL in in TM2, TM5, and SxKTL in TM7.  The TAS2 receptors have short N 
termini and are expressed in the tongue and palate epithelium (16).  The frizzled receptors have 
about 200-amino acid in the N terminus with conserved cysteines that are required for ligand 
binding.  This family regulates cell fate, proliferation, and polarity during metazoan development 
by mediating signals from secreted molecules (16, 25, 26).  Though GPCRs may have different 
amino acids sequences they all have overall similar structure-function relationships. 
 
The structure and organization of GPCRs: 
A recent focus in structural biology has been the determination of the structure of 
GPCRs.  Information about their structures is crucial for the understanding of their functions and 
importance for diseases and drug development.  Though intensive academic and industrial 
studies have been carried out on GPCRs, little is known about the structural basis of GPCR 
function (1, 5, 12).  Some of the methods used to gather information about protein structure 
include X-ray crystallography, electron microscopy or diffraction, NMR spectroscopy and 
molecular modeling.  However, these methods require high concentrations of dissolved purified 
protein and they are mostly insoluble in media that provide a good environment for 
crystallization or NMR study. The fact that need to be in a lipid-like environment to maintain 
their native structure makes their crystallization and NMR study much more difficult to achieve.  
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These characteristics of GPCRs make it difficult to determine the crystal structure. Recently, 
different tricks have been used to achieve the stability and conformational homogeneity required 
for GPCR crystallization including the use of antibody complexes, fusion proteins, binding 
ligands, stabilizing mutants, and special crystallization environments (27-35).  The crystal 
structures of four (bovine rhodopsin, human β2 adrenergic receptor (β2AR), the avian β1AR and 
the human A2A adenosine receptor) GPCRs obtained recently have been very crucial for the 
understanding of how GPCR structure dictates the unique functional properties of the complex 
signal transductions (1).  
The first crystal structure of GPCRs came from the protein bovine rhodopsin. The 
structure revealed a highly organized seven helical transmembrane (TM) bundle connected by 
alternating intracellular (IL) and extracellular loop (EL) regions (17, 36, 37).  The comparison of 
the 3D structures of rhodopsin and recently solved GPCR structures showed differences in the 
length of the loop and helix segments and of the arrangement, tilts, and kinks of the individual 
helices among the GPCRs.  Though rhodopsin is unique in that it has no soluble ligand, 
superimposing of all four known crystal structures on to each other indicated that they have a 
similar overall architecture (1).  The structure of rhodopsin has EL2 connected to TM3 via a 
disulfide bridge and fits tightly into the helix bundle of seven TMs.  On the extracellular surface, 
the EL2 forms a short β-sheet that creates a pocket for ligand binding.  The glycosylated amino 
terminus is important for ligand interactions (28-30, 38-40).  On the other hand, the EL2 regions 
of β1AR and β2AR receptors consist of a short α-helix that is stabilized by intra- and inter-loop 
disulfide bonds, and the cytoplasmic N-terminal regions are disordered, that is, they are not part 




Figure 2 : Comparison of GPCR structures.  Bovine rhodopsin (purple), avian β1AR (orange) 
and human A2A adenosine receptor (green) are each superimposed on the human β2AR structure 
(blue). The extracellular loop 2 (EL2), intracellular loop 2 (IL2), cytoplasmic helix 8 (H8) and 
transmembrane (TM) segments are labeled on one of the structures.  Figure adapted from 
Rosenbaum et al.(1). 
 
However, unlike rhodopsin the EL2 regions of β1AR and β2AR receptors have multiple disulfide 
bonds that form a cavity essential for ligand binding.  The ligand-binding pockets observed in all 




Rhodopsin has in the cytoplasmic surface an 'ionic lock' that is formed between the 
highly conserved E/DRY motif on TM3 and a glutamate residue on TM6.  In rhodopsin the ionic 
lock stabilize the receptor in its inactive state.  Mutations of the ionic lock in the β1AR and β2AR 
receptors increase constitutive activity (42-46).  Network interactions between adjacent acidic 
and basic residues on TM3 of the E/DRY motif are present in all four GPCR structures.   These 
interactions are important for conformational changes leading to the active state of the receptors.  
The IL2 of β1AR and A2A structures have a short α-helix that forms a hydrogen-bonding 
interaction with the E/DRY motif.  This interaction is not observed in β2AR and rhodopsin 
structures (35, 37).  All four structures have the highly conserved NPXXY motif at the 
cytoplasmic end of TM7 that plays an essential role in conformational changes during the 
activation of the receptors.  The proline in this motif is responsible for the distortion in TM7 
observed in all structures.  Interestingly, all crystal structures also revealed a short 8th 
cytoplasmic helix (H8), which runs parallel to the cytoplasmic membrane and a fourth 
intracellular loop (IL4).  The H8 and IL4 are thought to play a role in the coupling of the receptor 
with G proteins (1, 19, 37).  Thus, although GPCRs solved to date may have differences in 
helical packing interactions they all have a similar overall structure.  
The crystal structures of these GPCRs have been used as a template to model other 
GPCRs.  The low sequence similarity among GPCRs makes the homology modeling difficult for 
GPCRs in non-rhodopsin families.  However, this problem has been overcome in some cases by 
the development of secondary structure predictions and ab initio 3D modeling techniques with 
experimental constraints.  The modeling of GPCRs based on biophysical studies has also been 
very crucial for determining the structure and helical arrangements in GPCRs (14, 47-51).  This 
dissertation uses modeling programs to build models based on data collected. 
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 GPCRs in the membrane exist as monomers, dimers, or oligomers, with the dimer often 
regarded as the minimal oligomeric arrangement required for functional coupling to the G-
protein.  Experimental studies using animal models support a specific role for GPCR 
oligomerization in vivo and in human pathologies (52-54).  Detail analyses of oligomerization in 
rhodopsin have suggested that the dimer, or even a larger oligomer form of the receptor, is 
involved in the functional coupling of rhodopsin to the G protein transducin.  The monomer of 
rhodopsin is capable of activating transducin however, the dimeric form couples the G protein 
more efficiently (55-57).  It is not clear whether GPCR oligomerization plays a role in the 
chaperoning and cell transport of receptors, or in the control of signaling specificity and efficacy.  
Nevertheless, evidence of essential roles for dimerization in all GPCR families makes it an 
important phenomenon that needs investigation (52-54). 
Biophysical studies and computational analyses have been used to identify and predict 
the interface of GPCR oligomers.  One of the earliest studies to show evidence of GPCR 
dimerization demonstrated that overexpressed differentially tagged β2-adrenergic receptors 
(β2AR) form dimers and also showed that a peptide corresponding to the TM6 region of the 
β2AR could be used to disrupt the dimer and decrease receptor function implying that TM6 is 
important for dimer formation in β2AR (58).  Another study also showed that a dimer between 
the two different GABA receptors, GABABR1 and GABABR2, was required to form fully 
functional GABA receptors.  This study also suggested both GPCR subunits in a dimer seem to 
have distinct roles in the complex and that the GABABR1 seems to be responsible for ligand 
binding while the GABABR2 is required for G-protein coupling.  Thus, whereas some GPCRs 
such as the metabotropic glutamate (mGlu) receptors are strict dimers other GPCRs like the 




Figure 2: Oligomerization in GPCRs.  A; schematic oligomeric assembly of mGlu and 
GABAB receptors. Whereas the mGlu receptors are strict dimers, the GABA receptor assemble 
into dimers of dimers with possibly a single receptor entity activating G protein at a time. The 
figure was taken from Pin et al (53).  B; proposed models for GPCRs organization.  1; the 
domain-swapping model. 2; the contact model in which each receptor unit touches the other 
through interactions involving TM5 and TM6.  Figure taken from Bouvier (59). 
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Data from atomic force microscopy and the crystallographic structure of rhodopsin 
suggested that TM1, TM2, TM4, TM5, second intracellular loop (IL2), and the third intracellular 
loop (IL3) are involved in the formation of rhodopsin oligomers (55-57).  Some GPCRs have 
been shown to use different oligomerization interfaces to achieve functional activities (53).  The 
use of truncated receptors and other studies suggest that GPCR dimer formation may involve 
domain swapping or direct contacts of the receptor subunits (see Figure 2B).  Mutation and 
computational analyses all provide evidence of the involvement of TM5 and TM6 in the 
dimerization interface in both the swapping and direct-contact models in some GPCRs tested 
(59).  Although intensive studies have been done on GPCR oligomerization, the functional bases 
of these interactions are not well defined.  Knowledge about the interaction in GPCR 
oligomerization will enhance understanding of the molecular mechanisms underlying GPCR 
cellular function, with the promise of new and improved therapeutics targeting the complex 
structures and their mechanisms.  Part IV of this dissertation will discuss a dimer interface 
contact observed in vivo in a yeast GPCR. 
 
Ligand Binding in GPCRs: 
Despite variations in ligand specificity of the GPCRs, there are some similarities in the 
ligand interactions among the GPCR families. GPCRs ligands are classified as full agonist, 
partial agonists, inverse agonists, antagonist, and allosteric regulators.  These ligands induce 
different conformational changes in GPCRs and as well as produce different intracellular signals 
(4, 6, 11, 60, 61).  A full agonist produces a wild-type effect.  The partial agonists bind to 
GPCRs resulting in a lesser effect than full agonists.  Inverse agonists induce opposite effects on 
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the same GPCR as full agonists.  For example, whereas norepinephrine stimulates the β-
adrenergic receptor to increase adenylyl cyclase activity, inverse agonists would bind to 
constitutively active receptor to decrease adenylyl cyclase activity.  The antagonists on the other 
hand bind to GPCRs but have no intrinsic activity or effect other than blocking the binding of 
agonists.  Inverse and partial agonists are able to block the binding of full agonists to GPCRs by 
binding at similar binding pockets, which affect the activation of the GPCRs (11, 62). Allosteric 
regulators interact with GPCRs at sites different from the ligand binding domains.   Most 
allosteric regulators such as G proteins interact with the cytoplasmic domains of GPCRs (4, 63-
65). 
Another group of ligands known as synergists have also been identified.  Unlike the 
antagonist, inverse or partial agonists, the synergist does not show significant binding to the 
receptor but serves to increase the activities of the receptor in the presence of full agonist.  Thus, 
synergists do not block the binding of the full agonist but rather enhances its activities.  
Synergists have been found in the yeast α-factor pheromone receptor, Ste2p, but not much is 
known in other GPCR families (66, 67).  The developments of drugs targeting GPCRs are mostly 
based on the mechanisms of full, partial, and inverse agonists, as well as antagonist, synergists 
and allosteric modulators.  Thus, understanding the activities of these ligands will facilitate the 
design of drugs that target GPCRs (5, 11, 12). 
The binding mechanisms of ligands in GPCRs vary within different ligand groups.  Large 
ligands, such as proteins, bind to the extracellular loops of GPCRs, whereas the small molecules 
like ions bind within the transmembrane region of receptor.  Within the peptide-binding GPCRs 
a combination of ligand binding to the extracellular loops followed by ligand penetrating the 
transmembrane region and interacting with receptor residues buried in the membrane has been 
 
 15
observed (11, 68-70).  Ligand binding to GPCRs is predicted to trigger conformational changes 
within the receptor core (TM bundle), which are then propagated to the cytoplasmic surface of 
the receptor, which is involved in G protein recognition and activation.  Thus, ligand binding 
leads to the disruption of existing interhelical interactions, thereby promoting a set of interactions 
that leads to a new, energetically favorable conformational state of the receptor.  Ligands which 
bind to extracellular loops induce different conformational changes compared to small molecules 
that interact only with residues deep within the receptor core (69, 71-73). The multiplicity of 
recognition sites in peptide receptors are thought to provide the basis for understanding ligand 
interactions with GPCRs.  Understanding the peptide ligand interactions with its cognate GPCR 
is critical for elucidating other GPCRs-ligand interactions (7, 11).  However, less information 
exists concerning the binding sites of peptide-responsive GPCRs in comparision with the 
knowledge of binding of GPCRs activated by small ligands. 
 Structure-activity relationships involving ligand analogues and mutagenesis of receptors 
have been employed to discern receptor-peptide ligands interactions and how binding is 
transduced to activate intracellular signaling.  One of the most commonly used strategies is to 
label the peptide with a cross-linker that will attach to the receptor upon activation of the cross-
linker. In most cases the cross-linking studies are followed by enzymatic and/or chemical 
cleavage and mass spectrometry analysis of the fragmented product to identify the receptor 
region that cross-linked to the ligand (74-81).  For example, photocross-linking using 
photoactivatable peptide analogs carrying 4-benzoyl-L-phenylalanine (Bpa) have been used to 
provide biochemical evidence for contacts between the ligand and its receptor (82-85).  Other 
techniques and methods such as double-mutant cycle analyses have also been used to provide 
thermodynamic evidence for the interaction between groups within one protein or in ligand-
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protein complexes (86, 87).  Nevertheless, there are limitations to using these approaches 
including low yield of product and multiple cross-linked products making it difficult to define 
the exact residue-residue interactions involved in GPCR binding. 
The recent advent of the use of 3,4-dihydroxyphenyl-alanine (DOPA) to label protein or 
peptide ligand for cross-liking has been very effective.  DOPA-containing compounds were 
oxidized to form an o-quinone intermediate that could be attacked by a nearby nucleophile 
resulting in a stable, covalent cross-link (88-90).  The cross-linked product is resistant to 
chemical and enzymatic peptide cleavage.  Unlike most cross-linking methods, DOPA 
crosslinking produces a high yield with little or no nonspecific products observed, even in 
complex protein mixtures (89, 90).  The second part of this dissertation will focus on the use of 
peptide analogs carrying DOPA for cross-linking the peptide to its GPCR, and analysis of the 
results by mass spectrometry and site-directed mutagenesis.  The discussions of these 
methodologies are expanded in part II of this dissertation. 
 
Agonist-induced conformational changes in GPCRs: 
How agonist binding and the resulting changes upon interactions at the ligand-binding 
pocket lead to conformational changes that are transferred from the extracellular region to the 
cytoplasmic surface to activate G proteins for signaling still remains a fundamental puzzle in 
GPCR biology.  There are two models for GPCR activation. The first model also known as the 
“two-state model” is an extended ternary complex model which predicts that the receptor exists 
in an equilibrium between an inactive conformation (R) and an active conformation (R*).  In the 
absence of agonist, the inactive R state is predominant; however, the energy required to convert 
R to R* is low enough to allow a certain fraction of the receptors spontaneously to assume the 
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R* state.  Thus, the receptors isomerize between inactive (R) and active (R*) conformations; 
inverse agonists and agonists function by stabilizing R and R*, respectively (91-94).  
The second model is known as the “multi-state model” and suggests that the receptor 
alternates spontaneously between multiple active and inactive conformations.  Most experiments 
have provided strong support that GPCRs may exist in multiple conformational states making the 
second model more likely than the first (95).   This model also suggests that the ligand might 
play an active role to induce conformational changes in the receptor during activation that give 
rise to multiple states of the receptor.  Recently, the crystal structures and biophysical studies of 
rhodopsin, opsin and β1AR and β2AR receptors have shown that the activation of these GPCRs 
by their ligands is accompanied by similar changes in transmembrane helix packing and G 
protein signaling mechanism.  Thus, helical rearrangements of GPCRs induced by agonist are 
critical for activation and coupling with G proteins (1, 3, 96-100). 
Initial conformational changes in GPCRs during activation occur at the extracellular 
surface.  For example, in β2AR and β1AR agonists binding induce conformational changes at the 
ligand binding site accompanied by the movement of the upper region of TM5 to TM3.  The 
interaction of the ligand with TM5 via hydrogen-bonding and TM3/TM7–amine polar contacts 
initiate changes in the packing of nearby aromatic amino acids.  These movements at the 
extracellular surface results in a conformational change involving tightly packed rearrangements 
that shifts the helical bundles of the receptor towards the cytoplasmic surface.  It has been 
observed that adrenergic receptors have a disruption of the packing interactions allowing free 
transmembrane helix motions in the absence of an agonist (42, 44-46, 101).  Cysteine disulfide 
cross-linking studies of M3 muscarinic acetylcholine and metal-ion-mediated showed that 
receptor activation involves movements of the extracellular segments of TM7 and TM6 inward 
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towards TM3 (1).  It was proposed that the inward movement of the extracellular ends of TM6 
and TM7 may be a common structural feature of GPCRs (3).  These studies also suggested that a 
rotation and straightening of conserved proline bends found in TM5–TM7 may mediate these 
conformational changes.  It is not clear how these series of events, which occur at the 
extracellular region and within the receptor core, propagate changes at the intracellular receptor 
surface where G protein coupling occurs.  Overall structural changes observed at the 
extracellular surface of these receptors may be common in all GPCRs during activation (1, 3). 
GPCRs undergo more structural changes at the cytoplasmic surface than the extracellular 
surface. Comparing the crystal structure of opsin and rhodopsin shows that the cytoplasmic end 
of TM6 is shifted more than 6 Å outwards from the centre of the bundle relative to its position in 
the inactive state closer to TM5 in the active state.  It was observed that the cytoplasmic end of 
TM6 is stabilized by changes in interactions with TM5 (19, 102-105). The ionic lock observed in 
the inactive state is broken and new interactions are formed between TM3 and TM5 as well as 
between TM6 and TM5.  TM7 undergoes conformational changes and occupies the original 
position of TM6 (46).  Other studies have also shown that light-induced rhodopsin activation 
triggers an outward movement of the cytoplasmic ends of TM6 accompanied by a clockwise 
rotation of ~30o (103).  These movements have also been observed in other receptor such as M3 
and adrenergic receptors (Figure 3).  In M3 agonist binding increased the proximity between the 
cytoplasmic ends of TM5 and TM6.  Possible TM6 rotational movements were also observed in 
M3 receptor (3).  It remains unclear whether these conformational changes occur in a concerted 
manner or whether a primary structural change triggers secondary changes in the structure and 





Figure 3: Conformational changes at the cytoplasmic surface GPCRs. Conformational 
changes at the cytoplasmic surface GPCRs.  This model of the M3 receptor was built based on 
disulfide cross-linking and other studies.  Agonist binding to the M3 receptor causes TM6 to 
undergo a rotational movement and to move closer to the TM5.  Whereas the C-terminal portion 
of TM7 move closer to TM1, accompanied by a rotational movement and the N-terminal portion 
of helix 8 is move away from the cytoplasmic end of TM1.  The agonist-induced structural 
changes are thought to expose previously inaccessible receptor residues or surfaces such as the 
cytoplasmic ends of TM3, TM6 and TM7.  Figure taken from Wess et al.(3) 
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The result of these changes is the creation of a hydrophobic environment between TM3, TM5 
and TM6 in which the Gα protein interacts with the receptor as observed in opsin.   These 
phenomena are believed to be common features of all GPCRs (34).  Agonist induced 
conformational changes at cytoplasmic ends of TM5 and TM6 in a yeast GPCR is discussed in 
part IV of this dissertation. 
 
GPCRs interactions with G proteins: 
The cytoplasmic surfaces of GPCRs contain multiple contact regions responsible for 
receptor coupling to signal transduction complexes. The most prominent domains in GPCRs for 
coupling are the second and third intracellular loops as well as the C-terminal tail and TM 
boundaries (10, 11, 106-108). G proteins, which link GPCRs to second messenger systems, are 
among the intracellular modulators contacted by GPCRs.  The G protein consists of 
heterotrimeric complexes of α, β and γ subunits.  There are 18 Gα, 5 Gβ, and 11 Gγ subunits, 
involved in distinct heterotrimeric complexes in humans that are critical for signal transductions 
through the activation of different GPCRs (6, 11).  Following agonist induced conformational 
changes in GPCRs, a cascade of events known as the G protein cycle is initiated.  The G protein 
cycle (Figure 4) involves receptor interaction with the Gα subunit in an inactive state with GDP 
bound, which then switches to a state where the guanine nucleotide binding site is empty, and 
finally an active state where GTP is bound to the empty guanine nucleotide binding site, causing 
dissociation of the α subunit from the agonist-occupied receptor and the βγ subunits. The α 
subunit in the active state now interacts with specific effector proteins which results in changes 





Figure 4: The GPCR-G protein cycle.  Following agonist [A] binding to a GPCR, changes in 
the conformation of the receptor leads to the activation of heterotrimeric G protein (α, β, γ).  The 
α subunit, in the active state, interacts with specific effector [Eff] proteins which results in 
changes in the concentration of intracellular signaling molecules. Figure taken from Williams 
and Hill (6). 
 
The GTPase activity of the α subunit hydrolyzes GTP to GDP, resulting in conformational 
changes such that it dissociates from the effector(s). The inactive α subunit now reassociates with 
the βγ subunits and the cycle is repeated if an appropriate agonist-occupied receptor is available 
(9, 61, 63, 64, 109, 110).  The GPCR–G protein association has recently found to have 
interesting implications with regards to drug discovery.  If drugs can be identified to change the 
pattern of GPCR–G protein associations or cause a GPCR to preferentially associate with one G 
protein and not others, then it would be possible to regulate the activities and functions of a 
specific receptor (4, 5, 11, 12).   
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The Gα subunit of the heterotrimeric G protein is made up of GTPase domain (binding 
and hydrolysis of GTP) and a helical domain that buries the GTP within the core of the protein. 
The helical domain is also known to play a role in directing specificity of receptor- and effector-
G protein coupling.  The structure-function relationship of the helical domain is well 
documented, however, little is known about the structure of the extreme N- and C- terminal 
domains (9).  Comparison of inactive and active state crystal structures revealed that Gα has 
three flexible regions, known as switches I, II, and III, which become more rigid and well 
ordered in the GTP-bound active conformation.  The N-terminal region of Gα has been found to 
interact with the Gβ as well as receptor through an N-terminal coiled coil.  Some studies on the 
C-terminus showed that C-terminal synthetic peptide and/or antibodies against the C-terminal 
domain inhibited receptor-G protein signaling (111, 112). The α4-helix, α2-helix, α2-β4 loop 
regions, and α4-β6 loop domain are all shown to be critical mediators of receptor-G protein 
coupling (113, 114).   
 The recent crystal structure of opsin bound to a carboxy-terminal peptide of transducin 
(Gα of rhodopsin) reveals a cleft on the receptor that provides the interaction surface for the Gα 
protein.   The hydrophobic residues on one face of the transducin-derived peptide helix bind to a 
hydrophobic surface at the cytoplasmic ends of TM5 and TM6. Here the rearranged ionic-lock 
residues are thought to be critical for the formation of the receptor–transducin peptide complex.  
The orientation of the peptide binding is stabilized by a hydrogen-bonding network between the 
transducin residues and TM3, TM5, TM6 and helix 8 of opsin.  The peptide was also found to 
induce long-range stabilization effects into the ligand binding pocket (34).  Though the crystal 
structure of opsin bound to transducin peptide has provided information about the crucial binding 
epitope of the G protein on GPCRs cytoplasmic surfaces, the question of how the conformational 
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changes in GPCRs activate G protein and whether G proteins undergo any specific changes 
during this activation remains unsolved.  The fifth part of this dissertation will focus on the 
interactions of residues in the cytoplasmic ends of TM5-TM6 and intracellular loop 3 (IL3) of a 




α-factor Pheromone and its G Protein-coupled Receptor (Ste2p) of 
Saccharomyces cerevisiae 
 
The complexity of eukaryotic systems is one of the major roadblocks in GPCR research.   
The cross-talk between different types of receptors and a variety of G proteins regulating many 
different pathways that involve different modulators but similar signaling complicates 
biochemical and physiological studies in this complex biological system.  It is therefore 
convenient to use a simple biological system that will provide information on a given GPCR 
interacting with a specific modulator (G protein) that will reflect the specific activities of the 
given GPCR.  Saccharomyces cerevisiae is an attractive system because it has the genetics of a 
typical eucaryote while possessing only a few GPCRs and G proteins (2, 115). There is a high 
homology between the yeast pheromone signaling pathway that involves a mitogen-activated 
protein kinase (MAPK) system and that of mammalian GPCRs (figure 4).  Different GPCRs 
from mammalian and other systems have been successfully expressed in S. cerevisiae and have 
been shown to couple functionally to either the endogenous yeast Gα (Gpa1p), or co-expressed 
mammalian Gα subunits and respond to their native agonists or antagonists (115). S. cerevisiae 
has only three GPCRs, two pheromone receptors (either Ste2p or Ste3p) and Gpr1p, which is a 
carbohydrate sensor. While the pheromone and carbohydrate-sensing pathways share some 
down-stream components, there is no crosstalk between the two systems as the pheromone 
receptors and the Gpr1p couple to two different G proteins.  The binding of the pheromones, α- 
and a-factor to their GPCRs, Ste2p and Ste3p respectively, in S. cerevisiae and activation of 
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these GPCRs have been observed to be similar to other peptide-responsive GPCRs.  These 
characteristics make S. cerevisiae an attractive biological system for studying GPCRs (2, 115, 
116). 
 
GPCRs signal transductions in S. cerevisiae: 
 S. cerevisiae exist as haploid or diploid cell. The haploid cells exist as one of two mating 
types, MATa and MATα. The MATa cells express the GPCR Ste2p and secrete the pheromone, a-
factor, a hydrophobic farnesylated, carboxymethylated, dodecapeptide with the sequence 
YIIKGVFWDPAC(Farnesyl)-OCH3.  The MATα cells express the GPCR Ste3p and secrete the 
pheromone, α-factor, a tridecapeptide with the sequence WHWLQLKPGQPMY.  The binding of 
the pheromones, α-factor and a-factor, to Ste2p and Ste3p respectively, initiate mating and 
eventual fusion of two haploid cells resulting in a diploid cell.  The mating pathway in each 
haploid cell is mediated by the intracellular heterotrimeric G protein interactions. The yeast G 
proteins, which consist of Gpa1p, Ste4p and Ste18p subunits, are structurally and functionally 
similar to the mammalian Gα-, β- and γ-subunits, respectively.  Activation of Ste2p and Ste3p by 
the pheromones leads to G1 cell cycle arrest, and polarized cell growth before cellular fusion (2, 
115, 116).  
 Like all GPCRs, Ste2p and Ste3p activation is followed by GDP exchanged for GTP in 
Gpa1p and dissociates from the Ste4/Ste18 complex which in turn signals to Ste20p, a p21-
activated protein kinase-like kinase. Ste20 activates the Ste5p-scaffolded MAP kinase modules 
composed of Ste11p, Ste7p and Fus3p. Activation of MAP kinase cascade by phosphorylation of 





Figure 5: S. cerevisiae GPCRs and pheromone signaling pathway.  Pheromone (α/a factor) 
binding and activation of receptors (Ste2p/Ste3p) activates the MAP kinase cascade via Gpa1p 
activation and results in activation of nuclear proteins that control transcription, cell polarity and 
progression through the cell cycle. The figure was taken from Minic et al., (115). 
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Some of the effects of downstream MAPK cascades involve stabilization of the cyclin-dependent 
kinase inhibitor Far1p by Fus3p and Cdc28 protein kinase resulting in arrest of cell division in 
the G1 phase of the cell cycle.  Other downstream effects include inducing cell and nuclear 
fusion and also regulating genes that are involve in the mating process (117, 118).  The tips of 
the projections fuse to form a conjugation bridge followed by the nuclear migration across the 
bridge, and subsequent fusion to produce a diploid nucleus in the zygote.  The negative regulator 
of the pathway is the Gpa1-specific GTPase-activating protein, Sst2, a member of the RGS 
(regulator of G protein signaling).  Thus, pheromone stimulation of yeast results in 
phosphorylation of proteins in the MAP kinase cascade and activation of nuclear proteins that 
control transcription, which is similar to mammalian MAP kinase cascade.  S. cerevisiae, with its 
GPCR signaling pathway, is indeed a powerful tool for GPCR-ligand screening studies, and it 
has been successful used in pharmacological screenings (115). 
 
Structural analysis of Ste2p: 
The S. cerevisiae GPCR for α-factor pheromone, Ste2p, is a member of clan D GPCRs 
and shares common structure-function relationships with other GPCRs.  Though the underlying 
mechanisms of GPCR function may be well conserved, Ste2p shares only a few recognizable 
sequence similarities to mammalian GPCRs or the cognate yeast pheromone a-factor 
receptor,Ste3p.  Ste2p lacks the highly conserved E/DRY motif in the intracellular end of TM3 
present in most mammalian GPCRs.  However, comparison of Ste2p with some mammalian 
GPCRs (clan A) shows that they share an overall common structure (116).  Like most 
mammalian GPCRs, the core region of the seven TMs of Ste2p functions in ligand binding and 
the third intracellular loop plays a key role in G-protein activation (84-86, 116).  Ste2p has 
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conserved amino acids at specific positions similar to clan A receptors where mutations affect 
receptor activities.  Strong polar amino acids that mediate helix interactions and weakly polar 
amino acids that facilitate tight helix packing in clan A receptors are also identified in Ste2p at 
similar positions (116). Proline residues in TM6 and TM7 that are essential for conformational 
changes during activation of clan A receptors as well as amino acids and sites of constitutively 
active mutations on TM3, TM6 and TM7 are identical in clan A and D (Ste2p) receptors (119).  
Thus, there are similarities in the mechanism of receptor structure-function relationships among 
clan A and D receptors.   
 A detailed structural analysis of Ste2p using x-ray crystallography has been difficult to 
obtain due to the difficulties in obtaining sufficient amounts of pure protein, as in other GPCRs.  
Analysis of mutant receptors for structure-function studies has been an alternative to 
crystallographic information on GPCRs.  Scanning cysteine accessibility mutagenesis (SCAM) 
on each residues of the first extracellular loop (EL1) of Ste2p was used to create a structural 
model for the EL1.  This study predicted that the EL1 is comprised of a helix corresponding to 
EL1 residues 106 to 114 followed by two short β-strands comprising residues 126 to 135 (120).  
Hauser, et al, (121), using SCAM, also proposed that EL1 of Ste2p is structured such that parts 
of the loop are buried in the membrane making it inaccessible for interaction with the 
extracellular part of the TM bundle.  Other SCAM studies on the TMs of Ste2p showed that the 
TMs vary in length and that some of the TMs are buried and tilted relative to the plane of the 
membrane similar to the rhodopsin GPCR.  Ste2p shows overall similarity to many mammalian 
GPCRs in that the core region containing the TMs is involved in signal transduction and the C 
terminal tail is a target for posttranslational modifications (122). 
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Ste2p has been identified as oligomeric in intact cells and membranes.  Coexpression of 
Ste2p tagged with the cyan or yellow fluorescent proteins (CFP or YFP) resulted in efficient 
fluorescence resonance energy transfer (FRET).  The study also showed that dominant-
interfering receptor mutants inhibited signaling by interacting with wild-type receptors rather 
than by sequestering G proteins (123, 124).  Analysis of Ste2p truncated mutants showed that the 
N-terminal extracellular domain, TM1, and TM2, are involved in stabilizing receptor oligomers 
(125).  Recently, disulfide cross-linking studies have shown TM1 and TM4 as dimer contacts in 
Ste2p similar to that of the rhodopsin family of GPCRs.  The study suggests that similar dimer 
interface sites in Ste2p and rhodopsin-like receptors provide further evidence that many aspects 
of structure and function are highly conserved across GPCRs (126).  Subunits of Ste2p in a 
dimer complex have been found to be activated independently rather than cooperatively by 
agonist, but function together to promote G protein activation, possibly by contacting different 
subunits or regions of the G protein (127).  Despite the intensive studies on the structure-function 
relationship of Ste2p the mechanism underlying its activation is not well defined.  The fourth 
part of this dissertation will examine some of the possible helical movements that occur during 
the activation of Ste2p and also discuss dimer contacts involving the third intracellular loop. 
 
Function analysis of α-factor pheromone: 
The tridecapeptide α-factor pheromone (WHWLQLKPGQPMY) induces signal 
transduction upon binding to Ste2p.  Studies of α-factor indicated that Trp1-Leu4 residues are 
associated with receptor activation and signal transduction; Lys7-Gln10 residues are involved in 
the biologically active conformation and Gln10-Tyr13 residues are essential for receptor binding 
(66, 67, 128-131).  Alanine scanning studies showed that D-Ala series analogs, near the N-
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terminus, specifically [D-Ala2]α-factor, [D-Ala3]α-factor and [D-Ala4]α-factor had no 
detectable activity.  However, these peptides bound to Ste2p and antagonized the biological 
activity of the native α-factor.  Other studies from our laboratory showed that most of the 
antagonists discovered involved changes in residues near the N-terminus. Thus, residues at the 
N-terminus are critical for Ste2p activation and/or in stabilizing the activated state of this 
receptor (66, 67). 
 Alanine scanning studies of the carboxyl terminus of α-factor revealed that this region 
strongly influenced binding to Ste2p. Substitution of these residues with alanine caused 
decreases in binding affinity of up to about 3000-fold.  Deletion of the carboxyl terminal residues 
result in pheromones with drastically reduced receptor affinity and, in some cases, also with 
complete loss of affinity. Interestingly, some of these C-terminal deleted analogs have synergist 
activities (67).  For example,  an analog with the last two amino acids deleted 
(WHWLQLKPGQP) does not show any significant binding and does not block the binding of 
the agonist but rather enhances its activity as evidenced by the increased in signaling when the 
two peptides (synergist and agonist)  were mixed together for Ste2p activity.  Whereas deletion 
of the C-terminus results in synergist activity, the deletion of the N-terminus results in antagonist 
activities implying that α-factor contains domains that are critical for specific functions (67, 
132). 
 The central residues of α-factor comprising of sequence Lys7 to Gln10 assume a β-turn 
structure that is essential for the proper orientation of the signaling and the binding domains.  
This region is critical for maintaining the biologically active conformation of α-factor during the 
activation of Ste2p (128, 130, 131).  Alanine scanning studies of this portion of the peptide 
showed that whereas D-Ala9 analog had high activity and affinity, D-Ala7, D-Ala8 and D-Ala10 
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analogs had reduced receptor affinities and activities.  Other studies with biologically-active, 
covalently constrained analogs formed by synthetic cross-links between residues 7 and 10 
indicated that this region of the pheromone was involved in forming a conformationally active 
peptide (67, 130).  These data suggest that the middle portion of α-factor  serves to create the 
proper overall biologically active conformation (67).  It can therefore be concluded that α-factor 
is comprised of three domains (Figure 6), the N-terminus (activation domain), the C-terminus 
(binding domain) central residues (loop domain).  Other peptides with specific functional 
domains that bind GPCRs have been reported (133-136). 
 
Ste2p interaction with α-factor: 
The interaction between α-factor pheromone and its receptor Ste2p is one of the most 
extensively studied models for the peptide ligand-GPCR relationship.  Despite many techniques 
used to study the structure-function relationship for this receptor and its ligand, the question of 
exactly how and where the ligand binds to activate the receptor still remains not fully elucidated. 
This dissertation will discuss some of the possible residue-to-residue contacts (interaction) 
between Ste2p and α-factor.  Most of the information obtained from Ste2p and α-factor activities 
comes from the characterization of mutant receptors and α-factor analogs (2, 116). Another 
promising approach which has been adapted to the study of the dynamics of GPCR structure is 
the use of orthogonal pairs of tRNA/ aminoacyl-tRNA synthetases evolved and expressed in the 
target cell to incorporate unnatural amino acids (137-139).  In S. cerevisiae this approach has 
been used to incorporate a variety of unnatural amino acids, including the photoactivatable 
amino acid analog p-benzoyl-L-phenylalanine (Bpa) into soluble protein (140, 141). Details and 





Figure 6:  Functional domains of α-factor pheromone.  The cartoon indicates that the 
pheromone may be divided into three domains based biophysical studies.  The N-terminus 
(signaling domain) is critical for receptor activation and signaling; the central residues (loop 
domain) are required for conformational stability of the ligand; and the C-terminus (binding 
domains) is essential for receptor recognition and binding (2). 
 
Ste2p crosslinking studies using biotinylated α-factor analogs containing Bpa at different 
positions indicated that Trp1, Trp3, Gln5 and Tyr13 residues in α-factor interacts with residues 
of the extracellular domains of Ste2p.  The N-terminus of α-factor interacts with the receptor 
signaling domain, consisting of residues from extracellular ends of TMD5-TMD7 and parts of 
second (EL2) and third (EL3) extracellular loops, most likely Ser251-Met294 (85).  It was also 
shown that Tyr13 of α-factor may interact with Phe55 – Arg58 residues in Ste2p (84, 85, 142).  
Mutagenesis studies of residues 262 – 270 in Ste2p showed that the Tyr266 residue in the TMD6 
plays an essential role in ligand specificity and receptor activation (143). Double-mutant cysteine 
cycle scanning of the interaction of α- factor with Ste2p also showed that the amino terminus of 
α- factor interact with Asn205 and Tyr266 (86, 87).  The interactions of synthetic α-factor 
(position 10) analogs with mutations in Ste2p showed that Gln10 in α- factor interacts with Ser47 
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and Thr48 residues in Ste2p (144).  Replacing aspartic acid at position 275 in EL3 with 
asparagine affected both pheromone binding and signaling, suggesting that this position interacts 
directly with α-factor. Mutagenesis studies of Ala281 and Thr282 in TM7 suggested that these 
residues are involved in receptor activation.  These residues are in approximately the same 
position as Lys296 in rhodopsin, which is covalently linked to retinal (119).  
Studies using a fluorescent α-factor analogue in conjunction with flow cytometry and 
fluorescence microscopy showed that α-factor binding to Ste2p involves multiple steps. The 
initial interactions involve the binding of α-factor in a hydrophobic environment in Ste2p, 
followed by a conversion to a state in which the ligand moves to a more polar environment 
(145).  Based on biophysical studies from our lab a model showing possible contacts between α- 
factor and Ste2p has been proposed (Figure 7).  In this model α-factor is shown to bend around 
the Gly9-Pro11 residues with the Lys13 side chain interacting with a receptor binding pocket.  
The Gln10 side chain is proximal to residues 47 and 48 of Ste2p, whereas the Trp1 side chain is 
near a pocket formed by TM6-EL3-TM7. It is likely that Trp1 and Trp3 interact with an aromatic 
group near the interface of the transmembrane domains and the outside surface of the membrane 
(2, 144).  Detailed analyses of Trp1 and Tyr13 interactions with Ste2p are discussed in part II of 
this dissertation.   
 
Ste2p interactions with Gpa1p: 
 S. cerevisiae has two different Gα subunits, Gpa1p that interacts with Ste2p or Ste3p and 





Figure 7: Model of α-factor binding to its receptor, Ste2p.  Only residues 4–10 (Leu-Gln) of 
α-factor are labeled.  The N-terminus and C-terminus are in close proximity to TM1 and TM6 
respectively.  Gln10 is shown to interact with Ser47 and Thr48 of the receptor (144).  
 
Like all Gα subunits, Gpa1p is made up of a GTPase domain (binding and hydrolysis of GTP) 
and a helical domain that buries the GTP within the core of the protein. The helical domain is 
also known to play a role in directing specificity of receptor- and effector-G protein coupling (9).   
Gpa1p shows about 45% identity with mammalian Gα proteins and is most closely 
related to the Gαi subfamily.  The binding pockets of mammalian Gα subunits on their GPCRs 
are shown to contain a high number of hydrophobic residues that create an environment favoring 
Gα coupling.  Similar binding pockets have been predicted for Gpa1p suggesting that the 
underlying mechanism for interactions between the mammalian GPCRs and their Gα subunits is 
similar to that of Ste2p and Gpa1p interactions (118, 146). 
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Although Ste2p lacking a full C-terminal tail is still capable of signaling upon binding of 
α-factor, the asparagine-to-serine substitution (N388S) in the C-terminal tail of Ste2p resulted in 
defects in growth arrest, and impaired mating competence.  This study suggests that the C-
terminal tail of Ste2p may interact with G proteins in S. cerevisiae (147).  Cysteine scanning 
studies of the intracellular loops of Ste2p indicated that the central regions were all highly 
accessible (to solvent?) whereas residues near the ends of the loops (TMs boundaries) were less 
accessible.  However, these boundary regions are enriched in hydrophobic residues, suggesting 
that they may form a hydrophobic pocket for interaction with the G proteins (122).  Other studies 
of specific intracellular domains have also shown that the intracellular loop 3 (IL3) of Ste2p 
might be involved in Ste2p-Gpa1p coupling (148, 149).  However, alanine scanning and random 
mutagenesis of IL3 residues show that relatively conservative mutations did not result in strong 
defects, making it difficult to pinpoint specific residues that directly interact with Gpa1p (150-
152). 
The region of Gpa1p that has been predicted to most likely interact directly with Ste2p is 
the C-terminus.  Gpa1p C-terminus mutants in S. cerevisiae showed that truncation of the last 
amino acids and lysine-to-proline substitution (K467P) lead to mating defects.  This suggests that 
the C-terminal residues of Gpa1p, especially the last five amino acids, may be involved in Ste2p-
Gpa1p interactions (153).  Another group also proposed that the C-terminal domain of Gpa1p is 
essential for Ste2p-coupling, and that the C-terminus of Gpa1p forms a β-turn that correlates 
with the C-terminal region of mammalian Gα (154).  Screening for mutations in the N-terminal 
region of yeast Gpa1p also indicated some interactions with Ste2p (155). Other mutagenesis 
studies suggest that residues in different interface regions of Gpa1p contribute to activation of 
Ste2p and signaling (114).  To date no study has pinpointed specific residue-to-residue 
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interactions between Ste2p and Gpa1p.  In this dissertation specific residue-residue interactions 
between Ste2p and Gpa1p have been identified.  This is discussed in part four.  The findings of 
this study reveal strong evidence for similarities between Ste2p-Gpa1p mechanism of interaction 
and that of the mammalian GPCR transduction pathway.  Thus, knowledge about Ste2p 
structure-function relationship will be very helpful in understanding the mechanism of activation 
and signaling in other GPCR systems. 
This dissertation describes the use of α-factor analogs as probes to study receptor binding 
and activation and also examines the interactions between Ste2p and its cognate Gα subunit, 
Gpa1p.  Part two details the characterization and use of α-factor that contain DOPA (3,4-
dihydroxyphenyl-alanine) in determining ligand-receptor contact sites. A proposed ligand 
binding mechanism is also discussed.  The capturing of α-factor by Ste2p containing the 
unnatural amino acid p-benzoyl-L-phenylalanine (Bpa) via photoactivation cross-linking to 
determine which Ste2p residues interact with α-factor is discussed in Part three.  Part four 
investigates specific contacts between Ste2p and Gpa1p.  Conformational changes in both 
proteins upon ligand binding are examined. The use of a Ste2p-Gpa1p fused protein as a tool to 
study the interactions between Ste2p and Gpa1p is presented in Part five.  Finally part 6 is an 
overall evaluation of these studies, contributions to the working model of α-factor-Ste2p and 
Ste2p-Gpa1p interactions, and future studies that could be performed to refine these models.   
This dissertation will provide better understanding of how peptide ligands interacts with their 
GPCRs, and also how these interactions promote activation of the associated G proteins which 
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Cross-linking of DOPA-containing α-factor Pheromone 
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G protein-coupled receptors (GPCRs) are a large family of integral membrane proteins 
associated with signaling systems present in mammalians, plants, protozoans, fungi, and 
metazoans  (1).  Malfunctions of GPCRs contribute to diseases such as Alzheimer's, Parkinson’s 
disease, diabetes, color blindness, asthma, depression, hypertension, stress, cardiovascular, and 
immune disorders (2, 3).  All GPCRs share a common structure consisting of seven 
transmembrane domains (TMDs) connected by three extracellular and three intracellular loops 
(1, 4, 5).  Upon binding of their ligands, GPCRs undergo conformational changes that transduce 
the signal into the cell by activating a cascade of protein-protein interactions initiated through a 
heterotrimeric G protein complex (6). 
Ste2p, the Saccharomyces cerevisiae α-factor pheromone receptor, has been studied as a 
model for peptide-responsive GPCRs (7, 8). Though Ste2p does not share recognizable sequence 
similarity with mammalian GPCRs or even with Ste3p, the a-factor pheromone receptor of yeast, 
all GPCRs have strong structural and functional similarities (9, 10).  For example, the packing 
and interactions between the fifth and sixth transmembrane domains are essential for proper 
signal transduction to the G protein in both rhodopsin and Ste2p (11, 12).  Though there have 
been considerable studies on the GPCR binding sites of small ligands, less is known about the 
binding sites of peptide-responsive GPCRs.   
Studies on the tridecapeptide α-factor pheromone (Trp-His-Trp-Leu-Gln-Leu-Lys-Pro-
Gly-Gln-Pro-Met-Tyr) have contributed to the understanding of structure and function of peptide 
hormones.  Alanine scanning studies of α-factor indicated that Trp1-Leu4 residues are associated 
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with receptor activation and signal transduction; Lys7-Gln10 residues are involved in formation 
of the biologically active conformation and Gln10-Tyr13 residues are essential for receptor 
binding (13).  Photoreactive cross-linking studies, using 4-benzoyl-L-phenylalanine (Bpa)-
containing α-factor analogs at different positions indicated that position one, three, and thirteen 
in α-factor interacted with residues on the extracellular face of Ste2p (14-16).  The N-terminus of 
α-factor was shown to interact with  Ste2p residues from extracellular ends of the fifth, sixth and 
seventh TMDs and parts of the second and third extracellular loops, whereas the C-terminus 
interacted with part of the first transmembrane domain (14, 16, 17).    All of these studies 
revealed that generation of covalently linked ligand-receptor conjugates followed by detailed 
product analysis were an attractive approach to identify and map residues involved in Ste2p-
ligand interactions.  Nevertheless, limitations of using the cross-linking approaches performed to 
date are low yield of product and multiple cross-linked products making it difficult to define the 
exact residue-residue interactions involved in GPCR binding. 
 Recently, compounds containing 3,4-dihydroxylphenylalanine (DOPA) have been shown 
to cross-link efficiently to proteins (18).  DOPA-containing compounds were oxidized by sodium 
periodate to form an ortho-quinone intermediate that could be attacked by a nearby nucleophile 
resulting in a stable, covalent cross-link.  The ortho-quinone intermediate was shown to act as an 
electrophile that formed adducts with cysteine or histidine through the Michael addition reaction 
and also with lysine through the Schiff base formation (18, 19).  Unlike most chemical cross-
linking approaches, DOPA cross-linking occurs in high yield with little or no non-specific 
products observed even in complex protein mixtures (20).  This method has been utilized to 
identify the yeast Rpt6/Sug1 and Rpt4/Sug2 proteins as the direct targets of Gal4 transcriptional 
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activation domains within the 26S proteasome (21).  DOPA contained in RIP-1 (Regulatory 
Particle Inhibitor Peptoid-1) was also used to identify the yeast RIP-1 receptor (22).   
 Previously it was reported that an α-factor analog containing Bpa at positions 1 and 13 
cross-linked into portions of Ste2p comprising residues Ser251-M294 and Phe55 – Arg58 
respectively (14-16). However the exact residue of Ste2p that interacted with position 1 or 13 of 
α-factor was not defined.  In this study we investigated the periodate-mediated chemical cross-
linking of [DOPA1 Lys7(BioACA),Nle12]α-factor (Bio-DOPA1) and [Lys7(BioACA),Nle12, 
DOPA13]α-factor (Bio-DOPA13) into Ste2p. These α-factor analogs were potent agonists; Bio-
DOPA1 bound to Ste2p similar to the α-factor whereas Bio-DOPA13 bound with about 10-fold 
less affinity.  Matrix-assisted laser-desorption ionization-time-of-flight (MALDI-TOF) analysis 
revealed that Bio-DOPA1 and Bio-DOPA13 α-factor analogs cross-linked to fragments of Ste2p 
comprising residues Leu264-Val280 (specifically Lys269) and Phe55 – Met69, respectively. 
Cross-linking of the Bio-DOPA13 α-factor analog into a Ste2p mutant (Cys59Ser) devoid of 
cysteine was greatly diminished suggesting that DOPA13 of the α-factor analog interacted 
directly with Cys59 of Ste2p.  This represents the first time that DOPA oxidative cross-linking 
has been used to link a peptide hormone to a GPCR receptor and demonstrates the general utility 






Materials and Methods 
Media, Reagents, Strains and Plasmids: 
Saccharomyces cerevisiae strain LM102 [MATa, bar1, leu2, ura3, FUS1-lacZ::URA3, 
ste2∆ (23)] was used for growth arrest and binding assays and the protease deficient strain BJS21 
[MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 ste2::KanR (24)] was used for protein 
isolation and immunoblot analysis.  The plasmid pBEC1 containing C-terminal FLAG and His 
tagged STE2 (23) was transformed by the method of Geitz (25) into LM102 and BJS21 cells.  
Transformants were selected by growth on yeast media (26) lacking tryptophan (designated as 
MLT) to maintain selection for the plasmid.  The Cells were cultured in MLT and grown to mid-
log phase at 30 oC with shaking (200 rpm) for all assays. 
 
Synthesis and characterization of Peptides:   
The tridecapeptide pheromone α-factor analogs [DOPA1 Lys7(BioACA),Nle12]α-factor 
(designated Bio-DOPA1) and [Lys7(BioACA),Nle12,DOPA13]α-factor (designated Bio-DOPA13) 
were synthesized using automated solid-phase peptide synthesis with Fmoc/OtBu protection 
schemes. The hydroxyl groups of DOPA were protected as the acetonide derivative. All 
protected amino reagents were purchased from Advanced Chem Tech (Louisville, KY) and all 
solvents and reagents were of the highest purity available. α-Factor and α-factor analogs used in 
this study all contain norleucine in place of the native Met12 residue. Norleucine is isosteric with 
methionine and [Nle12] α-factor is isoactive and has the same receptor affinity as α-factor (27).  
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The syntheses of [Nle12]α-factor, desTrp1,desHis2[Nle12]α-factor and [Biotin7]α-factor were 
done as described previously (14, 28).  
To pre-swollen wang resin (0.145g, 0.1 mmol, 0.69mmol/g) in DMF (10 mL) was added 
Fmoc-DOPA(acetonide)-OH (115mg, 0.25 mmol), N-hydroxybenzotriazole (34mg, 0.25 mmol), 
4-dimethylaminopyridine (3.05 mg, 0.025 mmol) and diisopropylcarbodiimide (31.55 mg, 0.25 
mmol) and the resulting mixture was stirred at room temperature for 1h. The mixture was filtered 
and the resin was treated again with the reagents above in DMF (10 mL) at room temperature for 
1h. After filtration and washing with DMF  (10 mLx2), the resin was further treated with acetic 
anhydride (102 mg, 1.0 mmol) and N,N diisopropylethyl- amine (128 mg, 1.0 mmol) in DMF 
(10 mL) for 30 min to cap unreacted hydroxyl groups, followed by washing with DMF (3x10 
mL). The Fmoc-DOPA(acetonide)-O-Wang resin (0.1 mmol) was loaded on a Model 433A solid 
phase peptide synthesizer (Applied Biosystems, Foster City, CA) using 0.1 mmol single coupling 
chemistry and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetra-methyluronium hexafluorophosphate /N 
hydroxybenzotriazole as coupling reagents. After completing the chain assembly, the resin was 
dried under vacuum. To cleave the peptide the dry resin (550 mg) obtained above was added to a 
mixture of phenol (0.75g, ethanedithiol, 0.5mL, thioanisole (0.5mL), water (0.5mL) and 10 mL 
trifluoroacetic acid and the resulting mixture was stirred for 1.5h at room temperature. After 
filtration the volume of the filtrate was reduced by rotary evaporation in vacuo, the resulting 
residue was treated with 100 mL of ethyl ether and the precipitate was collected by filtration. 
The crude peptide (180 mg) was purified on preparative HPLC C18 column (19 mmX 300 mm) 
using gradient from 30% to 70% acetonitrile/H2O (0.1%TFA) over 90 mins to give pure Fmoc-
WHWLQLKPGQPNleDOPA-OH (70 mg). 
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To a vial covered with aluminum foil containing Fmoc-WHWLQLKPGQPNleDOPA-
OH (12 mg) and DMF (1mL), was added piperidine (0.1 mL, 18% in DMF) at 4 °C under an 
Argon atmosphere, and the solution was stirred at 4 °C for 30 min. The solution was neutralized 
by 2% HCl, after filtration, the filtrate was loaded onto a preparative HPLC (C18 column, 19 
mm X 300 mm) using a gradient of 20-50% acetonitrile (0.1% TFA) in water (0.1%TFA). 7.0 
mg of pure WHWLQLKPGQPNleDOPA-OH ([DOPA13]α-factor) was obtained. Yield: 64%, 
MW, calculated: 1681.97, found: 1680.9.  
To the solution of Fmoc-WHWLQLKPGQPNleDopa-OH (22 mg, 5.16μmol) in DMF 
(1mL) and sodium borate (1mL, 50 mM), was added biotinamidohexanoic acid N-hydroxy 
succinimide ester (7.04 mg, 15.48μmol) at 4 °C. The solution was stirred for 1h. (when HPLC 
indicated that the starting material had been converted to product), neutralized by 2% HCl, 
filtered and the filtrate was loaded on preparative HPLC (C18 column, 19X300mm) using a 
gradient from 20-70% acetonitrile (0.1%TFA)/water (0.1%TFA). Highly purified Fmoc-
WHWLQLK(BioACA)PGQPNleDOPA-OH (16mg; 72% yield) was recovered. This Fmoc-
peptide (16 mg) was dissolved in DMF (1.2 mL) at 4 °C and piperidine (66 μL, 18% in DMF) 
was added. The solution was stirred for 1h and then was neutralized and filtered, and the filtrate 
was loaded on preparative HPLC using a gradient of 20-50% acetonitrile(0.1% 
TFA)/water(0.1%TFA). 5.4 mg of WHWLQLK(BioACA)PGQPNleDOPA-OH was obtained, 






Mass spectrometric analysis of peptides:   
For matrix-assisted laser-desorption ionization (MALDI) analysis the peptides were 
resuspended in 50:50 water-acetonitrile with 0.1% trifluoroacetic acid (TFA) at a final 
concentration of 0.1µg/μL.  A 20mg/mL α-cyano-4-hydroxy-trans-cinnamic acid [(α-ACHA), 
Sigma/Aldrich Chemical Company, St. Louis, MO] matrix was prepared by dissolving 
recrystallized α-ACHA in 50:50 water-acetonitrile with 0.1% TFA.  An equal volume (0.5 μL) of 
peptide solution was mixed with matrix before spotting on the MALDI plate.  The MADLI-TOF 
spectra were acquired on a Bruker Daltonics (Boston, MA) Microflex using the reflector 
methods.  The tandem mass spectrometry (MS/MS) data was acquired by MALDI post-source 
decay on a Bruker Daltonics Microflex.  The interpretation of the MS/MS data was carried out 
using Bruker Daltonics BioTools software.  
 
Growth Arrest Assays:   
LM102 cells expressing C-terminal FLAG and His tagged Ste2p were grown at 30 ºC in 
MLT, harvested, washed three times with water and resuspended at a final concentration of 5 x 
106 cells/ml (24).  Cells (1 ml) were combined with 3.5 ml agar noble (1.1 %) and poured as a 
top agar lawn onto MLT medium agar plate.  Filter disks (BD, Franklin Lakes, NJ) impregnated 
with α-factor or various α-factor analogs were placed on the top agar.  The plates were incubated 
at 30 ºC for 18 hours and then observed for clear halos around the discs.  The experiment was 






Binding Competition Assays:   
This assay was performed using LM102 cells expressing C-terminal FLAG and His 
tagged Ste2p.  Tritiated [3H]-α-factor (10.2 Ci/mmol, 12 µM) prepared as previously described 
(24, 27) was used in competition binding assays on whole cells. The cells were grown at 30 ºC in 
MLT, harvested, washed three times with YM1 [ 0.5 M potassium phosphate (pH 6.24) 
containing 10 mM TAME, 10 mM sodium azide, 10 mM potassium fluoride,and 1% BSA] and 
adjusted to a final concentration of 2 x 107 cells per ml in YM1 plus protease inhibitors [YM1i 
(29)].  For the competition binding studies, cells (600 µl) were combined with 150 µl of ice cold 
5X YM1i supplemented with 6nM [3H]α-factor in the presence or absence α-factor or α-factor 
analogs and incubated at room temperature for 30 minutes.  The final concentrations of α-factor 
and α-factor analogs ranged from 0.5 x 10-10 to 1 x 10-6 M.  After incubation, triplicate samples 
of 200 µl aliquots were filtered and washed over glass fiber filter mats using the Standard Cell 
Harvester (Skatron Instruments, Sterling, VA) and placed in scintillation vials.  The radioactivity 
[3H] on the filter was counted by liquid scintillation spectroscopy.  The binding data were 
analyzed by non-linear regression analysis for one-site competition binding using Prism software 
(GraphPad Software, San Diego, CA) to determine the binding affinity (Kd) and potency (EC50) 
for each peptide.  The Ki values were calculated by using the equation of Cheng and Prusoff, 







DOPA chemical cross-linking:  
BJS21 cells expressing C-terminal FLAG and His tagged STE2 were grown and total cell 
membranes isolated as previously described (24).  Protein concentration was determined by 
BioRad (BioRad, Hercules, CA) protein assay (23).   The membranes were re-suspended in NE-
Buffer [20mM HEPES, 20% glycerol, 100mM KCl, 12.5mM EDTA, 0.5mM DTT (18)] 
incubated with Bio-DOPA-α-factor analogs (1 µM) in the presence or absence of 100 µM α-
factor (WHWLQLKPGQPNle12Y), 100 µM α-factor antagonist 
[desW1desH2WLQLKPGQPNle12Y] (28), 100 µM α-factor synergist [WHWLQLKPGQP] (28), 
or 2 µg of BSA (bovine serum albumin) for 120 minutes at4 oC.  For periodate mediated cross-
linking, a final concentration of 1.0mM NaIO4 was added to the mixture and incubated for 2 
minutes.  A final concentration of 100mM DTT (1,4-Dithiothreitol) was used to quench the 
reaction (18).  The cross-linked membranes were washed three times with CAPS buffer [N-
cyclohexyl-3-aminopropanesulfonic acid (Sigma, St. Louis, MO.), 10 mM, pH 10] by 
centrifugation to remove non-bound Bio-DOPA.  The washed, cross-linked samples were 
fractionated by SDS-PAGE and then immunoblotted.  The blots were probed with an antibody 
directed against the N-terminal 60 amino acids of Ste2p [generously provided by J. Konopka 
(30)] and with Neutravidin-HRP conjugate (Pierce, Rockford, IL) to detect the biotin tag on Bio-
DOPA pheromone covalently linked to the Ste2p.  The signal generated were analyzed using 
Quantity One software (Version 4.5.1) on a Chemi-Doc XRS photodocumentation system 






Purification of intact cross-linked Ste2p:   
The cross-linked Ste2p was enriched using His-SelectTM HC-Nickel affinity gel 
(Sigma/Aldrich Chemical Co., St. Louis, MO) following the manufacturer’s directions.  
Approximately 10 mg cell membrane containing cross-linked Ste2p were resuspended in ice-
cold solubilization buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100) with 
protease inhibitors (PMSF, pepstatin A and leupeptin) and incubated overnight at 4ºC with end-
over-end mixing, then centrifuged at 15,000 x g for 30 minutes to remove non-soluble material.  
The solubilized proteins were then mixed with His-HC-Nickel gel and incubated at 4ºC with 
end-over-end mixing for 1 hour.  The gel was collected by centrifugation at low speed (500 x g, 
1 minute) and resuspended and collected four times in wash buffer (50 mM sodium phosphate, 
pH 8.0, 0.3 M sodium chloride, and 5 mM imidazole).  Ste2p was eluted by resuspending the 
resin in 1 mL ice cold elution buffer  (50 mM sodium phosphate, pH 8.0, 0.3 M sodium chloride, 
and 250 mM imidazole) and incubated at 4ºC with end-over-end mixing for 10 minutes.  The 
resin was pelleted by centrifugation (2000 x g, 1 minute) and the supernatant, containing the 
eluted Ste2p, transferred to a fresh tube.  Purity and concentration of samples was estimated by 
Coomassie blue and silver staining of SDS-PAGE gels (data not shown).  The samples were also 
analyzed by immunoblotting using an antibody directed against Ste2p (30) and with Neutravidin-
HRP conjugate to detect the biotin tag on Bio-DOPA covalently linked to the Ste2p.  
 
Digestion of Cross-linked Ste2p: 
The enriched cross-linked Ste2p samples eluted from the His-Nickel column were 
digested with cyanogen bromide (CNBr). The eluted samples containing Ste2p (~20 µg) were 
dried by vacuum centrifugation (Thermo Scientific, Waltham, MA) then dissolved in 100% 
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trifluoroacetic acid (TFA) containing 10 mg/ml CNBr.  Deionized distilled water (ddH2O) was 
then added to adjust the final TFA concentration to 80%, and the samples incubated at 37°C in 
the dark for 18 hours (24, 31).  The samples were dried by vacuum centrifugation and washed 
three times with ddH2O, and then 1M Tris (pH 8.0) was added to neutralize the acidic mixture. 
 
Purification of cross-linked Ste2p-fragments:   
Fragments from the CNBr digestion of cross-linked Ste2p were resuspended in PBS 
buffer (0.1 M sodium phosphate, 0.15 M sodium chloride; pH 7), mixed with monomeric avidin 
resin (Pierce Thermo Scientific, Rockford, IL,USA) and incubated for 6 hours at 4ºC with end-
over-end mixing (16).  The resin was collected by centrifugation at low speed (1000 x g, 1 
minute) and resuspended and collected four times in PBS buffer.  The cross-linked Ste2p 
fragments were eluted by resuspending the resin in 200 µL ice cold elution buffer  (0.1 M 
glycine, pH 2.5) and incubating at 4ºC with end-over-end mixing for 5 minutes.  The resin was 
pelleted by centrifugation (2000 x g, 1 minute) and the supernatant, containing the eluted cross-
linked Ste2p fragments, transferred to a fresh tube containing 20 μl of TBS (0.5 M Tris HCl, pH 
7.4, 1.5 M NaCl). 
 
MALDI-TOF analysis of cross-linked peptides: 
The eluted samples from the avidin resin were further washed and concentrated using a 
pipette with C18 chromatographic media (ZipTipC18 pipette tips; Millipore Corporation, 
Billerica, MA) following the manufacturer’s directions and resuspended in 60% acetonitrile 40% 
water (0.1% TFA).  For MALDI-TOF analysis α-CHCA [20 mg/ml (in 50:50 acetone-
isopropanol)] was used as the matrix.  The samples (0.5 µL), were either mixed with 0.5 µL of 
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matrix before spotting on the target or 1.0 µL of matrix was spotted and allowed to dry before 
applying 1.0 µL of samples (24).  MADLI-TOF spectra were acquired on a Bruker Daltonics 
Microflex using the reflector method.  Masses were calculated using PROWL peptide mass 
























Synthesis and Characterization of Bio-DOPA- α-factor: 
The synthesis of analogs of α-factor containing 3,4-dihydroxyphenylalanine (DOPA) 
were carried out using automated solid phase synthesis on a WANG resin. The intermediate 
Fmoc protected peptide was obtained in high yield and purity and was used in the 
hydroxysuccinimiude mediated addition of biotinylamido caproate (14). The final peptides used 
in bioassays and cross-linking studies were virtually homogeneous as judged by gradient HPLC 
and had the expected molecular weights.  The structures and MALDI-TOF analyses of α-factor 
and Bio-DOPA-α-factor analogs are shown in figures 1 and 2, respectively.  The MS/MS spectra 
of the peptides are shown in figure 3.  The observed mass of the peptides as determined by 
MALDI-TOF were similar to masses predicted by the PROWL peptide mass prediction tools 
(32). The α-factor was observed as 1666.086 Da (predicted, 1665.96 Da), Bio-DOPA1 was 
1998.762 Da (predicted, 1998.221 Da) and Bio-DOPA13 was 2022.560 Da (predicted, 2021.43 
Da).  On both the α-factor and Bio-DOPA13 analogs spectra, 11 out of the 13 b ion fragments and 
10 out of the 13 y ion fragments were observed whereas 9 out of the 13 b ion and 5 out of the 13 
y ion fragments were observed on the Bio-DOPA1 spectrum (Figure 3).  In the MS/MS analysis 
of the Bio-DOPA1 a mass shift of about 333 Da was observed in b7-b12 compared to α-factor 
due to the tagging of biotinylaminocaproate onto Lys7 and the replacement of Trp1 with DOPA.  
The tagging of biotinylaminocaproate onto Lys7 and the replacement of Tyr13 with DOPA in 
Bio-DOPA13 were observed as evidence of a mass shift of 356 Da from y7-y13 fragment ions 





Figure 1: Structures of native and Bio-DOPA α-factor analogs.  In Bio-DOAPA1 and Bio-
DOPA13 Trp1 and Tyr13 residues of α-factor are replaced by DOPA, and biotin is conjugated 





Figure 2: Mass spectrometric analysis of α-factor and Bio-DOPA analogs. The observed 
masses of the peptides as determined by MALDI-TOF were similar to masses predicted by the 
PROWL peptide mass prediction tools (32): α-Factor 1665.96 Da; Bio-DOPA1 1998.221 Da and 







Figure 3: MALDI post-source decay spectra of α-factor and Bio-DOPA peptides. Inserts are 
one-letter amino acid residue abbreviations of the peptides labeled with the identified ion types.    
A mass shift of about 333 Da was observed in Bio-DOPA1 b7 to b12 fragments whereas Bio-




Bioactivity and Binding of Bio-DOPA-α-factor.   
Previously, it was reported that Bpa-α-factor analogs were useful for photoaffinity 
labeling of Ste2p (14, 15).  The diphenylketone side chain in Bpa is considerably larger than the 
side chain of any natural amino acid. Because of the structural similarity of DOPA to Tyr and 
Trp (See Figure 1), we believed that DOPA would make an equal or better replacement than 
Bpa.  Biotin was tagged onto Lys7 for detection purposes (16, 33).  α-factor analogs containing 
DOPA alone without biotin or biotin without DOPA were used as controls.  The replacement of 
DOPA at position 13 [WHWLQLKPGQPNle-Dopa] or (DOPA13) α-factor resulted in a 
biological activity of 83% and binding affinity (Kd, 19 nM) of 77 % compared to that of the 
native α-factor [WHWLQLKPGQPNleY] that had binding affinity (Kd) of 12nM (Figure 4B).  
Whereas Bio-α-factor [WHWLQLK(BiotinACA) PGQPNleY] exhibited a biological activity of 
39% and binding affinity of 13%.  For Bio-DOPA13 [WHWLQLK(BiotinACA)PGQPNle-Dopa] 
about a 3-fold (35%) and 10-fold (10%) reduction were observed in the biological activity and 
binding affinity (Kd, ~100 nM), respectively (Figure 4B).  We concluded that DOPA at position 
13 did not significantly alter the interaction of the C-terminus of α-factor with Ste2p.  The 
DOPA1 [Dopa-HWLQLKPGQPNleY] and Bio-DOPA1 [Dopa-HWLQLK(BiotinACA) 
PGQPNleY]α-factor analogs displayed 3- and 4-fold less activities than the wild-type α-factor, 
respectively (Figure 4A).  For the binding activities, DOPA1-α-factor displayed binding affinity 
of 20 nM and Bio-DOPA1 was 66.4 nM (Figure 4B).  Thus, the replacement of Trp at postion 1 
with DOPA in α-factor affected the ability of the peptide to activate Ste2p but did not affect the 
binding affinity. Thus, the reduction in the activities of Bio-DOPA13 and Bio-DOPA1 were 





Figure 4: Biological and binding assays of DOPA-containing α-factor analogs.  A: Growth 
arrest assay to determine the ability of the peptides to activate α-factor receptor, Ste2p.  B: The 
binding of the peptides were determined by competition binding with [3H]α-factor for Ste2p. The 




Bio-DOPA α-factor analogs Cross-link into Ste2p:  
Membranes from cells expressing Ste2p (His and FLAG tagged) were incubated with 
Bio-DOPA-α-factor and cross-linked by periodate oxidation.  Cross-linking was carried out in 
the absence or presence of α-factor, an α-factor antagonist, a synergist, or BSA as controls to 
evaluate the specificity of the cross-linking.  The antagonist binds to Ste2p with high affinity and 
the synergist does not bind to Ste2p yet influences its biological activity (28).  Following 
incubation with the peptide probes, the membranes were treated with sodium periodate to oxidize 
DOPA and initiate cross-linking. The reaction was quenched with DTT.  Membrane proteins 
were resolved on SDS-PAGE, blotted, and then probed with anti-FLAG antibody to detect Ste2p 
(Ste2p tagged with FLAG epitope tag) or NeutrAvidin HRP (Na-RHP) to detect biotin attached 
to Bio-DOPA α-factor analogs (Figure 5).  A band (~52-54 kDa) corresponding to the size of 
Ste2p was observed in all lanes on blots probed with the anti-FLAG and all these lanes shows 
similar signal intensity of the Ste2p band. When the immunoblots were probed with Na-HRP a 
distinct band at 54 kDa was detected in the lane where Bio-DOPA α-factor analogs were 
oxidized in the presence of Ste2p.  This band was absent in samples that were not treated with 
Bio-DOPA α-factor analogs, indicating that the ~54 kDa is a Ste2p-[Bio-DOPA]α-factor (~52 
kDa + ~2 kDa) cross-linked product.  The cross-linking was nearly eliminated in the presence of 
excess (100-fold) α-factor and significantly reduced in the presence of a 100-fold excess of the 
α-factor antagonist in both the Bio-DOPA1 and Bio-DOPA13 reactions.  In the presence of BSA 
no effect on the level of cross-linked product was observed.  However, in the presence of α-
factor synergist about 70% reduction of cross-linking signal was observed in Bio-DOPA1 but no 




Figure 5: Bio-DOPA α-factor analogs chemical cross-linking into Ste2p.  Cell membranes 
containing wild type Ste2p were incubated with Bio-DOPA analog alone or with Bio-DOPA 
analog in the presence of 100-fold wild-type α-factor, antagonist, synergist, or BSA.  The 
membranes were treated with sodium periodate to oxidize DOPA and initiate cross-linking, and 
the reaction was quenched with DTT.  The samples were resolved on SDS-PAGE and probed 
with anti-FLAG to detect Ste2p and with Neutravidin-HRP conjugate (Na-RHP) to detect the 
biotin tag on Bio-DOPA-α-factor.  Blots images of Bio-DOPA13 (A) and Bio-DOPA1.(B) cross-
linking are shown. 
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 As a control for the cross-linking of Bio-DOPA-α-factor into Ste2p, membranes prepared 
from cells devoid of Ste2p were mixed with Bio-DOPA α-factor analogs and treated with sodium 
periodate under the same conditions.   No detectable signal was observed on the anti-Ste2p 
antibody blots in the Ste2p-devoid samples (Figure 6), however, a weak signal (~52 kD) similar 
in size to that of Ste2p was detected on blots of membranes probed with Na-HRP that was the 
result of non-specific association of the Bio-DOPA13 with a membrane protein(s) in a Ste2p-
independent manner. To remove Bio-DOPA-α-factor that was noncovalently associated with 
Ste2p, Bio-DOPA-α-factor treated membranes from cells expressing Ste2p and lacking Ste2p 
were mixed with a His-HC Nickel resin after the cross-linking reaction.  A distinct band (~54 
kDa) corresponding to a cross-linked product of Ste2p and Bio-DOPA-α-factor was observed in 
enriched samples (Lanes labeled “P”) from cross-linked membranes containing Ste2p both on the 
anti-Ste2p antibody and Na-HRP blots.  However, this band was absent in the Ste2p deletion 
mutant (Lane “P”).  Thus, Bio-DOPA13 remained linked to Ste2p even after the harsh treatment 
for purifying Ste2p, indicating that a stable cross-link existed between Ste2p and Bio-DOPA13.  
Moreover, the Bio-DOPA13 that associated with non-Ste2p proteins could be completely 
removed by this treatment. 
 
Phe55-Met69 cross-linked to Bio-DOPA13.   
The cross-linked Ste2p samples were purified using His-HC Nickel resin and treated with 
CNBr to fragment Ste2p.  The digest was mixed with avidin beads to capture the CNBr fragment 





Figure 6:  Immunoblot analysis of Bio-DOPA13 reaction with membranes lacking Ste2p.  
Cell membranes containing and lacking Ste2p were treated with Bio-DOPA13 for cross-linking.  
The samples were separated on SDS-PAGE and probed with an anti-FLAG antibody directed 
against Ste2p and with Na-HRP to detect Bio-DOPA13.  M indicates membrane extract; P 
indicates enriched (purified) samples from His-HC Nickel resin.  
 
Samples were eluted from the avidin beads with 0.1M glycine, pH 2.5 and were concentrated 
using a Millipore ZipTip to remove detergent and compounds that might interfere with mass 
spectrometry analysis (34).  MALDI-TOF analysis Bio-DOPA13 cross-linking (Figure 7A) 
showed that the eluted sample contained two peaks, 3497.01 and 3815.21 Da, corresponding to a 
CNBr-Ste2p fragment, F55-M69 (1473.81 Da, assuming a homoserine lactone terminus) cross-
linked to Bio-DOPA13 (2021.43 Da)[Total calculated mass = 3494.24; Observed mass = 
3497.01], and a CNBr-Ste2p fragment F55-M71 (1792.22 Da, assuming a homoserine lactone 
terminus) cross-linked to Bio-DOPA13 (2021.43 Da) [Total calculated mass = 3812.65, Observed 
mass = 3815.21], respectively. The calculated masses were based on M +1H (mass spectrometric 






Figure 7: MALDI-TOF analysis of CNBr digested Ste2p-Bio-DOPA13 cross-linked peptides.  
A: spectrum for samples eluted from avidin resin cross-linked Ste2p samples.  The 3497 and 
3815 Da peaks correspond to Ste2p fragments F55-M69 and F55-M71 cross-linked to Bio-DOPA13 
respectively.  B; spectrum for samples eluted from avidin resin from CNBr digested Ste2p 
without cross-linking.  Two major peptides were detected which were also observed in cross-
linked Ste2p samples. C: immunoblot analysis images of samples used for the MALDI-TOF.   
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Two additional peaks (2134 and 2291) were also found in the cross-linked sample and a sample 
eluted from avidin beads mixed with CNBr-treated Ste2p that had not been subjected to cross-
linking (Figure 7B).  Thus, these additional peaks were associated with peptides that were co-
purified with Ste2p during the enrichment with the His-HC Nickel resin and were also retained 
by the avidin beads.The CNBr treated cross-linked Bio-DOPA13 purified samples used for the 
MALDI-TOF analysis were also resolved on SDS-PAGE.  The results (Figure 7C) also 
suggested about a the Ste2p-Bio-DOPA13 cross-linked fragment is about 4 kDa as observed on 
the Na-RHP blot in lanes treated with Bio-DOPA13 but not in lanes without the Bio-DOPA13 
treatment.  A fragment of about 6 kDa corresponding to the C-terminus of the Ste2p containing 
the FLAG epitope tag was observed in all lanes treated with CNBr on the anti-FLAG blot.  This 
implies that the Ste2p samples were digested by the CNBr. 
 
Ser251-Met294 cross-linked to Bio-DOPA1.   
MALD-TOF analysis of the Bio-DOPA1 cross-linking samples (Figure 8A) show that the 
sample eluted from the avidin resins contained a 6571.883 Da fragment, but the Ste2p without 
crosslinking (8B) had no detectable fragment.  The 6571.883 Da peak corresponds to Ste2p 
fragment Ser251-Met294 (4572.455 Da) cross-linked to Bio-DOPA1 α-factor (1998.221 Da).  
The observed mass (6571.883) on the MALDI-TOF spectrum is similar to the calculated mass 
(6568.676 Da).  The same samples used for MALDI-TOF analysis revealed that the Ste2p-Bio-
DOPA1 cross-linked fragment is about 7 kDa as observed on the Na-RHP immunoblot (Figure 
8C, lanes treated with Bio-DOPA1).  The MS/MS analyses (Figure 9 and Table 1) confirmed that 






Figure 8:  MALDI-TOF analysis of Ste2p-Bio-DOPA1 crosslinked fragment.  A: Ste2p- Bio-
DOPA1 crosslinked spectrum of peptides eluted from avidin resin.  A 6571.883 Da peak 
corresponds to Ste2p fragment, Ser251-Met294 (4572.455 Da) cross-linked to Bio-DOPA1 α-
factor (1998.221 Da) was observed. B:  Spectrum sample eluted from avidin mixed with CNBr-
treated Ste2p (without cross-linking).  C: Image of immunoblot analysis of samples used for 












Figure 9: MS/MS analysis of Bio-DOPA1-Ste2p cross-linked fragments.  Inserts are one-
letter amino acid residue abbreviations of the fragment labeled with the identified ion types.  A:  
MS/MS spectrum of fragment Bio-DOPA1 α-factor.  The spectrum shows that 9 and 8 out of 13 
b- and y-ion fragments, respectively.  B:  MS/MS spectrum of the cross-linked fragment.  Only 
the y-ions of Bio-DOPA1 α-factor were identified.  In the Ste2p fragment (Ser251-Met294) 8 b-
ions representing the N-terminus and 8 y-ions representing the C-terminus were identified. C:  
fragment ions corresponding to internal fragments of the cross-linked peptide are labeled with 
their amino acid sequences.  Lys269 in Step is observed to cross-link to Bio-DOPA1 α-factor in 
some of the fragments.  The oxidized form (+O) of some of the fragments were also observed.  A 
list of observed masses (m/z) of the fragment ions in all the spectra compared to the theoretical 




Table 1.  A list of observed masses of fragment ions in the Bio-DOPA1 cross-linked spectra. 
 
Bio-DOPA1 Spectrum fragments 
ion 
number 
b ions (m/z) y ions (m/z) 
Expected Observed Expected Observed 
2 317.33 317.15   
3 503.54 503.31 392.47 392.20 
4 616.70 616.21 520.61 520.39 
5 744.833 744.36   
6 857.99 857.40 674.77 674.31 
7 1325.46 1324.57 1142.24 1141.61 
8 1422.58 1421.70 1255.41 1254.50 
9 1479.64 1478.59 1383.54 1383.52 
10 1607.77 1606.65 1496.70 1496.92 
11   1682.91 1682.83 
 
Bio-DOPA1-Ste2p Cross-linked Spectrum fragments 
Fragment 
ion number 
Ste2p fragments (S251-M294) Bio-DOPA1 fragments 
b ions (m/z) y ions (m/z) y ions (m/z) 
 Expected Observed Expected Observed Expected Observed 
3 406.44 406.48 407.54 408.18 392.47 392.30 
4 519.60 519.20   520.61 520.20 
5 632.76 631.36     
6   704.89 704.47 674.77 674.29 
7 829.01 827.93 818.05 819.21 1142.24 1141.49 
8 916.09 916.68 917.18 918.01 1255.41 1254.66 
9   988.26 988.82 1383.54 1382.73 
10 1142.41 1142.65 1101.42 1102.53 1496.70 1497.92 
11 1289.58 1289.02 1214.58 1213.59 1682.91 1681.60 
12 1402.74 14021     
13       
14   1386.76 1386.48   
 
Bio-DOPA1 -Ste2p Spectrum fragments 
 
Residues 
Fragment size (m/z) 
Expected Observed 
PNQ 339.37 340.18 
PNQGTD 612.61 613.45 
IFILAYSL 922.81 924.75 
(Dopa-HW) + KPNQGTD 1243.32 1244.41 
(Dopa-HWL) + KPNQGTD 1356.48 1355.66 
(Dopa-HWL) + KPNQGTD (+O) 1374.56 1373.76 
(Dopa-HWLQL) + KPNQGTD 1597.77 1597.88 
(Dopa-H) + KPNQGTDVLTTVA 1639.82 1638.03 




Bio-DOPA13 cross-links to Cys59: 
It has been shown previously that the sulfhydryl group of cysteine is able to covalently 
cross-link to DOPA upon sodium periodate-mediated oxidation (19).  Since Cys is part of the 
Ste2p fragment detected in the Ste2p-Bio-DOPA13 fragment, we carried out a cross-linking 
experiment with a cysteine-less Ste2p (Cys59Ser, Cys252Ser).  Membranes were prepared from 
cells expressing Ste2p wild-type, the cysteine-less mutant, or no Ste2p.  The cross-linking and 
enrichment of Ste2p were carried out as described above.  The immunoblot analysis (Figure 
10A) showed that cross-linking of Bio-DOPA13 into the cysteine-less Ste2p was 83% less 
efficient in comparison to the wild-type receptor, although similar levels of Ste2p signal were 
detected in both the wild-type and Cys-less samples. Bio-DOPA13 cross-linked to a Cys59Ala in 
a wild-type background (maintaining Cys at 252) showed the same low level of cross-linking as 
that of the Cys59Ser mutant. Cross-linking of Bio-DOPA1 to the Cys-less receptor was not 
affected as (Figure 10C) indicating that the reaction of Bio-DOPA13 with Cys59 is specific. 
 Previous studies in our lab have suggested that the N-terminus of α-factor may interact 
with Tyr266 or Tyr203 in Ste2p (35).  We therefore carried out the cross-linking of the Bio-
DOPA1 with membranes of cells expressing Tyr266Cys (Y266C) and Tyr203Cys (Y203C) to 
test whether the presence of Cys at position 266 or 203 would affect cross-linking with Bio-
DOPA1.  These Cys mutants have the endogenous two cysteine residues replaced with serine 
residues (C59S, C252S) similar to the Cys-less receptor and bind α-factor effectively (35, 36).  
The cross-linking results indicated that Bio-DOPA1 cross-linking with the Y266C or Y203C 
were similar to the wild type. However, Bio-DOPA13 cross-linking was reduced in the Y266C 







Figure 10: Cross-linking of Bio-DOPA α-factor analogs to Ste2p Cys mutants.  A: 
immunoblot analysis of Cys-less and Cys59Ala mutant cross-linking with Bio-DOPA13.  M 
indicates membrane extract; P indicates enriched (purified) samples from His-HC Nickel resin.  
B:  Silver stained SDS-PAGE of purified Cys-mutants cross-linked with Bio-DOPA analogs.  C:  
immunoblot analysis of the cross-linked Cys mutants purified samples.  All Cys mutants cross-






Cross-linking studies followed by mass spectrometry analysis of the product has become 
increasingly used to elucidate contacts between ligands and their cognate receptors (37).   In 
addition, a few studies have pin-pointed a residue-to-residue interaction between a peptide and 
its GPCR using photoaffinity labeling (38-42).  Ste2p, the α-factor pheromone receptor of 
Saccharomyces cerevisiae, has been used as a model for interactions between small peptides and 
GPCRs.  Photochemical cross-linking, site-directed mutagenesis, and double mutant-cycle 
analysis approaches concluded that residues 1, 3, 10 and 13 of  α-factor are involved in binding 
to Ste2p (13, 43-46). Several regions of Ste2p that contact α-factor were previously identified 
(14-17, 24, 47).   However, in no case was the exact residue-residue interaction between α-factor 
and Ste2p determined. 
 Periodate-mediated cross-linking of DOPA has been shown to result in a stable covalent 
cross-link between interacting polypeptides (19, 20).  DOPA-mediated cross-linking was 
previously shown to be efficient and specific as only one protein was labeled using a mixture of 
ten proteins (18).  The methodology revealed contacts between Rpt6p/Sug1p and Rpt4p/Sug2p 
proteins and the Gal4 transcriptional activation domains (21) and was also used to investigate 
peptoid-inhibitor interactions with the 19S regulatory particle of the 26S proteasome (22).  
However, none of these studies defined the contact points between cross-linked molecules. The 
present study was conducted to explore the utility of 3,4-dihydroxylphenylalanine (DOPA) 
oxidative chemical cross-linking in analyzing hormone-receptor interactions.  The interaction of 
GPCR, Ste2p, and its cognate peptide ligand, α-factor, was used as the test system.    
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The results presented in this paper show that replacement of Trp1 or Tyr13 by DOPA in 
α-factor results in a high affinity, potent agonist (Figure 4).  Comparisons with control peptides 
allow the conclusion that the DOPA moiety in the Bio-DOPA α-factor peptides used in cross-
linking studies likely binds similarly to the phenol side chain in the native peptide. Thus reaction 
of this moiety with groups on the receptor should lead to information relevant to the natural 
ligand. 
 DOPA chemical cross-linking studies carried out using membranes prepared from cells 
expressing Ste2p showed that Bio-DOPA1 and Bio-DOPA13 cross-linked into Ste2p.  When the 
cross-linking was carried out using membranes lacking Ste2p under the same conditions only a 
small signal was observed and this was totally removed by treatment with an affinity column that 
recognized Ste2p (Figure 6).  The cross-linking of Bio-DOPA-α-factor analogs to Ste2p was 
prevented by 100-fold molar excess native α-factor and highly reduced by a lower affinity α-
factor antagonist (28) but it was not influenced by the presence of BSA.  These results showed 
that Bio-DOPA-α-factor binds and cross-links to the ligand binding site in Ste2p and that it could 
be used to determine the contact between positions 1 and 13 of α-factor and this GPCR.   
 The strong interaction between avidin and biotin has been very useful in affinity 
purification of biotinylated peptides (34) and together with MS analysis is widely used for 
detection of cross-linked products with high sensitivity and accuracy (48).  We reported 
previously on the purification and MS analysis of a biotinylated-α-factor cross-linked to a 
portion of Ste2p (16).  We applied this approach to analyze the cross-linking between Bio-
DOPA-α-factor and Ste2p.  The cross-linked Ste2p samples were fragmented with cyanogen 
bromide (CNBr) and the biotinylated fragments were captured by affinity purification.  MALDI-
TOF analysis of the CNBr fragments from cross-linked Bio-DOPA13 with Ste2p showed two 
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major peaks, 3497 and 3815 Da (Figure 7A).  In addition, two other peaks (2134 and 2291 Da) 
were detected which were also detected in samples from uncross-linked CNBr-treated Ste2p 
samples (Figure 7B).  These two minor peaks (2134 and 2291 Da) were due to proteins that were 
co-purified with Ste2p during the enrichment with the His-HC Nickel resin as observed on silver 
and comassie stained SDS-PAGE gels (data not shown).  Since the two major peaks (3497 and 
3815 Da) were only observed in the cross-linked Ste2p samples, we concluded that these 
fragments are composed of parts of Ste2p cross-linked to Bio-DOPA-α-factor.  Examination of 
the predicted sizes of CNBr fragments of Ste2p and the peaks detected revealed that the peak 
3497.01 Da corresponded to a CNBr-digested Ste2p fragment, Phe55-Met69 (1473.81 Da) cross-
linked to Bio-DOPA (2021.43 Da), whereas the 3815.21 Da peak corresponded to a CNBr-
digested Ste2p fragment Phe55-Met71 (1792.22 Da) cross-linked to Bio-DOPA (2021.43 Da).   
The approximately 3 Da difference between both experimental peaks and the theoretical values 
was due to averaging the observed isotopic mass of the peptides (32).  On the basis of this result 
and previous studies showing that [Bpa13]α-factor analog cross-linked to residues Phe55-Arg58 of 
Ste2p, we suggest that position 13 of α-factor interacts with a residue(s) within Phe55-Met69. 
Previous investigations determined that the ε-amino of lysine, the imidazole of histidine, 
and the thiol of cysteine were capable of attacking the ortho-quinone obtained on periodate 
oxidation of DOPA (19).  Based on these findings, the only nucleophilic side chain within the 
residues Phe55-Met69 (55FGVRCGAAALTLIVM69) that could attack the ortho-quinone 
intermediate is Cys59.  To efficiently couple to DOPA, the thiol group of cysteine and DOPA 
must be in close proximity (19).  Thus our results  suggest that DOPA at position 13 of Bio-
DOPA13 cross-links to Cys59 of Ste2p and that residue 59 of Ste2p and residue 13 of the α-factor 
ligand must be close proximity in the ligand bound state of the receptor. 
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 To investigate whether DOPA in Bio-DOPA13 cross-linked to Cys59 of Ste2p, 
experiments were repeated using membranes containing cysteine-less Ste2p mutant.  This mutant 
receptor has similar activities as the wild-type receptor (23).  Immunoblotting analysis (Figure 
10) showed that cross-linking of Bio-DOPA13 into the cysteine-less Ste2p and Cys mutants 
(Y266C and Y203C) was over 80% less efficient compared to wild-type.  This experiment was 
repeated at least three times and similar results were obtained.  We also changed Cys to Ala at 
position 59 while maintaining Cys at position 252.  This construct showed a similar reduction in 
cross-linking indicating that the majority of the cross-linked product involved Cys59 (Figure 
10A).  Thus, the substitution of cysteine with serine or alanine at position 59 of Ste2p reduced 
the cross-linking between linked Bio-DOPA13 and Ste2p, supporting the conclusion that the thiol 
functional group of Cys59 was cross-linked to Bio-DOPA13 and that Cys59 is in close proximity 
with position 13 of α-factor.  The proposed mechanism for the cross-linking of Bio-DOPA13 to 
Cys59 of Ste2p follows a reaction scheme suggested by the Kodadek group (22) and is outlined 
Figure 11.  The minor amount of cross-linking in the Cys-less still observed (about 20% of the 
wild-type level) may be due to other nucleophiles in proximity to position 59 of Ste2p.  Potential 
candidates are Arg58, His94, and Lys100 according to the model of Ste2p based on the 
rhodopsin x-ray structure (9, 10).  As stated above the significant reduction in cross-linking 
found with the Cys-less receptor is consistent with our conclusion that Cys59 is the contact point 







Figure 11: Proposed mechanism of cross-linking of DOPA at position 13 of α-factor and the 
Cys59 of Ste2p.  DOPA is oxidized to an intermediate ortho-quinone which is then attacked by 




Previous studies in our lab have suggested that the N-terminus of α-factor may interact 
with Tyr266 in Ste2p.  It was suggested in that study that the highly aromatic and hydrophobic 
N-terminus (W1H2W3L4) of α-factor probably binds to hydrophobic residues comprising the 
receptor residues such as Tyr266 and some aromatic residues (Tyr203 and Phe204) at the second 
extracellular loop and transmembrane five boundary (35).  To determine whether Trp1 of α-
factor is directly in contact or in close proximity with Tyr266 or Tyr203 in Step in its ligand-
bound state, Bio-DOPA1 cross-linking was carried out using membranes containing Cys-less, 
Tyr266Cys and Tyr203Cys Ste2p mutants.  The cross-linking of Bio-DOPA1 into all mutant 
receptors tested was similar to the wild type receptor (Figure 10C).  Thus, Bio-DOPA1 cross-
linking was not affected in the presence or absence of Cys at Tyr203 or Tyr266 implying that 
Trp1 in α-factor may not be in close proximity with Tyr203 or Tyr266 in the Ste2p-ligand bound 
state.   
The cross-linking of Bio-DOPA1 was reduced in the presence α-factor (~92%), α-factor 
antagonist (~85%) and α-factor synergist (~70%).  The MALDI-TOF analysis of Bio-DOPA1-α-
factor cross-linking into Ste2p revealed that this peptide cross-linked to a region in Ste2p 
comprising of Ser251 to Met294 (TM6-EL3-TM7) consistent with previous studies using Bpa at 
the same position of the ligand (15).  MS/MS analysis of Bio-DOPA1 cross-linked product 
confirmed that the region Ser251 to Met 294 cross-linked with Bio-DOPA1.  Whereas both the b- 
and y-ion fragments of Bio-DOPA1 were observed in the Bio-DOPA1 spectrum (Figure 9), only 
the y-ions of the ligand were identified in the cross-linked spectrum suggesting that the N-
terminus of the ligand containing DOPA is cross-linked to a fragment.  The b ions of residues 
Ser251-Ile263 and y ions of residues Leu283-Met294 were identified in the Ste2p fragment, 
Ser251-Met294.  The identification of the N- and C- termini of Ste2p fragment, Ser251-Met294 
95 
 
and C-terminus of Bio-DOPA1-in one spectrum indicate that all these fragments are in one piece 
(cross-linked fragment).  However, the instrument used for the MS/MS has a mass-charge ratio 
(m/z) limit of 2000 therefore it is not possible to obtain a fragment ion that is more than 2000 
m/z on the spectrum examined.  Since the Bio-DOPA1 is about 1999 Da (m/z) anything that 
cross-links with it will increase the mass to more than 2000 m/z hence will not be identified.  
Nevertheless the results implied that Bio-DOPA1 may cross-link with one of the residue in 
Leu264-Val280 (Figure 9B).  Detailed examination of fragment ions observed in the cross-linked 
spectrum indicates that Bio-DOPA1 is cross-linked to Lys269 (Figure 9C) located at the TM6-
EL3 boundary.  The effect of this residue on Bio-DOPA1 cross-linking was not tested and 
remains a target for future studies.   
The reduction of cross-linking in the presence of α-factor synergist observed in Bio-
DOPA1 but not Bio-DOPA13 can be attributed to the fact that this synergist may interact within 
the ligand signaling pocket (interaction site of α-factor N-terminus) but not the binding site 
(interaction site of α-factor C-terminus).  This α-factor synergist lacking the last two residues of 
wild type α-factor has been shown to have significantly reduced binding affinity for Ste2p 
however it enhances the activity of the wild-type α-factor (28).  Thus, due to the absence of the 
last two amino acids (M12W13) critical for binding this synergist doe not bind to the inactive 
Ste2p conformation but it interacts with Ste2p-α-factor active complex and increases the activity 
of the receptor more than wild type levels (28).  Exact interaction site of this synergist in Ste2p is 
unknown.   
The different cross-linking reactions of Bio-DOPA1 and Bio-DOPA13 in presence of the 
synergist can be explained by the fact that the binding of α-factor to Ste2p may involve two 
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binding steps as proposed in a mechanism in figure 11.  This mechanism is based on Trp1 and 
Tyr13 of α-factor cross-linking reactions with Ste2p residues Leu264-Thr282 and Phe55-Met69, 
respectively, reported in this study and other reports (14-16) as well as α-factor synergist 
inhibition of cross-liking at Leu264-Thr282.  It is proposed that the binding of α-factor to Ste2p 
involves initial binding of the C-terminus to the binding pockets (may include region Phe55-
Met69 and other regions) followed by The N-terminus penetrating the transmembrane regions of 
TM5-TM6 and interacting within the signal pocket (see Figure 12) required for receptor 
activation as observed in some peptide-responsive GPCRs (49-52).  This binding mechanism 
explains why the synergist was able to inhibit the cross-linking of Bio-DOPA1 but not Bio-
DOPA13.  Thus, in the presence of synergist both Bio-DOPA1 and Bio-DOPA13 binds to Ste2p 
without any inhibition by the synergist (since it does not bind) but it may interact within the 
same site in Ste2p as the N-terminus of the Bio-DOPA analogs. These interactions of synergist 
do not affect binding of these peptides but interferes with the cross-linking of Bio-DOPA1 that 
contains DOPA (replacing Trp1) at the N-terminus by blocking the reactions of DOPA.  The 
same blocking effect of the N-terminus interaction is suggested to occur with Bio-DOPA13 
however because the DOPA is located at the C-terminus (replacing Tyr13) in this peptide it does 





Figure 12: Proposed mechanism of α-factor binding to Step.  The C-terminus of α-factor 
binds Ste2p close to the TM1 region (Phe55-Met69) this causes conformational changes in Ste2p 
allowing the N-terminus of α-factor to penetrate and bind within the signaling pocket that may 
involve TM5-TM6-TM7 residues.  The extracellular loops are also involved in stabilizing the 
receptor-ligand complex. 
 
In the presence of 100-fold excess α-factor antagonist both Bio-DOPA1 or Bio-DOPA13 cross-
linking were inhibited because this antagonist binds efficiently and similar to α-factor (28); 
hence it is capable of blocking the binding (step 1 of mechanism shown above, of Bio-DOPA1 
and Bio-DOPA13. 
We therefore suggest that the synergist interacts within the same signaling pocket in 
Ste2p as the N-terminus of wild type α-factor in the receptor-ligand bound active complex 
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conformation.  This interactions may be responsible for the increase in Ste2p activity observed in 
previous studies (28) when both the wild type α-factor and its synergist are present. 
Previously we concluded that [Bpa13]α-factor cross-linked to the F55-R58 fragment of 
Ste2p using photoactivation approaches (14).  To probe this region further, site-directed single 
Ala mutations were constructed on residues 54-58 in Ste2p (data not shown).  Ste2p mutants 
R58A, R58D, and R58E exhibited a large increase in the Kd for binding [3H]α-factor. The other 
mutant receptors had a similar or slightly reduced binding affinity compared to that of the wild-
type receptor.   Photo-cross-linking of these Ala mutants to [Bpa13,K7(biotinylamidocaproate), 
Nle12] α-factor  showed that cross-linking to the R58A mutant was highly diminished, but cross-
linking to the F55A, G56A, and V57A mutants was not greatly affected.  These cross-linking and 
site-directed mutagenesis results suggested that position 13 of α-factor interacted with R58 of 
Ste2p. The finding that [Bpa13]α-factor and [Bio-DOPA13]α-factor cross-link to Arg58 and 
Cys59, respectively, provides strong evidence that the carboxyl terminal residue of the 
pheromone binds to this region of Ste2p.  The [Bio-DOPA1]α-factor was observed to cross-link 
to Lys269 of Ste2p.   It seems reasonable that the Tyr13 side chain is involved in a cation-π 
interaction with the Ste2p-Arg58 guanidinium moiety and a hydrogen bond with the Ste2p-
Cys59 sulfhydryl group (Figure 13).  In addition, the indole side chain of Trp1 of α-factor may 
be involve in a cation-π (or hydrogen bonding) interaction with the Ste2p-Lys269.  Although the 
insertion of Ser or Ala greatly diminished cross-linking to Bio-DOPA-α-factor it did not 





  A (top view)     B (top view)  
          
 
Figure 13: Proposed model of the interactions of Trp1 and Tyr13 of α-factor with Lys269, 
and Arg58/Cys59 residues of Ste2p, respectivcely.  The transmembrane domains (TM) are 
labeled in different colors in A and α-factor is shown as a pink ribbon. A: Topview showing 
overall interactions of the N-terminus (close to TM5-TM6) and C-terminus (close to TM1) of α-
factor with Ste2p.  Trp1 indole side chain of α-factor is propose to form a cation-π (or hydrogen 
bonding) interaction with Lys269 ε-amino group.  The Tyr13 side chain phenyl ring of α-factor is 
also proposed to be involved in a cation-π interaction with the Arg58 guanidinium moiety and 
the phenolic OH (Tyr13) forms a hydrogen bond with Cys59 sulfhydryl group.  The interactions 
between the residues are indicated by broken green lines.  B: Topview image of the electrostatic 
potential surface of Ste2p showing a potential binding pocket of α-factor.  
 
In an elegant study using model PNAs to  assure proximity between DOPA and potential 
nucleophiles, Kodadek and coworkers  concluded that sulfhydryl (Cys), imidazole (His) and 
primary amines (Lys) could react with the orthoquinone oxidation product (19).  Ser and Thr 
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hydroxyls were not found to interact under the experimental conditions reported by Kodadek and 
his group (19). Nevertheless, there are many examples of the nucleophilicity of Ser hydroxyl 
groups in proteins, and the hydroxyl oxygen has been shown to act as a nucleophile with a 
variety of electrophiles (53).  Partially buried in the hydrocarbon core of the membrane, the 
solvation of the hydroxyl side chain of Ser59 in the Ste2p binding site might be quite different 
from that found in the aqueous buffers used with the PNA model compounds investigated by the 
Kodadek group. Thus, it seems plausible that Ser and Thr moieties of protein receptors may be 
potential sites for cross-linking to orthodiquinones produced on periodate activation of ligands. 
At present the most detailed information pertaining to ligand binding sites of GPCRs 
comes from X-ray analysis of rhodopsin and β-adrenergic receptors (11, 54-57). These proteins 
bind retinal and inverse agonists, respectively, at sites located primarily in the TM core of these 
GPCRs.  No high resolution information is available on GPCRs that bind medium sized peptide 
hormones; most of our knowledge on binding sites is inferred from biochemical data. The cross-
linking information on α-factor-Ste2p interactions suggests that the carboxyl terminus of the 
tridecapeptide ligand contacts two polar residues (Arg58 and Cys59) that are near the 
extracellular end of TM1 of Ste2p (Fig. 9). Double mutant-cycle analyis (44) previously showed 
that Trp1 and Trp3 of α-factor interact strongly with N205 and Y266 residues that are located 
near the extracellular ends of TM5 and TM6, respectively (17, 58). Finally, the center of α-factor 
is thought to face toward the extracellular loop regions of Ste2p (17, 33). Thus, in contrast to 
covalently bound retinal and small biogenic amines, the α-factor tridecapeptide interacts 
primarily with the ends of TM domains and loops of Ste2p during activation of its GPCR. These 
interactions are consistent with the prevailing belief that the binding site for peptide ligands to 
their GPCRs involves ectodomains(59, 60).   
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Binding of α-factor is thought to elicit a significant conformational change in EL1 that is 
related to receptor activation. Intriguingly, the extracellular loop of rhodopsin is also believed to 
move during light activation of this GPCR, and the signaling role of extracellular loops in other 
Class A GPCRs is just starting to be revealed as well (61). Ste2p is a Class D GPCR and 
rhodopsin is a Class A GPCR. If extracellular loops are involved in activation of such 
evolutionary distinct receptors, it is not unreasonable to suggest that movements of extracellular 
loops may be an important, perhaps general, aspect of GPCR signal transduction. Evidently, 
different classes of GPCRs actuate these movements by distinct molecular interactions.  
In conclusion, we have synthesized and characterized α-factor analogs (Bio-DOPA-α-
factors) with DOPA replacing Trp1 or Tyr13 and biotin tagged on Lys7 and shown that these 
analogs linked covalently into Ste2p by periodate-mediated DOPA cross-linking.  Mass 
spectrometric analyses of the cross-linked fragments demonstrated that Bio-DOPA1 and Bio-
DOPA13 cross-linked into residues Leu264-Val280 (specifically Lys269) and Phe55-Met69 of 
Ste2p, respectively.  Replacing cysteine at position 59 with serine or alanine drastically reduced 
the cross-linking with Bio-DOPA13. Therefore, it is reasonable to conclude that Trp1 and Tyr13 of 
α-factor are in close proximity to Lys269 and Cys59 of Ste2p when α-factor is bound to Ste2p.  
Our results represent the first determination of a residue-to-residue contact point between α-
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G protein-coupled receptors (GPCRs) are activated upon binding their cognate ligands.  
Ligand binding initiates a change in the conformation of these integral membrane proteins. This 
promotes signal transduction across the membrane, and the activation of the G protein-mediated 
signal transduction cascade (1, 2).   The interactions between ligands and their receptors are 
defined for a number of GPCRs (3). However, the ligand-induced changes in protein structure, 
which initiate signal transduction, are difficult to study.  Although site-directed mutagenesis has 
been used to address the issue of GPCR activation, more methods for studying ligand-dependent 
conformational changes upon receptor activation are needed.  One promising approach which 
may be adapted to the study of the dynamics of GPCR structure is the use of orthogonal pairs of 
tRNA/ aminoacyl-tRNA synthetases evolved and expressed in the target cell to incorporate 
unnatural amino acids (4-7).  
Non-naturally occurring amino acids can be synthesized to contain a variety of chemical 
moieties for use as photoaffinity labels or fluorescent and/or spectroscopic probes.  To 
autonomously incorporate unnatural amino acids into proteins in living cells, the mutated tRNA 
is designed to recognize a specific codon, usually a nonsense codon, such as the amber TAG 
stop.  The evolved cognate aminoacyl-tRNA synthetase specifically charges its orthogonal tRNA 
with an unnatural amino acid added to the growth medium.  Provided that there is a sufficient 
quantity of the unnatural amino acid in the cytoplasm, the tRNA can be charged for delivery of 
the novel amino acid into the protein. 
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The genetic codes of E. coli, yeast and mammalian cells have been altered to allow the 
translational insertion of more than thirty unnatural amino acids with a variety of novel 
properties useful in the study of protein structure and function (5, 8).  Thus far, these applications 
have focused primarily on soluble proteins.  With respect to eukaryotic membrane proteins 
expressed in mammalian cells, unnatural amino acids have been introduced into the nicotinic 
acetycholine receptor in both CHO cells and cultured neuronal cells (9) and in the epidermal 
growth factor receptor in HEK293 cells (10).  A heterologous Xenopus oocyte expression system 
has also been used extensively to insert non-natural amino acids into the nicotinic acetylcholine 
receptor (11) the neurokinin-2 receptor (12), the GABAA receptor (13), the NMDA receptor (14) 
and numerous channel proteins including the serotonin-gated ion channel (15), the inwardly 
rectifying potassium channel (16) and the voltage-sensitive sodium channel (17) .  In both the 
mammalian and Xenopus expression systems, a tRNA chemically charged with the non-natural 
amino acid is introduced into the cell along with the target mRNA.  While these systems are 
useful for the short-term studies of protein properties, they are not amenable to large-scale 
production of proteins into which unnatural amino acids have been incorporated.   Recently, it 
was demonstrated in CHO cells that unnatural amino acids could be introduced into green 
fluorescent protein (GFP) using specific orthogonal tRNA/aminoacyl-tRNA synthetase pairs (6). 
Because the yeast Saccharomyces cerevisiae provides a tractable system in which to develop this 
methodology, we report here the genetic incorporation of an unnatural amino acid into a 
polytopic membrane protein in its native eukaryotic host cell .   
To date in S.  cerevisiae orthologous tRNA/aminoacyl-tRNA synthetase pairs have been 
used to incorporate a variety of unnatural amino acids, including the photoactivatable amino acid 
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analog p-benzoyl-L-phenylalanine (Bpa) (4), the fluorescent amino acid dansyl alanine (18) and 
acetylene and azide-containing amino acids (7, 19), into the soluble protein human superoxide 
dismutase.  Here we report the site-specific incorporation of Bpa into Ste2p, a yeast GPCR, using 
an orthologous tRNA/aminoacyl tRNA synthetase pair.  In this system, the amber TAG stop 
codon was engineered into specific sites within the STE2 coding region.  Bpa was supplied to the 
cells either as the free amino acid analog or as the dipeptide Met-Bpa. Upon translation of the 
message, Bpa was incorporated into the nascent Ste2p and ultimately expressed at the cell 
surface.    Two of our Bpa-Ste2p receptors were used to selectively photocapture biotinylated α-
factor. To our knowledge this is the first report of the expression in the native host cell of a 
GPCR containing a photoactivatable amino acid. The successful photocapture of α-factor by 
novel Ste2p mutants shows that GPCRs containing unnatural amino acids can be used to capture 




Material and Methods 
Media, Reagents, Strains and Plasmids: 
Saccharomyces cerevisiae strain DK102 (MATa, ura3-52 lys2-801am ade201oc trp1-Δ63 
his3-Δ200 leu2-Δ1 ste2::HIS3 sst1-Δ5.) was used for growth arrest and binding assays and the 
protease deficient strain BJS21 (MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 
ste2::KanR.) was used for protein isolation and immunoblot analysis.  C-terminal FLAG and His 
tagged STE2 was PCR amplified from plasmid pNED1 (20) and cloned into the plasmid p426-
GPD (21) to yield plasmid pCL01.  The plasmid pCL01was engineered by single-stranded 
mutagenesis to incorporate TAG stop codons at eight specific positions within the STE2 coding 
region (Fig. 1).  The sequence of all TAG mutants was verified by DNA sequence analysis 
completed by the Molecular Biology Resource Facility located on the campus of the University 
of Tennessee.  Mutagenic and sequencing primers were purchased from Sigma/Genosys (The 
Woodlands, TX) or IDT (Coralville, IA).  The pCL01 TAG mutant plasmids were co-
transformed by the method of Geitz (22) into DK102 and BJS21 cells along with plasmid 
pECTyrRS/tRNACUA, encoding the orthogonal amber suppressor tRNA synthetase-tRNA pair 
genetically modified to allow for incorporation of p-benzoyl-L-phenylalanine (Bpa) (4).  
Transformants were selected by growth on minimal medium (23) lacking tryptophan and uracil 
(designated as MLWU) to maintain selection for the plasmids.  Cells used in the assays described 
below were cultured in MLWU and grown to mid-log phase at room temperature with shaking 
(200 rpm) in the presence or absence of 2 mM Bpa, unless otherwise specified.  Methionyl-Bpa 
was synthesized by standard solution phase techniques (24) and purified by reverse-phase HPLC 
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to greater than 99% homogeneity.  All media components were obtained from BD (Franklin 
Lakes, NJ) and were of the highest quality available.  Bpa was purchased from Bachem 
(Torrance, CA) and was dissolved in NaOH (1N) at a final concentration of 100 mM 
immediately before use. 
 
Growth Arrest Assays:   
DK102 cells expressing the wild-type (WT) or TAG constructs were grown at 30ºC in 
MLWU, harvested, washed three times with water and resuspended at a final concentration of 5 
x 106 cells/ml.  Cells (1 ml) were combined with 3.5 ml agar noble (1.1 %) with or without the 
addition of Bpa (2 mM final concentration) and poured as a top agar lawn onto MLWU medium.  
Filter disks (BD, Franklin Lakes, NJ) impregnated with the tridecapeptide pheromone α-factor 
(WHWLQLKPGQPNle12Y) synthesized and characterized as previously described (25) were 




BJS21 cells expressing WT or TAG-STE2 constructs grown in the presence or absence of 
Bpa were used to prepare total cell membranes isolated as previously described (20).  Protein 
concentration was determined (BioRad, Hercules, CA) and membranes solubilized in SDS 
sample buffer.  Proteins (2 µg/lane for wild type, 30 µg/lane for mutants) were fractioned by 
SDS-PAGE and immunoblotted.  Blots were probed with FLAG antibody (Sigma/Aldrich 
Chemical, St. Louis, MO) or an antibody directed against the N-terminal 100 amino acids of 
117 
 
Ste2p generously provided by J. Konopka (26). The immunoblots were imaged and band density 
quantitated using Quantity One software (Version 4.5.1) on a Chemi-Doc XRS 
photodocumentation system (BioRad, Hercules, CA).   
 
Binding Assays:  
Tritiated α-factor (10.2 Ci/mmol, 12 µM) prepared as previously described (25) was used 
in saturation binding assays on whole cells.  DK102 cells expressing WT or TAG constructs 
were harvested, washed three times with YM1 (20) and adjusted to a final concentration of 2 x 
107 cells per ml.   Cells (600 µl) were combined with 150 µl of ice cold 5X binding medium 
(YM1 plus protease inhibitors [YM1i (20)] supplemented with [3H]α-factor) and incubated at 
room temperature for 30 minutes.  The final concentration of [3H]α-factor ranged from 0.5 x 10-
10 to 1 x 10-6 M.  Upon completion of the incubation interval, 200 µl aliquots of the cell-
pheromone mixture were collected in triplicate and washed over glass fiber filter mats using the 
Standard Cell Harvester (Skatron Instruments, Sterling, VA).  Retained radioactivity on the filter 
was counted by liquid scintillation spectroscopy. DK102 cells lacking Ste2p were used as a non-
specific binding control for the assays.  Specific binding for each mutant receptor was calculated 
by subtracting the non-specific values from those obtained for total binding.  Specific binding 
data were analyzed by non-linear regression analysis for single-site binding using Prism software 
(GraphPad Software, San Diego, CA) to determine the Km (nM) and Bmax values (receptors/cell) 






BJS21 cells expressing either the WT or G188TAG  Ste2p were grown in the presence or 
absence of Bpa and used to prepare total cell membranes as previously described (20).  
Approximately 3 mg cell membranes was resuspended in ice-cold solubilization buffer (50 mM 
Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) with protease inhibitors 
(PMSF, pepstatin A and leupeptin) and incubated overnight at 4ºC with end-over-end mixing, 
then centrifuged at 15,000 x g for 30 minutes to remove non-soluble material.  The solubilized 
proteins were then mixed with FLAG resin (Sigma/Aldrich Chemical Co., St. Louis, MO) and 
incubated at 4ºC with end-over-end mixing for 6 hours.  The resin was collected by 
centrifugation at low speed (800 x g, 1 minute) and resuspended and collected four times in TBS 
buffer (25 mM Tris-HCl, 140 mM NaCl, 3 mM KCl, pH 7.4).  Ste2p was eluted by resuspending 
the resin in 1 mL ice cold elution buffer (0.1 M glycine HCl, pH 3.5) and incubated at 4ºC with 
end-over-end mixing for 5 minutes.  The resin was pelleted by centrifugation (2000 x g, 1 
minute) and the supernatant, containing the eluted Ste2p, transferred to a fresh tube containing 
20 μl of 0.5 M Tris HCl, pH 7.4, 1.5 M NaCl.  Purity and concentration of samples was 
estimated by Coomassie blue and silver staining of SDS-PAGE gels.  The samples were also 
analyzed by immunoblotting using an antibody to the FLAG epitope on the C-terminus of Ste2p.  
Samples containing eluted Ste2p (~50 µg) were dried by vacuum centrifugation (Thermo 
Scientific, Waltham, MA) then dissolved in 100% trifluoroacetic acid (TFA) containing 10 
mg/ml cyanogen bromide (CNBr).  Deionized distilled water (ddH2O) was then added to adjust 
the final TFA concentration to 70%, and the sample was incubated at 37°C in the dark for 18 
hours.  The samples were dried by vacuum centrifugation and washed three times with ddH2O 
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and resuspended in 0.1% TFA.  The resulting CNBr peptide fragments were further washed and 
concentrated using ZipTip pipette tips (Millipore Corporation, Billerica, MA) following the 
manufacturer’s directions and resuspended in 70% acetonitrile 30% water (0.1% TFA). For 
MALDI-TOF analysis α-cyano-4-hydroxy-trans-cinnamic acid (ACHA, Sigma/Aldrich 
Chemical Company, St. Louis, MO) at a concentration of 20 mg/ml in 50% acetonitrile-50% 
water (0.1 % TFA) was used as the matrix.  The digested samples (0.5 µL eluate from ZipTip), 
were either mixed with 0.5 µL of matrix before spotting on the target or 1.0 µL of matrix was 
spotted and allowed to dry before applying 1.0 µL of samples.  MADLI-TOF spectra were 
acquired on a Bruker Daltonics (Boston, MA) Microflex using both reflector and linear methods. 
 
Crosslinking: 
A biotinylated form of α-factor [K7(biotinylamidocaproate), Nle12]α-factor was prepared 
as previously described (27).  Membranes prepared from BJS21 cells expressing the F55TAG, 
G188TAG and Y193TAG receptors, grown at room temperature in the presence or absence of Bpa 
(1 mM) were suspended in PPBi buffer (0.5 M potassium phosphate, pH 6.2, 10 mM TAME, 10 
mM sodium azide, 10 mM potassium fluoride, and 0.1% BSA), incubated with biotinylated 
pheromone (1 µM) in the presence of absence of non-biotinylated pheromone (100 µM) for 30 
minutes at room temperature, then chilled to 4ºC for the remainder of the procedure.  
Crosslinking was performed as previously described (27).  Briefly, the membranes were exposed 
to UV light at 365 nm using a Stratalinker (Stratagene, La Jolla, CA) for three 15 minute 
intervals.  The cross-linked membranes were washed three times with CAPS buffer [N-
cyclohexyl-3-aminopropanesulfonic acid (Sigma, St. Louis, MO.), 10 mM, pH 10] by 
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centrifugation to remove non-crosslinked biotinylated α-factor, fractionated by SDS-PAGE and 
immunoblotted with antibody to Ste2p and with Neutravidin-HRP conjugate (Pierce, Rockford, 
IL) to detect the biotinylated pheromone covalently linked to the receptor.  The signal generated 
by Neutravidin-HRP conjugate associated with the biotinylated ligand-receptor complex was 
quantitated by measurement of the band density using Quantity One software (Version 4.5.1) on 
a Chemi-Doc XRS photodocumentation system (BioRad, Hercules, CA).  Before fractionation 
by SDS-PAGE the amount of protein in each sample was determined, and amounts specified in 





Effect of Bpa Incorporation on Ste2p-Mediated Signal Transduction: 
The amber stop codon TAG was inserted into the STE2 coding sequence by site-directed 
mutagenesis at the eight sites indicated in Figure 1.  The sites were located in the first 
transmembrane domain (F55TAG), in the first (S107TAG, G115TAG, V127TAG) and second 
(Y193TAG and F204TAG) extracellular loops, at the border between the fourth transmembrane 
domain and the second loop (G188TAG) and in the sixth transmembrane domain (Y266TAG).  
These residues were selected based on several criteria: (i) location – either in an extracellular 
loop or near the interface between a TM and an extracellullar surface, (ii) prior site-directed 
mutagenesis studies indicating that the residues (S107, G115, V127, and G188) were tolerant to 
amino acid substitution (28), and (iii) conservation of the aromatic functional group (F55, F204, 
and Y266) (29, 30) .  The plasmids bearing these mutations and the plasmid 
pECTyrRS/tRNACUA, which encoded the tRNA/tRNA synthetase pair, were transformed into 
DK102 and BJS21 cells.   
To determine if the Ste2p-Bpa mutant proteins were able to bind ligand and ultimately 
transduce signal across the cell membrane, growth arrest or ‘halo’ assays were conducted on 
these transformed cells.  Disks impregnated with α-factor were placed onto a top agar lawn of 
DK102 cells putatively expressing Ste2p-Bpa receptors, and the plates were incubated at room 
temperature for 48-72 hours.  The rationale to conduct these studies was two-fold.  In the 
absence of Bpa, the tRNA should not be charged, resulting in the production of truncated Ste2p.  











































































S M I L
S Q
P V L L
I I S


















T Q AI M F
V R
A A
L T LI V M INQ
V
F L S
L I I L
A S H




















I Q VL L V
S I ET S L
F Q I
C




Figure 1: Sites targeted for Bpa insertion into Ste2p.The coding region of the STE2 gene was 
modified to introduce the amber TAG codon, resulting in the insertion of Bpa into Ste2p at the 
sites indicated in black (F55, S107, G115, V127, G188, Y193, F204, and Y266).  The FLAG and 
His tags are underlined and indicated by gray shading in the C-terminal tail. 
 
In the presence of Bpa, the TAG codon should be suppressed by the charged tRNA and full-
length protein should be synthesized.  If the incorporation of Bpa is tolerated, the mutant Ste2p 
proteins might bind pheromone resulting in the initiation of signal transduction ultimately 
resulting in growth arrest, indicated by the formation of a clear halo around the disk.  
For cells expressing wild-type Ste2p, dose-dependent halos were formed in both the 
presence and absence of Bpa indicating that Bpa addition to growth medium did not affect the 
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pheromone response (Figure 2A).  For the mutant at position Y193, no halos were formed in the 
absence of Bpa, suggesting that no functional Ste2p was expressed.  In contrast, in the presence 
of Bpa dose-dependent halos were formed indicating that Bpa was inserted in response to the 
TAG codon resulting in a functional protein.  Although the halo diameters of the Y193 mutant 
were comparable to those of the wild type strain, the zone of inhibition was not as clear and the 
edges not as clearly defined as for the wild type strain.  This is most likely due to decreased 
receptor number resulting from the Y193 mutation, as described below for the immunoblot 
results, or to more rapid desensitization of the Bpa mutant receptor, resulting in a recovery from 
the growth arrest response (31, 32).    
To compare the pheromone-dependent growth arrest, the halo diameters were measured 
for the wild-type and for each of the eight mutant receptors (Figure 2B), plotted as a function of 
α-factor concentration, and the amount of pheromone per disk necessary to generate a 25 mm 
diameter halo was determined.  In this bar graph the shorter the bar the more sensitive is the 
receptor to pheromone-induced growth arrest. For wild-type Ste2p, 0.84 ± 0.04 μg and 0.76 ± 
0.01 μg per disk for cells grown in the absence and presence of Bpa, respectively, were required 
to reach 25 mm zone of growth inhibition.  The G188TAG and Y193TAG receptors did not form 
halos in the absence of Bpa, but growth arrest did occur in the presence of Bpa.  While neither 
receptor was as sensitive as the wild type to pheromone, the Y193TAG receptor was more 































































Figure 2: Halo assays of wild-type and Bpa mutant receptors.  A. Wild-type or Y193TAG 
mutant cells were plated onto medium in the presence and absence of Bpa.  Disks containing α-
factor as indicated (µg per disk) were placed onto the lawn of cells.  B.  Halo diameters were 
measured for each TAG mutant and plotted as a function of pheromone dose, and the amount of 
α-factor required to produce a 25 mm halo was determined.  Open bars indicate cells grown in 
the absence of Bpa, filled bars indicate cells grown in the presence of Bpa, and an asterisk 
indicates no measurable halo.  In this graph the shorter the bar the more sensitive is the receptor 
to pheromone-induced growth arrest. 
125 
 
For the G115TAG and V127TAG receptors halos formed in the absence of Bpa (1.1 ± 0.06 and 2.0 
± 0.2 μg per disk respectively), indicating that there was some “read-through” of the amber stop 
codon in the absence of Bpa.  Several mutants (F55TAG, S107TAG, F204TAG, Y266TAG) did not 
support the production of halos in either the absence or presence of Bpa.  For the F55TAG, 
S107TAG, F204TAG receptors, immunoblot analysis (Figure 3) indicated that these receptors were 
expressed in the presence of Bpa, suggesting that Bpa was incorporated into Ste2p but was not 
tolerated at those positions, resulting in non-signaling receptors.  In contrast, the Y266TAG 
receptor was not functional in either the presence or absence of Bpa., and subsequent 
immunoblot analysis (Figure 3) indicated that this receptor was not expressed.  
 
Expression of Ste2p-Bpa in Cell Membranes: 
Cell membranes isolated from strain BJS21 expressing the TAG mutant constructs and 
the tRNA/tRNA synthetase pair were immunoblotted and probed with antibodies directed against 
the C-terminal FLAG epitope tag and the N-terminal 100 amino acids of Ste2p (26) to determine 
the effect of the amber stop codon on protein synthesis in the presence and absence of Bpa.  Full-
length wild-type Ste2p was synthesized in both the presence and absence of Bpa and could be 
detected by both N-terminal and C-terminal antibodies (Figure 3A and B).  The F55TAG and 
G188TAG mutants were not detected in the absence of Bpa (Figure 3A). In the presence of Bpa a 
distinct band was observed for F55TAG Ste2p and a weak but clearly discernible band was 
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Figure 3: Immunoblots of membranes isolated from cells expressing Bpa-mutant Ste2p.  In 
each panel the arrow at the left indicates the band corresponding to full length Ste2p. A. C-
terminal FLAG and B. N-terminal anti-Ste2p immunoblots prepared from cells expressing the of 
F55, G188 and Y193 receptors grown in the presence and absence of 2 mM Bpa.  In panel B the 
arrows in the lower portion of the figure indicate truncated forms of Ste2p.  C. FLAG 
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immunoblot of membranes prepared from cells expressing the F55TAG receptor in the presence of 
increasing concentrations of Bpa. 
In both cases the expression was at relatively low levels; fifteen times more protein was loaded 
for the mutants to allow for detection by immunoblot compared to that of the wild type (30 μg 
vs. 2 μg).  The G115TAG and V127TAG mutants were expressed in the presence of Bpa and their 
expression was not detected in the absence of Bpa (data not shown). In the absence of Bpa even 
though the amount of G115TAG and V127TAG receptors is below the limit of detection for the 
immunoblot, sufficient protein was made by read-through expression to give the biological 
response measured (Figure 2B).  For the Y193TAG mutant, a low level of expression was detected 
in the absence of Bpa, and this expression was enhanced in the presence of Bpa, but still not to 
the level of the wild type.  Results similar to those for the Y193TAG mutant were also observed 
for the S107TAG and F204TAG mutants (data not shown).  The Y266TAG mutant was not detected 
in the presence or absence of Bpa, indicating that this mutant is not expressed or is expressed at 
levels below the limit of detection for this system.   
C-terminally truncated forms of the receptor can be seen for the G188TAG and Y193TAG 
receptors using antibody to the N-terminus (Figure 3B).  Three major bands were detected at 23, 
21, and 18 kDa for the G188TAG and at 24, 22, and 19 kDa for the Y193TAG receptor.  These 
bands corresponded to the expected size of the non-glycosylated receptor and its two major 
glycosylated states truncated at the inserted stop codons (33). The origin of the bands of higher 
molecular weight (between 22 kD and 50 kD) in the G188TAG and Y193TAG lanes (Figure 
3B)was not investigated, although these bands are not related to the absence or presence of Bpa. 
Truncated forms of the F55TAG receptor were not detected with the N-terminus antibody (Figure 
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3B) since this antibody is directed against all 100 amino acids of the Ste2p N-terminus.  Note 
that the full-length Ste2p band intensity (52 kD) for the wild type strain is less intense as 
detected by the N-terminal antibody than that of the same membranes probed with the FLAG 
antibody (Figure 3A).  In our hands, the FLAG antibody always yields a stronger signal than the 
N-terminal antibody.   This provides an explanation for the observation that although full length 
Bpa-containing proteins can be detected with the FLAG antibody, they are barely discernable by 
the N-terminal antibody.  Expression of the full length F55TAG Bpa-containing receptor was 
enhanced in response to increased Bpa concentration in the growth medium (Figure 3C).  At low 
concentration (0.2 mM Bpa) no increase over control (no Bpa) was observed, while at higher 
concentrations (2 mM) the signal corresponding to Ste2p on the immunoblot was enhanced, 
increasing by 2.6 fold over control as measured by band intensity.  Similar results were obtained 
for the G188TAG and Y193TAG mutants (data not shown), suggesting that entry of Bpa into the 
cell is one factor determining the efficiency of Bpa insertion into the protein. 
 
Effect of Bpa-containing Peptides on the Expression of Ste2p: 
The data for the F55TAG, G188 TAG and Y193 TAG receptors described above suggests that 
the expression of Bpa-containing Ste2p could be enhanced if Bpa were more efficiently 
delivered into the cell.  It is known that small peptides enter yeast cells intact through the di-
/tripeptide transporter Ptr2p (34, 35) and upon entry into the cell, these peptides are hydrolyzed 
to free amino acids.  In an attempt to increase the delivery of Bpa into the cell, a Bpa-containing 
dipeptide (Met-Bpa) was synthesized.  Methionyl dipeptides and tripeptides are excellent 
substrates for the yeast peptide transport system (36). Cells expressing the F55TAG, G188TAG and 
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Y193TAG receptor constructs were grown in the presence and absence of Met-Bpa, and 
membranes were isolated and probed with the C-terminal FLAG antibody to detect full-length 
protein.  The expression of full length wild-type Ste2p was not affected by the presence of Met-
Bpa confirming that this compound did not interfere with normal Ste2p expression at the 
concentrations indicated (Figure 4A).  The Y193TAG mutant expressed minimal FLAG-reactive 
Ste2p in the absence of Bpa, but in the presence of Met-Bpa (Figure 4B), full length protein was 
detected.  Comparing the expression of Y193TAG grown in the presence of 0.1 mM Met-Bpa to 
that grown in the presence of 0.1 mM Bpa (Figure 4B), expression was greater for the dipeptide 
(3.1 fold increase).  At higher concentrations (0.5 mM and 2 mM) growth on Met-Bpa and Bpa 
yielded similar levels of expression (1.4 fold increase at each concentration).  Similar results 
were obtained for the F55TAG and Y193TAG mutants.  Growth on dipeptide at 0.1 mM resulted in 
2.4 fold and 2.0 fold increases in expression for the F55TAG and Y193TAG mutants, respectively.  
At higher concentrations of peptide (0.5 mM and 2 mM), growth on Met-Bpa did not increase 
Ste2p expression when compared to the same concentration of Bpa. 
 
Cell Surface Expression of Bpa Mutants Determined by Saturation Binding Assay: 
To characterize the cell surface expression and binding affinity of the Ste2p Bpa mutants 
DK102 cells expressing the F55TAG, G188TAG, and Y193TAG receptors were used in whole-cell 
binding assays. Binding of radiolabeled α-factor was detected for cells expressing the wild-type 
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Figure 4: Utilization of a peptidyl form of Bpa.  FLAG immunoblot analysis of membranes 
from cells expressing either wild type (A) or Y193TAG (B) Ste2p receptors grown in the presence 
of the dipeptide Met-Bpa or free Bpa at the concentrations indicated.  Protein loads were 2 μg 
and 30 μg for the wild type and Y193 mutant, respectively. 
 
 
In experiments using the wild type receptor, Bpa did not have any significant effect on the Bmax 
and binding affinity (Bmax= 152,470 ± 6,900 receptors per cell, KD = 9.7 ± 1.4 nM) when 
compared to cells cultured in the absence of Bpa (Bmax= 158,100 ± 6,500 receptors per cell, Kd = 
11.0 ± 1.0 nM).  For the mutant receptors, binding was not detected for cells grown in the 
absence of Bpa (data not shown).  However, for cells grown in the presence of Bpa, saturable 
binding was observed. (Figure 5).  The Bmax values for the mutants were reduced by 10- to 20-
fold compared to the wild-type receptor, which is consistent with the low level of expression 
observed in the immunoblots (Figure 3).   
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Figure 5: Whole cell saturation binding assay of [3H]α-factor to wild-type and TAG 
mutant receptors.  Cells expressing the wild-type receptor and the indicated Bpa mutants were 
grown in the presence of 2 mM Bpa.  Inset: Saturation binding assay for TAG mutant receptors 
plotted on an expanded scale.  The data represents specific binding to cells as determined by 
subtracting the binding to an isogenic strain lacking the receptor from binding to cells containing 




The binding affinity (Kd) of the Y193TAG and G188TAG mutants (12.8 ± 4.9 nM and 17.5 ± 5.7 
nM, respectively) were similar to that for the wild-type receptor, indicating that substitution of 
Bpa for the endogenous amino acid at these positions did not affect the interaction of the ligand 
with the receptor.  In contrast, for the F55TAG mutant the binding affinity was reduced to 78.9 ± 
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46.1 nM, indicating that the substitution of Bpa for phenylalanine at this position affected ligand 
binding which correlates to the relative low signaling activity of this receptor. 
 
MALDI-TOF indicates that Bpa is incorporated into Ste2p at position G188: 
To confirm the incorporation of Bpa into Ste2p, MALDI-TOF mass spectrometric 
analysis of purified wild-type and G188TAG receptors was performed.  We first carried out 
cyanogen bromide (CNBr) digest on purified wild type receptors and analyzed the fragments by 
MALDI-TOF as well as MS/MS to make sure that we can identify the Ste2p fragment containing 
Bpa using this method.  Analysis of the purified wild type receptors using the silver staining 
technique on the samples resolved on 4-12% SDS-PAGE (Figure 6A) indicated that two 
prominent bands, corresponding in molecular weight to the glycosylated and non-glycosylated 
forms of Ste2p (51-53 kDa) were present.  Immunoblot analysis confirmed that the two major 
bands were Ste2p (Figure 6B).   The MALDI-TOF analysis of the CNBr fragmented wild type 
Ste2p revealed 5 out of 10 Ste2p predicted fragments (Figure 7).  Whereas the MS/MS was able 
to identify and determined the amino acid sequences of 7 out the 10 predicted fragments 
covering about 65% of the entire Ste2p amino acid sequences.  The MS/MS fragmentation 
spectra of residues 181-189 is shown on Figure 8.   
The G188TAG receptor was chosen for to confirm the incorporation of Bpa into Ste2p 
based on nearby naturally-occurring methionine sites in Ste2p that would yield a small peptide 
(residues 181-189, easy to identify with MALDI-TOF, see Figure 7 and Figure 8) upon CNBr 






Figure 6: Analysis of purified wild type Ste2p samples.  The solubilized membranes 
containing Ste2p (with His and FLAG epitope tags) were mixed anti-FLAG resin.  The eluted 
samples from the FLAG resin were resolved on 4-12% SDS-PAGE and silver stained (A) and 
also immublotted using antibody directed against the N-terminus of Ste2p (B).  Two prominent 
bands, corresponding in molecular weight to the glycosylated and non-glycosylated forms of 
Ste2p (51-53 kDa) were present in all purified samples (A).  The bands were identified as Ste2p 






Figure 7:  MALDI-TOF analysis of CNBr digests of wild-type Ste2p.  Insert is a cartoon of 
Ste2p showing predicted CNBr fragments.  Fragments that correspond to the transmembrane 
domains and loops of receptor are shown with lines to their corresponding fragments of Ste2p.  
Peaks labeled with a dot do not correspond to any of the theoretical masses for CNBr cleavage 
fragments of Ste2p.  These are either fragments of proteins that were co-purified with Ste2p or 





Figure 8: MS/MS analysis of CNBr fragments of wild type Ste2p.  The samples were 
analyzed by reversed-phase liquid chromatography/tandem mass spectrometry. Top panel:  
MS/MS spectrum of fragment 181-189.  Inserts are one-letter amino acid residue abbreviations 
of the fragment labeled with the identified ion types.  The spectrum shows that 8 out 9 b ion 
fragments and 6 out of the 9 y ion fragments were identified.  Lower Panel:  A list of Ste2p 
CNBr fragments that were identified and sequenced.  The overall sequence covers about 65% of 
the entire Sre2p amino acid sequence. 
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The substitution of glycine (75.07 Da) for Bpa (269.30 Da) at position 188 should result in a 
mass shift of 194 Da in the 188Bpa-containing peptide.  To estimate purity and concentration of 
the samples prior to CNBr cleavage and MALDI-TOF analysis, Coomassie blue and silver 
staining of SDS-PAGE gels was performed on the purified G188TAG and wild-type receptors.  In 
the Coomassie stained gel, only two bands, corresponding in molecular weight to the 
glycosylated and non-glycosylated forms of Ste2p (51-53 kDa) were observed.  Using the more 
sensitive silver staining technique on the same sample, the same two bands were detected, along 
with some very faint bands not corresponding to Ste2p.  Immunoblot analysis confirmed that the 
two major bands were Ste2p (data not shown).  After CNBr cleavage of WT and G188TAG 
receptors, we carried out a MALDI-TOF analysis of the peptide fragments generated focusing on 
the molecular weight region corresponding to the peptide with the putative Gly to Bpa 
substitution.  
Our analysis of the CNBr-cleaved wild-type and G188TAG receptors (Figure 9), revealed a 
mass shift from 954.154 Da in wild-type to 1146.46 Da in G188TAG corresponding to a 192 Da 
increase (Figure 9, table). Other peaks of identical mass corresponding to CNBr fragments of 
Ste2p were observed in both the wild-type (1473.81Da, 1505.39 Da) and G188Bpa (1474.45 Da, 
1506.19 Da) receptors. Some peaks not corresponding to any of the theoretical masses of Ste2p 
CNBr fragments were also observed and are likely due to the degradation of Ste2p which 
occurred during the overnight incubation at 37C during CNBr cleavage or to the presence of 





Wild-type G188TAG (+ Bpa) Corresponding 
CNBr Fragment 









953.11 954.15 1147.34 1146.46 181 – 189 
1474.82 1473.81 1474.82 1474.45 55 – 69 
1506.77 1505.39 1506.77 1506.19 166 – 180 
 
Figure 9: MALDI-TOF analysis of CNBr cleavage fragments of wild-type and G188TAG 
receptors.  A peak (954.15 Da) corresponding to residues 181-189 (YFVSAVKGM) in the wild 
type receptor was not present in the G188TAG receptor.  A new peak (1146.46 Da) corresponding 
to 181-189 with Bpa at position 188 [YFVSAVK(Bpa)M] was detected.  Other peaks 
corresponding to residues 55-69 and 166-180 were observed for both wild type and G188TAG 
receptors.  Peaks labeled with a black dot do not correspond to any to the theoretical masses for 
CNBr cleavage fragments of Ste2p.  Summary of the MALDI-TOF results are shown on the 
table. The Masses of wild type fragment 181-189 and corresponding Bpa-mutant are in bold. 
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Bpa at positions F55 and Y193 can cross-link to the α-factor ligand: 
To determine if Bpa incorporated in Ste2p could be used to cross-link to and thus capture 
the α-pheromone, cells expressing the wild type,  F55TAG , G188TAG and Y193TAG receptors as 
well as cells lacking Ste2p as a control were grown in the presence of Bpa.  Membranes were 
prepared and incubated with or without [K7(biotinylamidocaproate)]α-factor, an α-factor analog 
which contains biotin on the position seven lysine of the pheromone and binds to the receptor 
with high affinity (27). Crosslinking was also evaluated in the presence or absence of 100-fold 
excess non-biotinylated α-factor. Following incubation, the membranes were exposed to UV 
light to activate capture of pheromone to the Bpa-labeled receptor.  The membranes were 
fractionated by SDS-PAGE, blotted and then probed with FLAG antibody to detect Ste2p 
(Figure 10A) or NeutrAvidin HRP to detect biotinylated ligand (Figure 10B). Wild-type receptor 
was expressed at levels higher than any of the mutant receptors as seen in previous experiments 
(Figure 3). When the immunoblots were probed with NeutraAvidin-HRP (Figure 10B) a distinct 
band was detected at the size expected for Ste2p in the F55TAG and Y193TAG receptors indicating 
that the biotinylated α-factor was cross-linked.  Despite the fact that at least 20 times as much 
wild-type Ste2p was expressed when compared to the  F55TAG or Y193TAG receptors (Figure 
10A), labeling as detected with NeutraAvidin-HRP was significantly higher for the mutants (Fig. 
7B). Moreover, labeling of the F55TAG  and Y193TAG Bpa containing receptors was reduced in 
the presence of excess non- biotinylated α-factor (Figure 10B) by 83% and 64%, respectively, as 
determined by quantitation of band density.  Similar results were observed in three independent 
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Figure 10:  Cross-linking of biotinylated α-factor into Bpa-containing receptors.  
Membranes prepared from cells expressing the wild-type, F55TAG, G188TAG, and Y193TAG 
receptors grown in the presence of Bpa were incubated with biotinylated-α-factor (1 μM) in the 
presence (+) or absence (-) of non-biotinylated-α-factor (100 μM) as indicated in the figure.  
Membranes were also prepared from cells lacking the receptor as a negative control.  A:  
Following photoactivation, membranes (2 μg for wild-type and 25 μg for mutants and the 
negative control) were immublotted and probed with FLAG antibody to detect Ste2p.  B:  
Membranes (25 μg for each lane) were immunoblotted and probed with avidin-HRP to detect 




For membranes prepared from cells lacking the receptor, as well as for the WT and the G188TAG 
receptors a faint band at approximately 50 kD was observed (Figure 10B) that was dependent 
upon incubation of the membranes with biotinylated pheromone.  The signal was not affected by 
the presence of non-biotinylated pheromone, and could be detected regardless of the Bpa-
containing status of the receptor.  Thus this signal is the result of non-specific association of the 






Many experiments have been performed with a variety of methodologies to provide a wealth 
of knowledge concerning GPCR structure and function.  However, an understanding of the 
mechanism of activation is still in its infancy.  The gold-standard would be to obtain crystal 
structures of the GPCR in both the resting and active state.  Thus far, bovine rhodopsin and the 
human β-adrenergic receptor are  the only GPCRs to have had their crystal structure solved (37-
39). For rhodopsin, the receptor was crystallized in the inactive state, although recent reports of 
an active state crystal at moderate to low resolution (2.7–5.5 Å) have been published  (40).  
Crystallization of the β-adrenergic receptor required expression as a fusion protein (39) or 
interaction with an inverse agonist (38) to stabilize receptor conformation.  The use of unnatural 
amino acid replacement provides an alternate method for examining receptor structure as well as 
exploring the changes which occur in GPCRs upon receptor activation.   
In an earlier study a fluorescent amino acid was incorporated into a GPCR, the neurokinin-2 
receptor, using heterologous expression in Xenopus oocytes (12).  In this communication we 
report the first evidence that an unnatural amino acid can be incorporated into the GPCR Ste2p 
expressed in its native environment in the yeast cell and still retain function.  The incorporation 
was verified by mass spectrometry, and our studies indicate that once incorporated the 
photoactivatable Bpa in Ste2p can be used to covalently link the α-factor ligand to the receptor.   
Although there are many examples in the literature of photoactivated cross-linking of ligand to 
receptor, in all those cases the ligand contained the photoactivatable moiety. To our knowledge 
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our study represents the first example of cross-linking of ligand to a GPCR in which the receptor 
contained the photoactivatable group used to “capture” the ligand.   
We demonstrated that incorporation of Bpa into both the F55 (located in TM1) and Y193 
(located in EL2) receptors resulted in capture of biotinylated pheromone.  Photochemical capture 
of the ligand could be largely inhibited by the presence of excess non-biotinylated pheromone.  
While F55 is positioned in the binding pocket of the receptor and was expected to interact with 
the pheromone (27), the ability of Y193 to capture the ligand suggests a possible role for EL2 in 
ligand binding. Previous studies using domain swapping indicated that EL2 was not a 
determinant of ligand specificity of the S. cerevisiae and S. kluyveri α-factor receptors (41). Thus 
our observation of a putative contact between the EL2 region of Ste2p and α-factor indicates the 
need for further study of EL2-α-factor interactions.  In contrast the G188 receptor was not 
functional with respect to ligand capture, despite the fact that this receptor was determined to 
contain Bpa by mass spectrometry analysis (Fig. 6).  The failure of the G188 receptor and the 
wild-type receptor to capture α-factor provides a critical control showing that the crosslinking 
with F55 and Y193 represent residue specific receptor-ligand interactions.  
In addition to ligand capture experiments, we can envision other applications of this 
mutagenesis methodology such as studying changes in domain-domain interactions upon ligand 
binding which will shed light on the receptor activation mechanism. An advantage of using the 
orthologous tRNA/aminoacyl tRNA synthetase pair to incorporate Bpa into Ste2p in the yeast 
cell is that the GPCR remains in its native environment, and is thus able to interact with 
downstream effector molecules, such as the heterotrimeric G-proteins, thus making assessment 
of both ligand binding and signal transduction possible.   
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Although the use of unnatural amino acids has the potential to answer very important 
questions in GPCR biology, there are still obstacles to overcome.  In the experiments presented 
in this paper, eight mutant STE2 constructs (F55TAG, S107TAG, G115TAG, V127TAG, G188TAG, 
Y193TAG, F204TAG and Y266TAG) were created with the amber TAG stop codon engineered at 
different sites within the open reading frame.  Theoretically, when the cells expressing these 
mutant receptors were grown in the presence of Bpa, the unnatural amino acid would be 
incorporated into the protein by the cognate tRNA/aminoacyl-tRNA synthetase also expressed in 
the cell.  In the absence of Bpa, it was expected that the TAG codon would result in termination 
of protein synthesis, resulting in a truncated protein.  For the mutants G188TAG and Y193TAG, this 
was the case –in the presence of Bpa, cells responded to pheromone (Fig. 2), full-length receptor 
was detected by immunoblot analysis (Fig. 3) and both bound ligand (Fig. 5) with near wild-type 
affinity. However,  mutants with TAG amber stops at positions G115 and V127 exhibited 
significant amounts of inefficient stop codon recognition, or read-through, expression, as 
evidence by halo assay which in the context of the present experiments results in the production 
of full-length protein even in the absence of Bpa.   
The efficiency with which nonsense codons – such as the UAG amber stop in mRNA – are 
suppressed can be affected by the context of the adjacent codons and poses a challenge (42).  In 
S. cerevisiae nucleotides within 6 bases flanking the stop codon can influence the efficiency of 
termination (43) and it has been determined that “backup” or tandem stop codons can be found 
three codons downstream of the authentic stop for some genes (44).  In the case of read-through, 
non-cognate tRNA species can misread the stop codon and insert an inappropriate amino acid.  
In the case of the UAG codon in yeast mRNA, the tRNAGlnGUC can insert glutamine at the stop 
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codon when it is present in a context unfavorable for release factor recognition (45).  In another 
tRNA/aminoacyl tRNA synthetase system evolved to incorporate the fluorescent amino acid 
dansyl-alanine in response to the amber stop codon,  read-through in the absence of dansyl-
alanine was eliminated by mutation of the aminoacyl-tRNA synthetase to increase selectivity of 
the enzyme for dansyl-alanine (18).  Thus in order to optimize the system for insertion of Bpa 
into Ste2p, genetic manipulations in protein translation machinery (i.e. ribosomes, tRNAs, etc.) 
might be warranted.  Interestingly, for the mutants F55TAG, S107TAG, and F204TAG protein 
function, but not expression, was eliminated when the cells were grown in the presence of Bpa 
(Fig. 2 and Fig. 3).  This indicates the unnatural amino acid was incorporated into the protein, 
but did not result in a signal-transducing receptor at the cell surface.  The presence of mutant 
Ste2p or other classes of GPCRs that bind ligand but do not signal has been extensively reported 
(3). Indeed binding without signaling is characteristic of antagonists and mutation of GPCRs to 
preferentially recognize antagonists has been documented (29, 30).   
Incorporation of Bpa into the various TAG mutant receptors was not 100% efficient, as 
can be seen by the presence of truncated receptors on immunoblots (Fig. 3B), which could 
potentially interfere with the function of a full length receptor.   However, previous studies 
showed that overexpression of 14 different truncated Ste2p receptors failed to produce any 
significant alteration in Ste2p function (46).  Thus loss of signaling function (F55TAG , S107TAG, 
F204TAG) in the halo assays that we observed likely results from intolerance of Bpa at the 
positions into which it was inserted, rather than to the interference by truncated receptors. 
Using the orthologous tRNA/aminoacyl-tRNA synthetase pairs to incorporate Bpa at the 
engineered amber stop codon requires the presence of Bpa in the cytoplasm at sufficient 
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concentration to allow for effective charging of the tRNA.  We have utilized a novel means to 
supply Bpa to yeast cells via the di/tripeptide transport system that is common to many 
eukaryotes (47, 48).  In yeast, di/tripeptides as well as oligopeptides (tetra/pentapeptides) are not 
cleaved outside the cell, but are transported intact across the plasma membrane (49, 50). 
Expression of the Y193TAG receptor, as well as the F55TAG and G188TAG receptors was 
noticeably greater when the cells were grown in the presence of Met-Bpa at 0.1 mM when 
compared to Bpa (Fig. 4).  Since peptide transporters are ubiquitous in living cells (48), this 
method might be used to enhance the delivery of unnatural amino acids and extend this approach 
to amino acids that cannot enter cells through amino acid permeases. 
In summary, in this report we provide the first evidence that the unnatural photoactivatable 
amino acid p-benzoyl-L-phenylalanine can be incorporated into a G protein-coupled receptor in 
its native cell. Several of the mutant receptors responded to their natural ligand, the α-factor 
tridecapeptide, and bound this molecule with nM affinity. The mutant receptors were expressed 
at the membrane at levels from 5 to 10% of the wild-type receptor under identical conditions. 
Mass spectrometry proved that Bpa was incorporated at the expected position for the G188TAG 
receptor. Expression could be increased when the unnatural amino acid was delivered as a 
dipeptide via the peptide transport system of S. cerevisiae. Two Bpa-containing receptors were 
able to capture ligand after photoactivation providing evidence for the utility such labeled 
GPCRs to determine ligand-receptor interactions.  These results set the stage for the use of 
unnatural amino acids technology in exploring the structure and function of integral membrane 
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with the biochemical studies, Julie Maccarone determined the phenotypes of the Ste2p mutants 













G-protein coupled receptors (GPCRs) are integral membrane proteins with seven 
transmembrane (TM) helical segments, which are known to play important roles in cell 
communication by activating intracellular events through both G protein-dependent and –
independent processes (1-3). These receptors are encoded by the largest gene family in 
mammals, constitute the main target of prescribed drugs on the market, and still represent the 
most promising targets for new drug development (1, 3-6).  Although these GPCRs are part of a 
very complex receptor-signaling system, this complexity is even higher when considering that 
these receptors can organize into homo-dimers and homo-oligomers (7-11). However, the 
existence of such high ordered GPCRs assemblies in native systems and their functional 
consequences remain unsolved (12, 13). 
GPCRs have been observed to exist in membranes as monomers, dimers or oligomers in 
intact cells and in membranes prepared from cells, with the dimer often regarded as the minimal 
oligomeric arrangement required for G protein coupling.  Animal model studies show that GPCR 
oligomers play an essential role in human pathologies (4, 11, 13).  Although the monomer of 
GPCRs is capable of activating G proteins, the dimeric form couples the G protein more 
efficiently in some GPCRs (7, 14, 15).  One of the earliest studies to show evidence of GPCR 
dimerization demonstrated that overexpressed, differentially tagged β2-adrenergic receptors 
(β2AR) form dimers and also showed that a peptide corresponding to the TM6 (transmembrane 
domain 6) region of the β2AR could be used to disrupt the dimer and decrease receptor function 
implying that TM6 is important for dimer formation in β2AR (16).  Dimers between the two 
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different GABA receptors, GABABR1 and GABABR2, were shown to be required to form fully 
functional GABA receptors.  The study also suggested that both GPCR subunits in a dimer seem 
to have distinct roles in the complex and that the GABABR1 seems to be responsible for ligand 
binding while the GABABR2 is required for G protein coupling (12, 13).  Thus, whereas some 
GPCRs such as the metabotropic glutamate (mGlu) receptors are strict dimers, other GPCRs like 
the GABA receptors form oligomers that may couple with only one G protein (13). 
Detailed examination of the crystallographic structure of rhodopsin suggested that TM1, 
TM2, TM4, TM5, the second intracellular loop (IL2), and the third intracellular loop (IL3) are all 
involved in the formation of rhodopsin oligomers.  Thus, it seems that oligomerization of 
rhodopsin-like family of GPCRs involves more than one contact (7, 14, 15).  Some GPCRs have 
been shown to use different oligomerization interfaces to achieve functional activities (13).  The 
use of truncated receptors and other studies suggest that GPCR dimer formation may involve 
domain swapping or direct contacts of the receptor subunits.  Mutation and computational 
analyses all provide evidence of the involvement of TM5, TM6 and IL3 in the dimerization 
interface in both the swapping and direct-contact models in some GPCRs tested (9).  Even 
though many physiological activities have been assigned to the role of GPCRs oligomers, it is 
not clear whether GPCR oligomerization plays a role in the chaperoning and cell transport of 
receptors, or in the control of signaling specificity and efficacy.  Nevertheless, evidence of 
dimerization in all GPCR families makes it an important phenomenon that needs investigation 
(4, 11, 13). 
The yeast Saccharomyces cerevisiae GPCR, Ste2p, has been shown to form dimers in 
intact cells and membranes.  Co-expression of Ste2p tagged with the cyan or yellow fluorescent 
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proteins (CFP or YFP) resulted in efficient fluorescence resonance energy transfer (FRET).  The 
study also showed that dominant-interfering receptor mutants inhibited signaling by interacting 
with wild-type receptors rather than by sequestering G proteins (17, 18).  Analysis of Ste2p 
truncated mutants showed that the N-terminal extracellular domain, TM1, and TM2 are all 
involved in receptor oligomerization (19).  Recently, disulfide cross-linking studies have also 
shown TM1 and TM4 as dimer contacts in Ste2p similar to that of the rhodopsin family of 
GPCRs (20).  Our lab has also shown that TM7 is a dimer contact in Ste2p (Kim, Heejung, 
personal communication).  Subunits of Ste2p in a dimer complex have been found to be activated 
independently rather than cooperatively by agonist, but function together to promote G protein 
activation, possibly by contacting different subunits or regions of the G protein (21).  Despite the 
intensive studies on Ste2p dimer formation, the role and organization of the dimers are not well 
defined.   
 This study identifies residues in IL3, the intracellular loop between TM5 and TM6, as a 
dimer contact in Ste2p.  Residues in IL3 may be critical for dimer stability during receptor 
activation that involves rearrangement of the helices.  Overall replacement of individual residues 
with cysteine did not significantly affect Ste2p activity, with the exception of R233C that 
displayed about 70% of wild type activity.  Dimer formation via a Cys-Cys disulfide bond was 
reduced at the cytoplasmic ends of TM5 and TM6 in the presence of ligand implying that 
activation of Ste2p involves ligand-induced conformational changes in these portions of TM5 
and TM6.  This study is the first to identify IL3 as a dimer contact and also pinpoint specific 
residues that may be involved in stabilizing the oligomer form of Ste2p.  We also propose an 




Materials and Methods 
Media, Reagents, and Strains and Transformation: 
Saccharomyces cerevisiae strain LM102 [MATa, bar1, leu2, trp1, ura3, FUS1-
lacZ::URA3, ste2∆ (22)] was used for Step2 growth arrest and FUS1-LacZ assays and the 
protease deficient strain BJS21 [MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 
ste2::KanR (23)] was used for protein isolation and immunoblot analysis.  The STE2 mutant and 
GPA1 plasmids were co-transformed by the method of Geitz (24) into LM102, and BJS21 cells 
along with GPA1 mutant plasmids.   
For all transformation cells were cultured in their selective media and grown to mid-log 
phase at 30oC with shaking (200 rpm) overnight. The cells (5 ml culture) were then harvested 
and washed with sterile water and 100 mM LiAc (lithium acetate) by centrifugation at 4000g for 
5 minutes.  The pellet was resuspended in transformation mixture [240µl of 50% PEG 
(polyethylene glycol); 36µl of 1.0 M LiAc; 25µl of salmon sperm DNA; and 50µ water with 
plasmid DNA (5 µg)].  The mixture was incubated at 30o C for 30 minutes and then heat shock at 
42o C for 25 minutes.  The cells were separated from the mixture and resuspended in sterile 
water for plating on selective media.  Transformants were selected by growth on minimal 
medium (25) lacking tryptophan and uracil (designated as MLTU) or tryptohan and histidine 
(designated as MLTH) to maintain selection for the plasmids.  All media components were 





Cysteine scanning mutagenesis: 
C-terminal FLAG and His tagged STE2 with the two cysteine residues (Cys59 and 
Cys252) substituted with serine and cloned into the plasmid p424-GPD to yield plasmid pBEC2 
(22) was used for expressing Ste2p.  The plasmid pBEC2 was engineered by site-directed 
mutagenesis to replace 22 residues, one at a time, in Ste2p (A228-I249) with cysteine.  The open 
reading frame of GPA1 was PCR amplified from the plasmid YepGαβγ (26) and cloned into the 
plasmid p426-GPD (27) to yield plasmid pBUG6.  Primers used for the mutagenesis are listed in  
Table 1.  The sequence of all cysteine mutants was verified by DNA sequence analysis 
completed by the molecular biology resource facility located on the campus of the University of 
Tennessee.  Mutagenic and sequencing primers were purchased from Invitrogen (Carlsbad, CA) 
 
Membrane extraction and Immunoblots: 
BJS21 cells expressing STE2 and GPA1 constructs grown in their selective media were 
used to prepare total cell membranes isolated as previously described (28).  Cells were harvested 
and lysed by agitation with glass beads in 700 μL of HEPES buffer (50 mM HEPES, 150 mM 
NaCl, pH 7.5) and the following concentrations of protease inhibitors: 1.0 mM leupeptin, 10 μM 
pepstatin A, and 5.0 mM phenylmethanesulfonyl fluoride.  The lysate was cleared by 
centrifugation at 3000g for 2 minutes. The membrane fraction was harvested by centrifugation at 
15000g for 30 minutes and was then resuspended in the HEPES buffer with 20% glycerol. 
Protein concentration was determined by BioRad (BioRad, Hercules, CA) protein assay (22).  
For immunoblot analyses the membrane extract was solubilized in SDS sample buffer (BioRad, 
Hercules, CA) and 5 µg were fractioned by SDS-PAGE.   
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Table 1: Primers used for the mutagenesis. 
 
 
Blots were probed with FLAG antibody (Sigma/Aldrich Chemical, St. Louis, MO) to detect 
Ste2p.  The signals generated were analyzed using Quantity One software (Version 4.5.1) on a 
Chemi-Doc XRS photodocumentation system (BioRad, Hercules, CA). 
 
Growth Arrest Assays: 
LM102 cells expressing C-terminal FLAG and His tagged Ste2p were grown at 30 ºC in 
MLT (minimal medium (25) lacking tryptophan), harvested, washed three times with water and 
resuspended at a final concentration of 5 x 106 cells/ml (23).  Cells (1 ml) were combined with 
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3.5 ml agar noble (1.1 %) and poured as a top agar lawn onto MLT medium agar plates.  Filter 
disks (BD, Franklin Lakes, NJ) impregnated with α-factor pheromone (0.125 – 2.0 μg) were 
placed on the top agar.  The plates were incubated at 30 ºC for 18 hours and then observed for 
clear halos around the discs.  The diameter of halos around the discs were measured and 
analyzed by linear regression analysis using Prism software (GraphPad Software, San Diego, 




LM102 cells expressing C-terminal FLAG and His tagged Ste2p Cys mutants were 
grown at 30 ºC in selective media, harvested, washed three times with fresh media and 
resuspended at a final concentration of 5 x 107 cells/ml.  Cells (0.5 ml) were combined with α-
factor pheromone (final concentration of 1 μM) and incubated at 30 ºC for 90 minutes.  The cells 
were transferred to a 96-well flatbottom plate in triplicates, permeabilized with 0.5% Triton X-
100 in 25 mM PIPE buffer and then β-galactosidase assays were carried out using fluorescein di-
β-galactopyranoside (Molecular Probes, OR) as a substrate (29).  The reaction mixtures were 
incubated at 37oC for 60 min and 1.0 M Na2CO3 was added to stop the reaction.  The 
fluorescence of the samples (excitation of 485nm and emission of 530 nM) was determined using 
a 96-well plate reader Synergy2 (BioTek Instruments, Inc., Winooski, VT).  The data were 
analyzed using Prism software (GraphPad Software, San Diego, CA).  The experiments were 





Membrane proteins (in HEPES buffer, 20% glycerol) extracted from BJS21 cells 
expressing Ste2p mutants or co-expressing with Gpa1p mutants were treated with Cu-P (1.0 μM 
Cu and 3.0 μM 1,10-phenanthroline) according to optimum concentrations for Cu-P determined 
in part 5 of the dissertation,  Membrane samples were incubated  with Cu-P at room temperature 
for 30 min.  The reaction was quenched by addition of EDTA to final concentration of 10 mM.  
The cross-linked samples were resuspended in non-reducing SDS sample buffer (BioRad, 
Hercules, CA) and resolved on SDS-PAGE as described above.  The disulfide reaction was 
reversed by reducing with 4% 2-mercaptoethanol (β-ME) in the SDS sample buffer before 
resolving it on SDS-PAGE.  To investigate the effects of ligand or GTP on cross-linking,  
membrane fractions were incubated in HEPES buffer containing 5μM α-factor 
(WHWLQLKPGQPNle12Y) or 20 μM α-factor antagonist (WLQLKPGQPNle12Y) in the 
presence or absence of 0.1 mM GTP or GTP-γ-S (1) before Cu-P treatment. 
For in vivo cross-linking, cells were grown to mid-log phase, harvested and washed with 
water by centrifugation (4000g for 5 min).  The cells were resuspended in 100 mM LiAc and 
incubated at 30 oC for 30 min with mixing. After centrifugation, the cells were resuspended in 
25% PEG with 250 mM LiAc for another 60 min incubation.  Cells were washed with HEPES 
buffer three times after LiAc treatment.  For whole cell ligand binding prior to cross-linking, 
cells were first incubated with KF (10 mM) and  NaN3(10mM) in HEPES buffer at room 
temperature for 15 min to inhibit receptor endocytosis (30) and then ligand added to final 
concentrations of 5μM for native α-factor or 20 μM for α-factor antagonist for another 30 min.  
Disulfide cross-linking was induced by adding Cu-P to final concentrations of 0.5 mM Cu and 
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1.5 mM 1,10-phenanthroline (20).  Control cells without cross-linking were treated with 
equivalent volume of HEPES buffer.  The mixture was incubated at room temperature for 60 min 
with end-over-end mixing.  EDTA (ethylenediamine-tetraacetic acid) and NEM (N-
Ethylmaleimide) to final concentrations of 10 mM were added to stop the reaction.  The cells 
were washed three times with HEPES buffer containing EDTA (10 mM) and NEM (10 mM).  
Membrane extraction was carried as described above with HEPES buffer containing 10 mM 
EDTA/NEM.  Reducing condition of disulfide bond were carried out by resuspending membrane 
samples in SDS-PAGE sample buffer containing 4% β-ME and incubating at room temperature 
for at least 15 min. 
 
Prediction and modeling: 
All models of 3-D structures were generated by the Phyre Structural Bioinformatics 
Group prediction tools (31).  The structures were viewed and labeled with the PyMOL pdb 







Phenotypes of Ste2p IL3 Cys substitution mutants: 
The signaling activities of the cysteine mutants were examined by α-factor induced 
growth arrest and FUS1-LacZ induction assays.  The growth arrest assay is a sensitive test that 
measures the ability of cells expressing Ste2p to maintain pheromone-induced cell division arrest 
at the G1 phase over a period of time.  One of the early responses of the yeast cell to pheromone 
is the transcription of the gene FUS1.  The FUS1 gene product is involved in the fusion of cells 
during conjugation. The strains used in this study contain a reporter gene construct consisting of 
a fusion between FUS1 promoter and the lacZ gene encoding the enzyme β-galactosidase (32).  
This allows for rapid, sensitive detection of mating pathway activation by assessing β-
galactosidase activity in response to mating pheromone (29).   
The Cys-less Ste2p engineered as the background for the specific cysteine mutations has 
been previously shown to have biological activities identical to the wild type receptor as 
determined by assays used in our lab.  Both endogenous cysteine residues at positions 59 and 
252 were substituted with serine to create a Cys-less receptor (22).  We grouped the intracellular 
loop 3 (IL3) residues into three categories based on their phenotypes as follows:  group 1 (TM5-
IL3 boundary) residues, L228-S232; group 2 (middle IL3) residues, R233-Q240; and group 3 
(IL3-TM6 boundary) residues, F241-I249.  Ste2p with mutated group 1 residues (L228C-S232C) 
were expressed at levels similar to the Cys-less receptor as determined by FLAG immunoblot 




Figure 1: Phenotype of IL3 Cys mutants.  A: Immunoblot analysis of IL3 Cys-mutants 
expression.  The plots were probed with anti-FLAG to detect Ste2p.  B: Representative images of 




They also exhibited biological activities similar to the Cys-less receptor.  Group 2 (R233C-
Q240C) mutants demonstrated 65-75% of Cys-less receptor expression level.  These mutants 
have growth arrest activities similar to that of the Cys-less receptor, with the exception of 
R233C.  The R233C mutant displayed about 65% activities relative to the Cys-less receptor.  
However, the FUS1-LacZ gene induction activities were less than the Cys-less receptor for the 
group 2 mutants.  The differences in the growth arrest and Fus1-LacZ activities may be due to 
the fact that whereas growth arrest assay measures overall, long-term effects of the pheromone 
response pathways, the Fus1-LacZ measures the induction of a specific gene (Fus1) in the 
pathway.  Hence, the group 2 mutations affected the induction of Fus1 but overall did not have 
significant effects on cell cycle arrest required for mating.  The group 3 mutants (F241C-I249C) 
have characteristics similar to those of the group 1 mutants. They are expressed at levels similar 
to the Cys-less receptor and have only slightly reduced (80-90%) growth arrest activities.  
However, the FUS1-lacZ activities vary among these mutants.  Overall the substitution of 
cysteine into various positions in IL3 of Ste2p did not significantly affect receptor activity with 
the exception of the mutation of R233C, which displayed the strongest defects in all the assays 
tested.  A summary of the mutant phenotypes is shown in the table below on Table 2. 
 
Dimer formation in IL3 Cys-mutants: 
The IL3 Cys mutants were generated to determine possible interactions with Gpa1p Cys 
mutants (see part V of dissertation), however preliminary Cu-P treatment of Ste2p R233C and 
R234C mutants showed that all the samples treated with Cu-P had increased dimer formation 
which could be reversed by reduction with 4% β-ME (Figure 2).   
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Table 2: Phenotypes of IL3 Cys substitution mutants. 










L228C 100 90 110 
A229C 100 90 75 
I230C 100 85 100 
R231C 100 90 100 





R233C 65 70 60 
R234C 75 100 80 
F235C 75 100 80 
L236C 75 90 70 
G237C 75 100 75 
L238C 75 100 75 
K239C 75 100 80 






F241C 100 100 80 
D242C 85 85 85 
S243C 100 95 100 
F244C 100 90 95 
H245C 90 90 70 
I246C 100 90 70 
L247C 100 90 75 
L248C 100 85 95 





Figure 2: Copper treatment of Ste2p Cys mutants, R233C and R234C.  The samples were 
untreated (lanes, -, -) or treated with 1.0 μM Cu-P (lanes, [-, +] and [+,+]).  Dimer formation in 
R233C and R234C Ste2p mutants increased with copper oxidation.  This was reversed by the 
reducing agent βME (4%) after the Cu-P treatment (compare lanes, [+, -] and [+, +]). 
 
The IL3 of rhodopsin has been identified to be involved in oligomerization (8).  We therefore 
hypothesized that IL3 of Ste2p may be involved in dimer (oligomer) formation.  To investigate 
this we treated all IL3 Cys mutant receptors generated in this study with Cu-P to determine 
whether dimers were formed.  The results showed that the IL3 Cys mutant receptors showed 
increased dimer formation when treated with Cu-P varying from 5% to 90% of monomer forms 
(Figure 3).  The entire group 1 (L228C-S232C) and group 3 (F241C-I249C) residues, with the 
exception of A229C and H245C, had about 5-10% dimer formation.  In contrast, Group 2 
(R233C-Q240C) mutants showed elevated (45-95%) dimer formation.  The higher degree of 
dimerization in these residues suggested that TM5-TM6 may be in a dimer interface for Ste2p.  










Figure 3: Analysis of IL3 Group 1 and 2 Cys-mutants for the ability to form dimer via a 
disulfide cross-links.  The receptors were co-expressed with or without wild type Gpa1p.  The 
blots were probed with anti-FLAG antibody to detect the presence of Ste2p at either the 
monomer (M, 53-55 kDa) or dimer (D, 106-110 kDa) positions, respectively. Each preparation 
was untreated (lanes -, -) or treated with Cu-P (lanes -, +) or with α-factor and Cu-P (lanes α, +) 
or with α-factor antagonist and Cu-P (lanes a, +). 
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However, we were concerned that protein-protein interactions may have occured using 
membranes which would not ordinarily occur in an intact cell. To determine whether dimer 
formation was the same or different in whole cells in comparison to membrane preparations, an 
in vivo Cu-P treatment assay was performed.  Normally, Cu-P is not permeable to yeast cells; 
therefore, we adapted a method to permeabilize cells to Cu-P.  Genetic transformation of the 
yeast S. cerevisiae by plasmid DNA is possible by pretreatment of the cells with LiAc and PEG.  
The treatment of cells with LiAc makes their membrane/cell wall more permeable without 
killing the treated cell; the treatment is temporary since the cells recover and can grow when 
cultured in growth media (24, 33).  This approach was used to make the yeast strains expressing 
Ste2p Cys-mutants permeable to Cu-P for in vivo (whole cell) induced disulfide cross-linking.   
 Seven IL3 Cys-mutants were treated with Cu-P in vivo, using live permeabilized cells 
(Figure 4).  Microscopic observation (Figure 4A) showed that the cells were not morphologically 
affected by Cu-P treatment and these cells were fully viable upon plating on growth media (data 
not shown).  Comparison of dimer formation in vitro and in vivo (Figure 4B-C) shows that the 
dimer formation is not due to an artifact of the membrane preparation and does indeed occur in 
intact cells.  On SDS-PAGE (4-12% gradient), the monomer, dimer, tetramer, hexamer were 
observed (Figure 4E).  The monomer form predominates in SDS-PAGE because the non-
covalent bonds between receptors in the oligomer are broken by the conditions of the SDS-
PAGE and yet some of these interactions persist as seen in the cysless receptor samples.  IL3, 
TM5 and TM6 all have been identified as dimer interface in separate studies using different 
receptors (7, 8, 16).  We therefore propose that the cytoplasmic ends of TM5 and TM6 including 






Figure 4: In vivo Cu-P treatment of IL3.  The receptors were co-expressed with wild type 
Gpa1p.  A: Images of cells at various stages of treatments during whole cell disulfide cross-
linking Cu-P treatment.  B: The blot images of seven mutants selected for whole cell cross-
linking.  The samples were probed with anti-FLAG antibody to detect the presence of Ste2p at 
either the monomer (M, 53-55 kDa) or dimer (D, 106-110 kDa) positions, respectively. Each 
preparation was untreated (lanes -, -) or treated with β-ME (lanes -, +) or Cu-P (lanes +, -) or 
with Cu-P and β-ME (lanes +, +). C: comparison of in vitro with in vivo cross-linking. D; Blot of 
whole cells expressing L228C and I249C treated with Cu-P in the presence of absence of ligand 
or antagonist.  E:  Blot image of Cys-less and K239C showing oligomer formation in Ste2p. 
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Conformational changes in TM5 and TM6 upon α-factor binding: 
Since the cross-linking of Ste2p to Gpa1p was carried out in the absence and presence of 
ligand (α-factor), the Cu-P treatment of IL3 Cys-mutants was repeated on membranes incubated 
with α-factor prior to treating with Cu-P.  While ligand binding did not affect dimer formation in 
receptors expressing receptors carrying mutations in residues R23I to I246 (See Figure 3 lanes 
labeled “α”), a reduction in dimerization was observed for mutation in the TM5 (L228C and 
I230C) and the TM6 boundaries (L247C to I249C).  The results suggest that the TM5 and TM6 
cytoplasmic boundaries undergo conformational changes upon α-factor binding to Ste2p such 
that these residues are shifted away from the “dimer interface”, hence no dimers were formed 
when Cu-P was added.  These α-factor-induced reductions in dimer formation in IL3 were also 
observed in vivo (Figure 4D) when whole cells were used for the disulfide cross-linking. The 
conformational changes at the cytoplasmic ends of TMs especially TM5 and TM6 are thought to 
play an important role in GPCR activation (2, 34, 35).  We therefore suggest that conformational 
movements occur at the cytoplasmic end of TM5 and TM6 in Ste2p upon ligand binding.   
 
Antagonist induced dimer reduction similar to agonist in the absence of Gpa1p: 
Biochemical and cross-linking studies using both photoaffinity (36) and DOPA-mediated 
reactions  (see part 2 of this dissertation) in our lab have shown that the N-terminus of α-factor is 
necessary for activation but not binding to Ste2p and that position 1 of α-factor most likely 
interacts with residues in the region of S251-M294 (TM6-EL3-TM7) of Ste2p.  The question of 
whether the N-terminus of α-factor is important for the dimer reduction at the cytoplasmic ends 
of TM5 and TM6.  The Cu-P treatment of receptors expressing the mutant IL3 residues were 
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repeated this time with both 5 μM α-factor (WHWLQLKPGQPNle12Y) and 20 μM α-factor 
antagonist (WLQLKPGQPNle12Y) binding before the Cu-P treatment.   Because the α-factor 
antagonist was shown to bind to Ste2p at a slightly lower affinity than that of  native α-factor 
(37), we therefore used 4-fold amount of α-factor for antagonist to make sure all Ste2p molecules 
were saturated.  The results (Figure 3, compare lanes label “α” and “a”) showed that both the 
native α-factor and antagonist almost completely blocked dimer formation at the TM5 (A228C 
and I230C) and TM6 (L247C to I249C) boundaries.  Thus, the first two amino acids (WH) of α-
factor may be essential for the reduction of dimer formation observed at the TM5 and TM6 
cytoplasmic ends of Ste2p. 
 
Gpa1p expression affected dimer formation in IL3: 
 The recent crystal structure of opsin with the 11 C-terminal residues of the Gα protein led 
the authors to conclude that the active conformation of this GPCR was stabilized by Gα (38).  
Another study also reported GTP may affect the interaction of receptor with Gα (39).  We 
therefore determined whether co-expression (similar amount) of Ste2p and Gpa1p in the 
presence or the absence of GTP will affect IL3 dimer formation.   To test these effects we co-
expressed all the IL3 Cys-mutants with wild-type Gpa1p under the control of the same promoter 
and repeated the Cu-P treatment.  Preliminary studies with A228C and I249C of IL3 indicated 
the presence of approximately equal levels of Ste2p and Gpa1p led to increased dimer formation 
in IL3 in comparison to when more Ste2p was expressed than was Gpa1p.  In contrast, GTP 
addition had no affect on dimer formation with either equal level of Ste2p and Gpa1p expressed 




Figure 5: Effects of Gpa1p and GTP on IL3 conformation. The receptors, A228C and I249C 
were co-expressed with or without wild type Gpa1p and their membranes treated with or without 
ligand in the presence or absence of 0.1mM GTP prior to Cu-P treatments.  The blots were 
probed with anti-FLAG antibody to detect the presence of Ste2p at either the monomer (M, 53-
55 kDa) or dimer (D, 106-110 kDa) positions, respectively.  Each preparation was untreated 
(lanes -, -) or treated with Cu-P (lanes -, +) or with α-factor and Cu-P (lanes α, +) or with α-
factor antagonist and Cu-P (lanes a, +). 
 
The results (Figure 6) of Cu-P treatment of all IL3 Cys mutants co-expressed with Gpa1p show 
that L228C and H245C that did not form dimer in the absence of Gpa1p expression (see Figure 










Figure 6: The Effects of Gpa1p expression on dimer formation.  The receptors were co-
expressed with wild type Gpa1p.  The blots were probed with anti-FLAG antibody to detect the 
presence of Ste2p at either the monomer (M, 53-55 kDa) or dimer (D, 106-110 kDa) positions, 
respectively.  Each preparation was untreated (lanes -, -) or treated with Cu-P (lanes -, +) or with 
α-factor and Cu-P (lanes α, +) or with α-factor antagonist and Cu-P (lanes a,+). 
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While dimer formation in receptors carrying mutations in residues S232-I246 was not affected, a 
reduction in dimerization was observed for mutation in the TM5 (L228C, A229C, I230C, and 
R231C) and the TM6 boundaries (L247, L248C, and I249C) in presence of α-factor (Figure 6, 
see lanes labeled “α”).Although α-factor reduced dimer formation at the TM5 and TM6 
cytoplasmic ends, the antagonist was only able to reduce dimerization by about 50% (Figure 6, 
compare lanes labeled “α” and “a”).  Thus, antagonist may induce a different (or partial) 
conformation from α-factor-induced changes that are required for Ste2p activation in presence of 
an equal amount of Gpa1p.  The first two amino acids of the ligand that are lacking in the 
antagonist may be essential for proper changes in the TM5 and TM6 of Ste2p.  The co-
expression of Ste2p and Gpa1p did not have any significant effects on the group 2 residues 
(R233C to Q240C) indicating that Gpa1p may not interact with these residues but rather the 





Although the third intracellular loop (IL3) of Ste2p is suggested to directly interact with 
Gpa1p, there has been no report about its involvement in Ste2p homo-dimer formation.  Most 
studies reported that individual residue mutations in IL3 did not significantly affect receptor 
activity.  Most strong defects in receptor were observed in multiple or non-conservative 
mutations that altered the overall charges of specific regions that are suggested to interact with G 
proteins (32, 40, 41).  Consistent with previous studies (42), IL3 was observed to tolerate Cys 
substitutions in our experiments except for the R233C receptor that displayed the most defects 
compared to the other mutants.  Although the L236H and L236R mutations have been observed 
to cause partial defects in Ste2p activation (42, 43), the L236C mutant displayed only a slight 
decrease in activity relative to the Cys-less receptor as observed in previous studies.  Overall the 
substitution of residues to cysteine in IL3 did not significantly affect the activities of the 
receptor.  The tolerance for substitutions in IL3 suggests that activation of G protein by Ste2p 
involves multiple intramolecular interactions as observed for mammalian GPCRs (44, 45).  Thus, 
the overall interactions of all IL3 residues are essential for proper Ste2p function and interaction 
with Gpa1p.   
It is interesting to observe that strong dimer formation occurred in the IL3 Cys mutants; 
however this is not surprising since IL3 in rhodopsin has been identified to play a role in 
oligomerization (7, 8, 14).  In addition, molecular dynamics simulations, correlated-mutation 
analysis and evolutionary-trace analysis all support the involvement of IL3 in the dimerization 
interface (9).  The dimer formation observed in this study was also detected in intact cells, 
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indicating that the disulfide bond formation between the two units of Ste2p occurs in the native 
environment of the receptor.  We therefore suggested that IL3 is a dimer contact in Ste2p 
oligomer formation.  The presence of higher order of oligomers of Ste2p observed in this study 
(Figure 4E) indicates that Ste2p has multiple contacts in the oligomer form.  Other studies have 
also shown that the N-terminal extracellular domain, TM1, TM2 (19), TM4 (20) , and TM7 
(Heejung Kim, personal communication) are involved in oligomer formation in Ste2p similar to 
that of the rhodopsin family of GPCRs.  In rhodopsin the strongest dimer contacts were found 
between TM5 and TM4, whereas TM1, TM2 and IL3 displayed fewer contacts.  The weakest 
contact was the extracellular surface of TM1.  The only interactions between the rhodopsin 
dimers observed were at the cytoplasmic ends, which involved K231, Q236, Q238 (all in IL3), 
K339 and T340 (all at the C-terminus).  These IL3 and C-terminal residues in rhodopsin are 
thought to be involved in hydrogen bondings that stabilize the oligomers (7, 8, 15). 
The role of IL3 in Ste2p oligomer formation is suggested to be similar to that of 
rhodopsin.  The pattern of dimer formation in Ste2p IL3 (Figure 6) indicates that the side chains 
of R233, L236 and K239 all points towards the dimer interface.  These residues form about 85-
95% of dimer when treated with Cu-P.  Interestingly, the residues in rhodopsin IL3 regions that 
are essential for dimer stabilization seem to be located at positions similar to those for Ste2p IL3 
residues that are suggested to face the dimer interface.  Although most individual mutations in 
IL3 do not display any significant defect in receptor activity, mutations of R233 (R233C) and 
L236 (L236H and L236R) have been observed to cause strong defects in Ste2p activation (42, 
43).  We therefore propose that these residues (R233, L236 and K239) in the IL3 region of Ste2p 
are involved in hydrogen bonding that stabilizes the Ste2p dimers.  The similarity in dimer 
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interface sites between Ste2p and rhodopsin-like receptors provide further evidence that many 
aspects of structure and function are highly conserved across GPCRs, irrespective of primary 
amino acid sequence.  A schematic arrangement of higher order organization of Ste2p compared 
with rhodopsin is shown in Figure 7.  The model is based on the results of this study and other 
reports (19, 20). 
 Interactions of cognate ligands at the ligand-binding pocket of GPCRs, lead to 
conformational changes that are transferred from the extracellular surface of the receptor to the 
cytoplasmic domain involved in G-protein binding (2).  One of the most commonly used 
strategies to investigate GPCRs agonist-induced conformational changes is disulfide cross-
linking involving cysteine-substituted mutant GPCRs.  This approach involves detection of 
dimer formation or intact receptor after enzymatic or chemical cleavage to assess disulfide bond 
formation between two Cys residues (9, 15, 20).  Several recent disulfide cross-linking studies 
including those using β2-adrenergic and M3 muscarinic acetylcholine receptors as models all 
showed that conformational changes in these receptors were associated with a clockwise rotation 
of the cytoplasmic end of TM6 of ~30o (35, 46-48).  The dimer disappearance of the Cys mutants 
at the cytoplasmic ends of TM5 and TM6 in Ste2p in the presence of bound ligand observed in 
this study indicates that these regions of the receptor undergo conformational changes similar to 
what has been observed in other GPCRs.  Comparison of the crystal structure of opsin and 
rhodopsin also show that the cytoplasmic end of TM6 in opsin (active receptor) is shifted about 6 
Å outwards from the center of the TM and undergoes a clockwise rotation of ~30o at the 




Figure 7: Model for the packing arrangement of rhodopsin and Ste2p in their oligomer 
forms.  The transmembrane helices are labeled in numerical order 1-7.  A: rhodopsin assembles 
into dimers through a contact provided by TM4 and TM5. Dimers form rows as a result of 
contacts between IL3 and helices I and II from the adjacent dimer. Rows assemble through 
extracellular contacts formed by TM1. Figure taken from Liang et al (8).  B:  Ste2p assembles 
into dimers similar to rhodopsin.  Dimers form rows through contacts of IL3.  The IL3 regions 
are anti-parallel as predicted in some GPCRs (9) between dimers (e. g. AB - EF, or CD - GH).  
Dimers may also interact through contacts in TM1, TM2, TM4 and TM7 as observed in some  
studies (19, 20).   
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Both TM5 and TM6 were observed to move from their original positions in opsin.  These 
changes, and other changes at TM3 and TM5, result in the creation of a binding domain which 
favors activation of the G protein transducin (38).  We therefore propose that TM6 of Ste2p 
undergoes a clockwise rotation of about ~30o at cytoplasmic surface, similar to other GPCRs (35, 
46-48).  The TM6 helix may also shift during Ste2p activation as observed in most GPCRs; 
however there is no evidence in the data presented in this study to support such movement.  
Based on the reduction of dimer formation observed in this study in residues at the ends TM5, 
we also propose that the TM5 cytoplasmic end undergoes a conformational change (probable an 
anti-clockwise rotation of about ~30o).  This needs further studies to confirm such movement.  
These proposed conformational changes at the cytoplasmic ends of TM5-TM6 in Ste2p did not 
alter IL3 involvement in dimer interactions as observed in the group 2 residues (Figure 6).  This 
phenomena of ligand binding or receptor activation having no effects on dimerization in Ste2p 
has also been reported previously (18).  Thus, the hydrophilic residues located in the middle of 
the loop (R233-Q240) that are proposed to be involved in hydrogen bonding in this study are 
required to stabilize dimers during rearrangements of the helices leading to receptor activation.   
Dimer formation involving the cytoplasmic ends of TM5-TM6 and changes induced by 
ligand were affected by the expression of Gpa1p.  Thus, the binding of Gpa1p may affect both 
IL3 and α-factor interactions.  These phenomena have been observed when the crystal structure 
of opsin was compared with that of opsin-GαCT (opsin with the C-terminus of Gα transducin 
bound).  The study suggested that GαCT binding plays a role in stabilizing the ligand binding 
pocket of the receptor as well as receptor conformation.  The interactions of residues such as 
K296, S186, E181, Y268, C110 and C187 were found to be different in opsin when compared to 
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opsin-GαCT (38).  Thus, the active conformation of the receptor is stabilized by both ligand and 
G protein binding.  It is therefore not surprising that similar observations were made in this study 
when Ste2p was expressed with or without Gpa1p.  When Gpa1p was co-expressed the side 
chain orientations of A229, I230, and R231 all at the cytoplasmic end of TM5 were altered so 
that their dimer formation was reduced in the presence of ligand binding, which was not 
observed in the absence of Gpa1p.  At the cytoplasmic end of TM6, H245 also shows some 
reduction in the presence of ligand binding.  The only change that occurred in the middle of the 
IL3 loop was a possible switch in orientation between R233 and R234.  In the absence of Gpa1p, 
the side chain of R234 may point away from the receptor bundle facing towards the dimer 
interface, whereas the R233 side chain may point partially away from the dimer interface.  In the 
presence of Gpa1p it seems that the opposite occurs, such that the R233 side chain may now 
points toward the dimer interface and the R234 may be oriented partially away from the 
interface.  It is not clear whether these residues are involved in G protein interactions.  However, 
some of these residues such as R231, R233, R234 and K239 may be involve in hydrogen 
bonding that are required for stabled Ste2p conformation. This study is the first to report that IL3 
residues play essential role in mediating Ste2p-Ste2p interactions in the oligomer form. 
The first amino acid of α-factor, Trp1 is suggested to interact with Ste2p residues, S251-
M294 which comprises of TM6, the third extracellular loop (EL3), and part of TM7 [(36) and 
part 2 of this dissertation].  We investigated the role of the N-terminus of α-factor by examining 
the effects the α-factor antagonist (WLQLKPGQPNle12Y), which lacks the first two amino acids, 
on dimer formation in the IL3 Cys mutants.  In the absence of Gpa1p changes in dimer formation 
at the cytoplasmic ends of TM5-TM6 induced by the antagonist was similar to that of the native 
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α-factor ligand (WHWLQLKPGQPNle12Y).   However, co-expression of Ste2p Cys mutants 
with Gpa1p showed that the antagonist was able to reduce dimer formation by 50% compared to 
the native α-factor.  Since co-expressing Ste2p and Gpa1p reflect the interactions in the natural 
environment, we suggest that antagonist binding to Ste2p does not induce the proper 
conformational changes at the TM5-TM6 cytoplasmic ends that are required for receptor 
activation.  This implies that the first two amino acids of α-factor may be required for these 
changes and signaling in the presence of Gpa1p.  The partial changes that were observed at 
TM5-TM6 ends induced by the antagonist may be due to the interactions of position 3 (Trp3) of 
α-factor that is still present in the antagonist.  Previous studies have shown that Trp3 of α-factor 
may interact within the TM5-TM6-EL3 regions of Ste2p similar to Trp1 (49).  Thus, 
conformational changes at the cytoplasmic ends of TM5 and TM6 in Ste2p require interactions 
of the N-terminal amino acids of α-factor, especially the first three (WHW) residues.  It is 
therefore logical to propose that the first three amino acids of α-factor interact within a 
“signaling pocket” in Ste2p that may be comprised of residues in TM5 and TM6 as well as part 
of the EL2-TM5 and TM6-EL3 extracellular boundaries. 
This study has revealed a unique characteristic of IL3 involvement in dimer formation in 
Ste2p that has not been observed for other GPCRs.  Conformational changes at the cytoplasmic 
ends of TM5 and TM6 may be similar to other mammalian GPCRs.  The N-terminus of α-factor 
is suggested to be important for changes in TM5 and TM6 in that the binding of an antagonist 
(lacking the first two residues) does not induce the same conformational changes in these regions 
as does binding of agonist.  The information obtained in this study will serve as a platform for 
further understanding of GPCR oligomerization and their role in signal transduction. 
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The Saccharomyces cerevisiae pheromone receptor encoded by the STE2 gene belongs to 
the medically important family of G protein-coupled receptors (GPCRs) that transduce signals 
for a variety of stimuli (1-3).  These receptors are comprised of seven transmembrane domains 
(TMs) and function by activating the Gα subunit of a heterotrimeric G protein.  GPCRs are the 
most diverse group of membrane-bound receptors and are the targets of most of the current 
prescription drugs due to their association with a broad range of diseases, such as retinitis 
pigmentosa, inflammation, diabetes, cancer, and hypertension (4, 5).   Despite the availability of 
crystal structures for G proteins (6-8) and GPCRs (9-12), the molecular mechanisms leading to 
activation of G proteins upon ligand binding to GPCRs remain unclear.  GPCR–G protein 
interactions have recently found to have interesting implications with regards to drug discovery. 
If drugs can be identified that interfere or promote GPCR-G protein interaction, change the 
pattern of GPCR–G protein associations, or cause a GPCR to preferentially associate with one G 
protein and not others, then it would be possible to regulate the activities and functions of a 
specific receptor (4, 13-15) 
Ligand binding to GPCRs induces receptors to undergo conformational changes, which 
enables them to activate Gα to exchange GDP for GTP.  The GTP-bound Gα releases Gβγ and 
then either Gα or Gβγ can further activate downstream effectors, which result in increase or 
decrease of secondary (signal) molecules (16-21).  Several biochemical and biophysical 




between the TMs of the receptor which in turn affects the conformation of cytoplasmic domains 
that directly interact with G proteins (14, 22-25).  Recently the crystal structure of opsin bound to 
the carboxyl-terminal peptide of transducin (Gα) revealed that the peptide occupies a cavity 
created between the cytoplasmic ends of TM3, TM5 and TM6 (26).  Though this structure is the 
first to document that the C-terminus of the Gα interacts within a cavity in the receptor, the study 
did not define the mechanism that induces the activation of Gα upon interaction with the 
receptor. Several models have been proposed for signal transfer from the activated receptor to 
the G protein. The “gear shift”, “lever arm” and “sequential fit” models have in common that the 
α5 helix (C-terminus) of Gα is the key transmission domain for the receptor-G protein signal 
transfer (27-30).  Other regions of Gα such as the α4-helix, α2-helix, α2-β4 loop regions, and α4-
β6 loop domain have also been implicated to directly interact with the receptor during signal 
transfer (31, 32). 
 Knowledge about the mechanism of GPCR-G protein signal transfer has been limited 
because of the problems working with membrane-bound receptor proteins and the difficulties in 
identifying conserved sequence motifs in the intracellular domains of GPCRs that might be 
involved in G protein activation.  In addition, the complexity of mammalian GPCR cross-talk 
with different G proteins and other modulators within the same cell makes it difficult to assign 
specific signal transfer to a given GPCR and a specific Gα (1, 3).  The mating pathway of S. 
cerevisiae has been a valuable tool for studying GPCR signal transduction mechanisms for many 
reasons such as the ease of mutagenizing components of the system and the ability to express 
active mammalian GPCRs in yeast.  Furthermore, the yeast mating pheromone receptors activate 




and its Gα (3, 33, 34).  Ste2p, the α-factor pheromone receptor of S. cerevisiae, shows overall 
similar structural architecture to mammalian GPCRs and the yeast Gpa1p shows about 45% 
sequence similarity with mammalian Gα (34, 35).  Comparison of Ste2p with the rhodopsin 
(class A) subfamily of GPCRs suggests that there are underlying similarities in the mechanism of 
signal transduction between Ste2p and the Class A GPCRs (2).  These characteristics of Ste2p 
make it a good model for peptide-responsive GPCRs and other GPCRs that are difficult to study. 
 Studies on the interactions between Ste2p and Gpa1p indicate that Ste2p is similar to 
other GPCRs in that the third intracellular loop (IL3) is involved in Gpa1p activation (2, 36-41).  
Part of the Ste2p C-terminus was also shown to be involved in G protein interaction (41).  
However, specific residues that were important for G protein activation have not been identified 
to date because conservative mutations in any one residue did not result in significant defects (2, 
36-41).  Like the mammalian Gα, the region of Gpa1p that has been most commonly predicted to 
interact with Ste2p is the C-terminus (42-44).  Truncation of the last five amino acids and lysine-
to-proline substitution (K467P) of Gpa1p lead to pheromone signaling and mating defects 
suggesting that the C-terminal residues of Gpa1p, especially the last five amino acids, may be 
involved in Ste2p-Gpa1p interactions (45).  Other studies have also proposed that the C-terminal 
domain of Gpa1p is critical for Ste2p-coupling, and that the C-terminus of Gpa1p forms a β-turn 
that correlates with the C-terminal region of mammalian Gpa1p (46).  Mutagenesis studies 
suggest that residues in additional interface regions of Gpa1p contribute to activation of Ste2p 
and signaling (32, 47).  Despite the intense studies carried out on the interactions of Ste2p with 
Gpa1p, the mechanisms of the interactions and specific residue-to-residue involved have not 




 This study identifies specific residue-to-residues interactions between Ste2p and Gpa1p.  
A proposed mechanism for receptor-Gα signal transfer involving conformational changes in both 
proteins is also discussed.  To identify specific residue-to-residue contacts that are involved in 
the Ste2p-Gpa1p interaction, cysteine disulfide cross-linking was carried out on residues in IL3 
of Ste2p and the C-terminus of Gpa1p.  Disulfide cross-linking studies suggested that the 
extreme C-terminus of Gpa1p interacts with the cytoplasmic boundaries of TM5 and TM6 
similar to the interaction of transducin with opsin (26).  The pattern of Gpa1p interaction with 
the inactive and active forms of Ste2p suggest possible rotational and translational shift 
movements at the C-terminus of Ste2p that are required for proper Gpa1p coupling during 
activation of both proteins.  This study is the first to identify specific residues in Ste2p that 
interact with specific residues in Gpa1p, and also provides experimental evidence of possible 
conformational changes at the C-terminus of a Gα during receptor-G protein activation.  The 
information in this study will be crucial for future studies on Ste2p and Gpa1p interactions as 






Materials and Methods 
Media, Reagents, and Strains and Transformation: 
Saccharomyces cerevisiae strain TM5117 [MATa, bar1, leu2, his3, ura3, FUS1-
lacZ::URA3, ste2∆, gpa1∆ (48)] was used for Gpa1p Fus1-LacZ activities and the protease 
deficient strain BJS21 [MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 ste2::KanR (49)] 
was used for protein isolation and immunoblot analysis.  The STE2 and GPA1 mutant plasmids 
were co-transformed by the method of Geitz (50) into TM5117 and BJS21 cells.   
For all transformations, cells were cultured in their selective media and grown to mid-log 
phase at 30oC with shaking (200 rpm) overnight. The cells (5 ml culture) were then harvested 
and washed with sterile water and 100 mM LiAc (lithium acetate) by centrifugation at 4000g for 
5 minutes.  The pellet was resuspended in transformation mixture [240µl of 50% PEG 
(polyethylene glycol); 36µl of 1.0 M LiAc; 25µl of salmon sperm DNA; and 50µ water with 
plasmid DNA (5 µg)].  The mixture was incubated at 30o C for 30 minutes and then heat shocked 
at 42o C for 25 minutes.  The cells were separated from the mixture and resuspended in sterile 
water for plating on selective media.  Transformants were selected by growth on minimal 
medium (51) lacking tryptophan and uracil (designated as MLTU) or tryptohan and histidine 
(designated as MLTH) to maintain selection for the plasmids.  All media components were 






Cysteine scanning mutagenesis: 
The open reading frame of GPA1 was PCR amplified from the plasmid YepGαβγ (52) 
and cloned into the plasmids p426 and p423-GPD (53) to yield plasmids pBUG6 and pBUG3, 
respectively.  Primers used for the mutagenesis are listed in Table 1.  The pBUG6 and pBUG3 
were engineered by site-directed mutagenesis to replace 11 residues in Gpa1p (I461-I471) with 
cysteine.  The sequence of all cysteine mutants was verified by DNA sequence analysis 
completed by the molecular biology resource facility located on the campus of the University of 
Tennessee.  Mutagenic and sequencing primers were purchased from Invitrogen (Carlsbad, CA).  
 
Membrane extraction and immunoblots: 
BJS21 cells expressing STE2 and GPA1 mutant constructs grown in their selective media 
were used to prepare total cell membranes isolated as previously described (54).  Cells were 
harvested and lysed by agitation with glass beads in 700 μL of HEPES buffer (50 mM HEPES, 
150 mM NaCl, pH 7.5) and the following concentrations of protease inhibitors: 1.0 mM 
leupeptin, 10 μM pepstatin A, and 5.0 mM phenylmethanesulfonyl fluoride.  The lysate was 
cleared by centrifugation at 3000g for 2 minutes. The membrane fraction was harvested by 
centrifugation at 15000g for 30 minutes and was then resuspended in the HEPES buffer with 
20% glycerol. Protein concentration was determined using the BioRad (BioRad, Hercules, CA) 
protein assay (48).   
For immunoblot analyses the membrane extract was solubilized in SDS sample buffer 














Blots were probed with FLAG antibody (Sigma/Aldrich Chemical, St. Louis, MO) to detect 
Ste2p or an antibody directed against Gpa1p (Santa Cruz Biotechnology, Inc., CA).  The signals 
generated were analyzed using Quantity One software (Version 4.5.1) on a Chemi-Doc XRS 
photodocumentation system (BioRad, Hercules, CA). 
 
Fus1-LacZ Assays: 
TM5117 cells co-expressing wild type Ste2p and the various Gpa1p mutants were grown 
at 30 ºC in selective media, harvested, washed three times with fresh media and resuspended at a 
final concentration of 5 x 107 cells/ml.  Cells (0.5 ml) were combined with α-factor pheromone 
(final concentration of 1 μM) and incubated at 30ºC for 90 minutes.  The cells were transferred to 
a 96-well flatbottom plate in triplicate, permeabilized with 0.5% Triton X-100 in 25 mM PIPES 
buffer and then β-galactosidase assays were carried out using fluorescein di-β-galactopyranoside 
(Molecular Probes, OR) as a substrate (55).  The reaction mixtures were incubated at 37oC for 60 
min and 1.0 M Na2CO3 was added to stop the reaction.  The fluorescence of the samples 
(excitation of 485nm and emission of 530 nM) was determined using a 96-well plate reader 
Synergy2 (BioTek Instruments, Inc., Winooski, VT).  The data were analyzed using Prism 
software (GraphPad Software, San Diego, CA).  The experiments were repeated at least three 
times and reported values represent the mean of these tests.   
 
Disulfide cross-linking: 
Membrane proteins (in HEPES buffer, 20% glycerol, pH 7.5) extracted from BJS21 cells 




μM Cu and 3.0 μM 1,10-phenanthroline) according to optimum concentrations for Cu-P 
determined in this part of the dissertation (see below),  Membrane samples were incubated  with 
Cu-P at room temperature for 30 min.  The reaction was quenched by addition of EDTA to a 
final concentration of 10 mM.  The cross-linked samples were resuspended in non-reducing SDS 
sample buffer (BioRad, Hercules, CA) and resolved on SDS-PAGE as described above.  The 
disulfide reaction was reversed by reducing with 4% 2-mercaptoethanol (β-ME) in the SDS 
sample buffer before resolving it on SDS-PAGE.  To investigate the effects of ligand or GTP on 
cross-linking,  membrane fractions were incubated in HEPES buffer containing 5μM α-factor 
(WHWLQLKPGQPNle12Y) or 20 μM α-factor antagonist (WLQLKPGQPNle12Y) in the 
presence or absence of 0.1 mM GTP or GTP-γ-S (15) before Cu-P treatment. 
For in vivo cross-linking, cells were grown to mid-log phase, harvested, and washed with 
water by centrifugation (4000g for 5 min).  The cells were resuspended in 100 mM LiAc and 
incubated at 30oC for 30 min with mixing.. After centrifugation, the cells were resuspended in 
25% PEG with 250 mM LiAc for another 60 min incubation.  Cells were washed with HEPES 
buffer three times after LiAc treatment.  For whole cell ligand binding prior to cross-linking, 
cells were first incubated with KF (10 mM) and  NaN3 (10mM) in HEPES buffer at room 
temperature for 15 min to inhibit receptor endocytosis (56) and then ligand added to final 
concentrations of 5μM for native α-factor or 20 μM for α-factor antagonist for another 30 min.  
Disulfide cross-linking was induced by adding Cu-P to final concentrations of 0.5 mM Cu and 
1.5 mM 1,10-phenanthroline (57).  Control cells without cross-linking were treated with 
equivalent volume of HEPES buffer.  The mixture was incubated at room temperature for 60 min 




ethylmaleimide) to final concentrations of 10 mM were added to stop the reaction.  The cells 
were washed three times with HEPES buffer containing EDTA (10 mM) and NEM (10 mM).  
Membrane extraction was carried as described above with HEPES buffer containing 10 mM 
EDTA/NEM.  Reducing condition of disulfide bond were carried out by resuspending membrane 
samples in SDS-PAGE sample buffer containing 4% β-ME and incubating at room temperature 
for at least 15 min. 
 
Prediction and modeling: 
All models of 3-D structures were generated by the Phyre Structural Bioinformatics 
Group prediction tools (58).  The structures were viewed and labeled with the PyMOL pdb 
viewer software (DeLano Scientific LLC, Palo Alto, CA).  Aligment of the last 11 amino acids 
of transducin (Gα of rhodopsin) with Gpa1p was carried out using European Bioinformatics 





     Results 
Expression and activities of Gpa1p Cys-mutants: 
 The expression and biological activities of the third intracellular loop (IL3) of Ste2p Cys 
mutants used for the disulfide cross-linking with Gpa1p have already been reported in a previous 
study (see part 4 of this dissertation).  It was shown that all the IL3 Cys mutants displayed 
activities similar to the Cys-less receptor except for R233C which was about 30% reduced in 
biological activity compared to all of the other IL3 Cys mutant receptors.  The Gpa1p Cys 
mutants generated in this study have expression levels similar to wild type Gpa1p (Figure 1B).  
The high molecular weight protein (denoted as NS in Figure 1B) that reacted with anti-Gpa1p 
was seen also in extracts from TM5117 cells deleted for Gpa1p (data not shown).  The yeast 
strain TM5117 used to express the Gpa1p mutants has the endogenous GPA1 deleted resulting in 
high basal FUS1-LacZ activities because the free Gβγ subunits constitutively activate the signal 
transduction pathway.  When bound, the Gα subunit (GDP-state) renders the Gβγ subunits 
inactive.  However in the presence an activated receptor, Gα-GDP exchanges GDP for GTP and 
the now active Gα-GTP subunit dissociates from Gβγ thus allowing these units to become active 
(19).  The subsequent hydrolysis of GTP to GDP makes the Gα-GDP available for another cycle 
(19).  Expression of the mutant Gα subunits showed that all could interact with the endogenous 
Gβγ subunits leading to reduced FUS1-LacZ activities in the TM5117 yeast strain (Figure 1C).  
In the presence of ligand bound Ste2p, the FUS1-LacZ activities increased, implying that all the 






































































Figure 1: Expression and activities of Gpa1p Cys-mutants. A: alignment of Gpa1p and 
transducin Gα last 11 amino acids.  B: immunoblot image of Gpa1p Cys mutants.  All the 
mutants have similar expression level as wild type Gpa1p. A non-specific signal (NS) was 
observed on the blot in all samples. C:  relative Fus1-LacZ activities of the mutants.  All mutants 




However, the mutants K468C, I469C and I471C all exhibited about 50% capacity to activate 
signal transduction as measured by FUS1-LacZ activity in comparison to the other Cys-mutants.  
 
Copper treatment of IL3 Cys mutants and Gpa1p: 
 The initial studies involving copper treatment of membranes using 5-100 μM Cu showed 
that the Gpa1p could not be detected using anti-Gpa1p after the treatment.  Copper interference 
with western blots observed in previous studies in another lab showed that aggregation of 
proteins occurred at high copper concentrations (59).  Therefore, to determine the optimum 
concentration of Cu-P for cysteine disulfide cross-linking between IL3 Cys-mutants and Gpa1p 
C-terminal Cys-mutants, cells expressing R233C receptor (observed to form strong dimers) and 
wild type Gpa1p were treated with different amounts of copper.  The amount that induced 
significant cross-linking with minimal effects on the detection of Gpa1p protein was 1.0 μM 
(Figure 2).  Subsequently, for disulfide cross-linking, Cu-P [Cu(II) (1,10-phenanthroline)3] at a 
final concentration of 1.0 μM Cu and 3.0 μM 1,10-phenanthroline was added to membrane 
samples and  incubated at room temperature for 30 min. The reaction was quenched by addition 
of EDTA to final a concentration of 10 mM.  These treatment conditions were used for the 
disulfide studies unless otherwise stated. 
 
Disulfide cross-linking of Ste2p and Gpa1p: 
 To determine whether IL3 residues in Ste2p interacted with the C-terminal (I461-I471) 
residues in Gpa1p as measured by disulfide crosslinking, the IL3 Cys-mutants were each co-





Figure 2:  Copper treatment of Ste2p Cys mutants and wild type Gpa1p.   The samples were 
incubated with different concentrations of copper at room temperature for 30 min.  Significant 
disulfide bond was formed with 1.0 μM copper (A) with a minimal effect on Gpa1p detection 
(B). 
 
Thus 23 different IL3 receptors each with only one Cys residue in IL3 were co-expressed with 12 
different Gpa1p proteins each with only one Cys residue in the C-terminus to give 276 different 
combinations of Ste2p/Gpa1p Cys-mutants.  Membranes extracted from all the different 
combinations were incubated with or without 5 μM α-factor and then treated with Cu-P as 
mentioned above (see materials and methods for detail).   
The Cys-less Ste2p with His- and FLAG-epitope tags used to generate the IL3 Cys 
mutntants is about 51 kDa.  This receptor is normally observed as a monomer (51-55 kDa, with 
three poorly dissociated bands due to N-glycosylation at two sites on the N-terminus) and a 
dimer (106-110 kDa) on blots [(48) also see part 4 of this dissertation].  The wild type Gpa1p 
used in this study is observed at a 52-54 kDa position (Figure 2).  The Ste2p-Gpa1p disulfide 
cross-linked product (~103-108 kDa) is therefore expected to be at similar position as that of the 




to form homo-dimers (this dissertation, part 4) we were concerned that a 103-108 band would 
represent a Ste2p homo-dimer and and not a Ste2p-Gpa1p heterodimeric cross-linked product at 
similar position on immunoblots.  To detect the Ste2p-Gpa1p cross-linked product we used an 
antibody directed against Gpa1p.  This antibody should react with 52-54 kDa (Gpa1p) and 103-
108 kDa Ste2p-Gpa1p heterodimer (if cross-linked) since Gpa1p does not form a homo-dimer; 
the only signal at the 103-108 position should correspond to the cross-linked product.  The 
Ste2p-Gpa1p cross-linking results are shown in figures 3 showing those combinations that 
yielded cross-linked products. Those that were not included in the figures are combinations 
without any detectable cross-linked product, although for purposes of comparison, one example 
without detectable cross-linking is shown (Figure 3, I246C).   
Out of the 22 Ste2p Cys-mutants tested, 5 mutants (L228C, S243C, L247C, L248C and 
I249C) showed a cross-linked band with 5 Gpa1p Cys-mutants (Q463C, N465C, K467C, I469C 
and G470C).  In the inactive state (without α-factor) L248C in IL3 reacted with I469C in Gpa1p, 
whereas both L247C and I249C in IL3 reacted with N465C in Gpa1p.  Although previous studies 
showed that I246C is highly accessible to a sulfhdryl reagent (60) this residue did not react with 
the Gpa1p residues tested in this study.  No detectable disulfide product was observed in residues 
located in the middle of the IL3 loop or the TM5 boundary in the inactive conformation of Ste2p. 
Thus, in the inactive state of Ste2p the C-terminus of Gpa1p may be in close proximity 
to, or tilted more towards, the cytoplasmic end of TM6 than TM5.  In the ligand-bound, active 
conformation (α-factor “+” lanes) both A228C (TM5) and I249C (TM6) reacted with G470C of 
Gpa1p.  S243C and L247C of the receptor reacted with Q463C of Gpa1, whereas receptor I249C 


























Figure 3: Disulfide cross-linking between of Ste2p and Gpa1p Cys-mutants.  The blot 
images represent individual IL3 Cys-mutants co-expressed with Gpa1p Cys-mutants.  Each 
preparation was untreated (lanes -, -) or treated with Cu-P (lanes -, +) or with α-factor and Cu-P 
(lanes +, +).  The samples were probed with anti-Gpa1p antibody to detect the presence of 
Gpa1p (Gα) at either the 52-54 kDa or 103-108 kDa (Ste2p-Gα cross-linked) position. The blot 





The Cu-P treatments of mutants with detectable cross-linked products were repeated (Figure 4).  
The samples were immunoblotted with both anti-Gpa1p and anti-FLAG to detect Ste2p-
monomer (53-55 kDa), Ste2p-dimer (106-110 kDa) and Ste2p-Gpa1p cross-linked product (103-
108 kDa).  The Ste2p-Gpa1p cross-linked product was reversed by treatment with 4% β-ME (see 
Figure 4, last three lanes for I249C-G470C), indicating that there was a disulfide bond forming 
the heterodimeric Ste2p-Gpa1p. 
To test whether the IL3-Gpa1p interactions observed in the membrane samples existed in 
the cell, in vivo CuP treatment was carried out on whole cells.  For these experiments, cells co-
expressing Ste2p-I249C and Gpa1p mutants, N465C, L466C, K467C, K468C, I469C, G470C 
and I471C in the presence or absence of α-factor were used.  The results (Figure 5) show that the 
in vivo interaction of receptor mutant I249C with Gpa1p is similar to what was observed in 
membrane preparations. 
The close proximity of A228, I247, L248, and L249 of Ste2p with the extreme C-
terminus of Gpa1p indicate that these residues may be essential for Gpa1p coupling with Ste2p.  
The reaction of S243 (Ste2p) with Q463 and K467 (Gpa1p) suggest that these residues may be 







Figure 4: Disulfide cross-linking between of Ste2p IL3 and Gpa1p Cys-mutants.  The 
samples were resolved on a 4-12 % gradient SDS-PAGE (non-reducing).  A: The blots were 
probed anti-FLAG to detect the presence of Ste2p at either ~51-55 kDa (Ste2p monmer) or ~108-
110 kDa (Ste2p-dimer) or ~103-108 kDa (Ste2p-Gα cross-linked) position.   B: The blots were 
also probed with anti-Gpa1p antibody to detect the presence of Gpa1p (Gα) at either the ~53-54 
kDa or ~103-108 kDa (Ste2p-Gα cross-linked) position.  The blot images were spliced together 
from different gels.  In the anti-FLAG blots a band below the Ste2p dimer position 
corresponding to Ste2p-Gpa1p cross-linked product was observed in lanes that show similar 






Figure 5:  In vivo cross-linking of Ste2p and Gpa1p.  Cells expressing Ste2p-I249C mutants 
the Gpa1p-Cys mutants (N465C-I471C) were treated with CuP for in vivo induced cross-linking.  
Membrane samples were probed with anti-Gpa1p.  Ste2p-I249C show similar reactions with 
Gpa1p Cys mutants in vivo as observed in vitro.  Each preparation was untreated (lanes -, -) or 







Heterotrimeric G proteins transduce the signals for a wide range of medically important 
GPCRs (4, 15, 61).  The Gα subunits are composed of two domains: the core and helical 
domains. The guanine nucleotide (GDP or GTP) is bound within a deep pocket between the core 
and helical domains.  The C terminal regions of the Gα subunit, which is suggested to be 
involved in receptor interactions, consist of two α-helices and a β strand, where the α5-helix 
comprises the extreme C-terminus (19, 46).  Activation of Gα subunit by GPCR alters 
interactions between GDP and residues of both the helical and core domains; these interactions 
are proposed to open the GDP-binding pocket, allowing GDP dissociation and the subsequent 
binding of GTP (15, 25, 62).  Despite intensive studies on GPCR-G protein interactions the 
mechanisms by which Gα subunits are stimulated to bind GTP are not well defined.  In this study 
specific residue-to-residue interactions between Ste2p, the S. cerevisiae pheromone receptor, and 
Gpa1p, its cognate Gα, have been identified by disulfide cross-liking.  Conformational changes 
at the C-terminus of Gpa1p during Ste2p activation are also discussed. 
The alignment of Gpa1p used in this study with the last 11 amino acids of transducin 
showed that these two proteins are 50% identical and 70% similar at the C-terminus (Figure 1A).  
This portion of transducin was suggested to directly interact with opsin and was used for co-
crystallization with opsin to determine its binding to opsin (26).  The C-terminus of Gpa1p has 
been identified to interact with Ste2p and truncation of the last five amino acid residues (K468-




showed that triple mutations to alanine at Q464, N465, and L466, at K467, K468, and I469 or at 
G470, I471, and I472 of the last nine amino acid residues resulted in defects in mating activities. 
Single alanine mutations within the QNL and KKI triplets did not affect mating, however the 
single mutants, K468P, G470A, I471A, I471T and I472T all resulted in mating defects (46).  
Activities of cysteine substitutions of the eleven residues (I461-I471) tested in this study 
indicated K468C, I469C and I471C all resulted in partial pheromone response activities 
consistent with previous studies (32), whereas the other eight mutants did not display any 
significant defects.  Defects caused by mutations of the last five residues of Gpa1p have been 
consistent in most studies suggesting that these residues are indeed critical for proper receptor 
coupling and Gpa1p activation.  None of these mutations affected the coupling of Gpa1p with the 
Gβγ protein subunits as observed in the FUS1-LacZ assay (Figure 1C), implying that the 
carboxyl tail of Gpa1p is essential for receptor coupling but not Gβγ proteins interaction as 
observed in mammalian cells (36). 
The crystal structure of opsin in its G protein-interacting conformation shows that the 
cytoplasmic ends of TM5 and TM6 provides a surface for hydrophobic interactions with the C-
terminus of transducin Gα.  Residues at the cytoplasmic ends of TM3 also interact with the C-
terminus of transducin Gα (26).  The disulfide cross-linking studies presented in this dissertation 
indicated that the C-terminus of Gpa1p interacts with Ste2p at similar regions of TM5 and TM6.  
In opsin, TM5 and TM6 are involved in van der Waals interactions with the C-terminus of 
transducin and hydrogen bonding linking the transducin residues to opsin residues in the network 
(26).  It has been shown in the fourth part of this dissertation that α-factor binding to Ste2p 




ends.  Out of the three residues (L228, A229 and I230) that were affected by conformational 
changes only L228 was observed to interact with G470C in the active conformation of the 
receptor.  On the other hand, all residues (L247, L248 and L249) that were affected by changes 
at the intracellular end of TM5 were observed to interact with Gpa1p.  The close proximity of 
A228, I247, L248, and L249 of Ste2p to the extreme C-terminus of Gpa1p indicates that these 
residues provide a hydrophobic environment that favors the Gpa1p C-terminus interactions.  The 
reaction of S243 (Ste2p) with Q463 and K467 (Gpa1p) suggests that these residues are involved 
in a hydrogen bonding network, with hydrogen bridges between these three residues.  These 
hydrogen bridges may be required for receptor activation, since this was only observed in the 
active form of the receptor.  However, this is just a part of a network of interactions, so it may 
not be essential for full activation of the receptor and/or Gpa1p.   
The last five residues (with the exception of I472 that was tested) of Gpa1p were all 
found to interact with IL3 residues.  Most of these residues were found to interact at the 
cytoplasmic ends of TM6 in the active conformation of the receptor.  In the opsin-GαCT 
complex it was observed that the binding of the Gα to the TM5-TM6 regions creates a network 
of interaction that stabilizes the ligand binding pocket of the receptor.  We propose similar 
interactions between Gpa1p and TM5-TM6 in Ste2p.  For instance, the deletion of the first two 
amino acids of α-factor prevents proper TM5-TM6 conformational changes as seen using the α-
factor antagonist in part 4 of this dissertation.  Thus, for receptor activation these two residues of 
α-factor may interact within a binding pocket that is stabilized by the interactions of the C-
terminus of Gpa1p so that in the absence of these ligand residues (W1H2) the receptor does not 




coordinated for full activation of Ste2p.  The fact that substitution of cysteine for residues in 
Gpa1p C-terminus did not significantly affect activities of either the receptor nor Gpa1p suggest 
that receptor-G protein coupling is mediated by more general structural features that involve 
network interactions between residues of both proteins.  Since this study was done with a limited 
number of residues (L228-I249) it is likely that additional residues before L228 in TM5 and/or 
after I249 in TM6 and also some TM3 residues may interact with Gpa1p in Ste2p in the 
inactive/active state.  
 Activation of the G protein by the receptor has been observed to alter interactions of 
residues in the GDP binding domains that open the GDP-binding cleft, allowing GDP 
dissociation and the subsequent binding of GTP.  Since the receptor binding domain of Gα is on 
the opposite face from the GDP-binding cleft, the interaction with the activated receptor must be 
transmitted by conformational changes to give rise to release of GDP.  Mutagenesis studies of 
the C-terminus of Gpa1p suggest that the C-terminus adopts different conformations during 
interaction with Ste2p and Ste3p (46).  However, this study could not predict the conformational 
changes that occur at the C-terminus of Gpa1p during receptor activation.   
Several models have been proposed for the mechanism of G protein activation.  In 
general, the models suggest that the α5-helix which comprises the C-terminus is the key 
transmission domain for signal transfer from the activated receptor to G protein (31, 32).  
Recently, conformational changes at the C-terminus of transducin Gα were proposed, based on 
structural and kinetic modeling by comparing the crystal structure of Gα and opsin-GαCT.  This 
helix switch mechanism suggests that the α5 helix (C-terminus) undergoes a rotational and 




α5-helix rotates counter-clockwise around its axis by 90° and tilts relative to the membrane 
normal by 42°.  This movement is accompanied by formation of hydrogen bonding networks 
between α5 and the active receptor (30).  
 In this study, two conformational changes are proposed based on the reactions of residues 
at the extreme end of the Gpa1p C-terminus with residues at the cytoplasmic ends of TM5-TM6 
in Ste2p.   The first conformational change observed was similar to the helix mechanism model 
of rotational movement of the C-terminus of Gpa1p (30).  This movement is supported by the 
switch of the interactions from Gpa1p-N465C/Ste2p-L247C or Gpa1p-N465C/Ste2p-I249C in 
the inactive conformation to Gpa1p-K467C/Ste2p-L247C or Gpa1p-I469C/Ste2p-I249C in the 
active conformation respectively (see Figure 6).  Since the C-terminus of the Gpa1p is predicted 
to have a helical structure (32) it will require about ~120o rotation of the helix to move K467 
from the inner core of the receptor to the IL3-Gpa1p interface, and vice-versa for N465.  Also, 
since TM6 of Ste2p has been suggested in this study to undergo ~30oC clockwise rotation upon 
ligand binding (see Part IV), similar to other GPCRs (63), it is proposed that Gpa1p may not 
have to undergo the full ~120o rotation as noted, but rather ~90o anti-clockwise rotation. 
The second conformational change is what we call the “withdrawal” movement, similar 
to the “translational” movement predicted by the helix switch mechanism (30).  This movement 
is observed in the switch of the interactions between Gpa1p-N465/Ste2p-I249 in the inactive 
conformation to Gpa1p-I469/Ste2p-I249 in the active conformation.  These changes in 
interaction will require the C-terminus of Gpalp to move about the height of the pitch of a helix 





Figure 6: Proposed 3D model of conformational changes in Ste2p TM5-TM6 cytoplasmic 
ends and C-terminus of Gpa1p during activation.  Ste2p and Gpa1p residues are labeled 
green and blue, respectively.  A, (inactive state): The C-terminus of Gpa1p is suggested to be 
closer to TM6 than TM5 in the inactive state.  Upon α-factor binding changes occur at the 
cytoplasmic ends of TM5 and TM6.  TM5 and TM6 are proposed to undergo rotation of ~30o in 
the anti-clockwise and clockwise directions, respectively (indicated by green arrows) similar to 
other GPCRs (63, 64).  The C-terminus of Gpa1p undergoes two possible changes (indicated by 
blue arrows), an anti-clockwise rotation of ~90o and a withdrawal of ~5.0 Å (horizontal and 
vertical shifts) from the inner core of the receptor to the cytoplasmic end.  B (active state):  TM5 
and TM6 are closer due to a shift in TM6 towards TM5 as observed in other GPCRs (63, 64).  
The C-terminus of Gpa1p is now closer to TM5 and withdrawn into the cytoplasmic surface of 




The vertical and horizontal movements result in a translational shift of the Gpa1p C-terminus 
from TM6 towards TM5 and probably TM3.  Since the data presented in this study can not 
differentiate between vertical and tilt movements, we can not assign any angle of translational 
movement.  However, the data show evidence for movement at the C-terminus of Gpa1p that 
results in about a 5.0 Å shift from the inner bundle of the receptor to the cytoplasmic surface.  
This “withdrawal” movement concurs with the α5-transmission rod concept that movement at 
the C-terminus of Gα opens the GDP-binding cleft, allowing GDP dissociation and the 
subsequent binding of GTP (19).   
We therefore propose that the C-terminus of the Gpa1p, upon activation of Ste2p, 
undergoes a ~90o anti-clockwise rotation and at the same time withdraws from the inner core of 
the receptor which involves a vertical shift of about 5.0 Å.  These conformational changes bring 
TM5 and TM6 closer to each other positioning L228 (TM5) and I248 (boundary between IL3 
and TM6) in close proximity to contact I469 and G470 of Gpa1p. It also generates new contacts 
between IL3 of Ste2p and C-terminal helix of Gpa1p; S243 interacts with Q463 and K467 with 
multiple hydrogen bonds, and L247 is located in close proximity with K467 probably mediated 
by hydrophobic interaction.  .  These conformational changes are consistent with a proposed 
model for transducin (30).  These movements may be critical for GPCR-Gα coupling and 
activation.  Further experimental work, such as identifying other residues in Ste2p and Gpa1p 
that are involved in these movements, will be needed to refine the mechanism of activation. 
 This study is the first to report specific residue-to-residue interactions between Ste2p IL3 
and Gpa1p.  The hydrophobic residues at the cytoplasmic ends of TM5 and TM6 are suggested 




conformational changes that occur at the extreme C-terminus of Gpa1p that may be required for 
receptor coupling and activation.  Overall the results presented indicate that Ste2p-Gpa1p 
interactions are similar to those observed for mammalian GPCRs especially the rhodopsin-like 
family receptors.  The information obtained in this study will serve as a platform for further 
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Part VI presents collaborative work with Dr. Fred Naider’s laboratory at the City University of 
New York, Staten Island. George K. E. Umanah performed all the work.  The pheromone 













Many external stimuli such as hormones, neurotransmitters and pheromones exert their 
effects in cells through G-protein-coupled receptors (GPCRs) that activate heterotrimeric G-
proteins leading to changes in the activity of effectors.  The heteromeric G proteins are 
comprised of three subunits, α (alpha), β (beta) and γ (gamma). Following ligand binding to 
GPCRs,  a cascade of events occur (1, 2).  The receptor interacts with a GDP-bound, inactive Gα 
subunit, which switches to a state where the guanine nucleotide binding site is empty.  GTP 
binds and activates the Gα subunit, causing dissociation of the α subunit from the ligand-
occupied receptor and dissociation of the βγ subunits. The activated Gα subunit now interacts 
with specific effector proteins, which results in changes in intracellular signaling.  The GTPase 
activity of the Gα subunit hydrolyzes GTP to GDP, resulting in conformational changes such that 
the subunit dissociates from the effector(s). The inactive GDP-bound Gα subunit now 
reassociates with the βγ subunits, and the cycle can be repeated if an appropriate agonist-
occupied receptor is available (6-11).   
In humans, GPCRs are encoded by about 900 genes, whereas the various Gα subunit 
proteins are encoded by less than 20 genes.  However, within a given cells type,  GPCRs are 
usually co-expressed with at least 7 different Gα protein subunits, each expressed to varying 
degrees.  This has been a major setback in understanding activation of G proteins by a GPCR in 
the mammalian system, and for pharmacologists who wish to understand aspects of GPCR–G 
protein interaction selectivity (1, 2, 12).  These challenges have been approached in most studies 
by co-expressing a specific G protein with its GPCR, and yet it remains impossible to insure that 
233 
 
the expression levels and cellular distribution of the individual G proteins are such that GPCR to 
G protein stoichiometry is constant for different pairings (5, 12).   
One of the most successful approaches used to maintain constant GPCR to G protein 
stoichiometry is the generation of a GPCR-Gα fusion protein.  The 1:1 stoichiometry imposed in 
fusion proteins has been a very useful tool for understanding GPCR-G protein interaction.  
GPCR-Gα fusions have been used to obtained information about ligand efficacy, intrinsic 
activity, kinetics of the receptor G-protein interaction, and the importance of post-translational 
acylation (12-15).  The fusion proteins, in most cases, are constructed by direct fusion of the 
GPCR C-terminus to the N-terminus of Gα (5, 12), however, some are constructed with a linker 
between the two proteins and/or truncation of the C-terminus of the receptor.  Most of these 
fusions have been shown to display wild type or constitutive activities (12).   
The use of GPCR-Gα fusions to obtain crystal structures of GPCRs has recently been 
given some attention.   Recent tricks used to achieve the stability and conformational 
homogeneity required for GPCR crystallization included the use of antibody complexes, fusion 
proteins, binding ligands, stabilizing mutants, and special crystallization environments (16-24).  
Although the crystal structures were resolved using these tricks, there were concerned about the 
disruption or deletion of receptor regions, such as the third intracellular loop, that are essential 
for receptor activity; raising the questions about how the complete, intact receptor interacts with 
its G protein and cognate ligand (25).  The use of a fusion protein to obtain crystal structures of 
GPCRs will provide new information regarding the structure of an intact receptor, which will be 
an advancement over the recent structures obtained.  
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The yeast Saccharomyces cerevisiae uses GPCRs for signal transduction in a manner 
similar to that observed in mammalian systems. The interactions between the S. cerevisiae α-
factor pheromone receptor, Ste2p, and its cognate Gα subunit, Gpa1p, have been shown in 
several studies to serve as a good model system for most GPCRs, (26-30).   It has also been 
shown that the Ste2p and Gpa1p fusion protein was functional with respect to signal 
transduction.  In addition, even a fusion between Ste2p and a chimeric yeast–mammalian Gα 
subunit was able to transduce signal efficiently (31).  However, detail activities of Ste2p-Gpa1p 
fusion was not reported .  The success of this construct in yeast demonstrated that Ste2p-Gpa1p 
fusion can serve as a tool to understand the interactions between these two proteins and will 
provide critical information regarding interactions that regulate protein activation and ligand 
binding.   
In this study, different variants of fusion proteins between Ste2p and the Gpa1p have 
been successfully constructed and shown to transduce signals efficiently.  These fusion proteins 
have biological activities similar to wild type Ste2p or Gpa1p and are capable of complementing 
the deletion of Ste2p and/or Gpa1p.  The fused proteins can be separated using factorXa protease 
to cleave a site that links the two proteins.  Truncation of the C-terminus of Ste2p that is not 
essential for signaling but for endocytosis (32) in the fusion construct increased both expression 
and activities of the fusion protein.  The use of the fluorescent guanine nucleotide analog 
BODIPY guanosine 5 ′-O-thiotriphosphate (BODIPY-GTPγS) has been adapted for use in an 
assay that allow for GTPase activities of the fusion protein to be measured.   This assay is based 
on the fact that the binding of BODIPY-GTPγS to Gα subunits, or any protein with GTPase 
activity, will yield increasing fluorescence signal making it possible to determine the GTP 
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binding activities of these proteins (33-35). Results indicate that this assay will be very useful in 
determining the activities of purified and reconstituted GPCR-Gα complexes.  The fusion 
construct will be used to investigate Ste2p-Gpa1p interactions using approaches such as the 
incorporation Bpa (described in part 3 of this dissertation) for photoaffinity cross-linking, 
cysteine disulfide cross-linking (described in part 5 of this dissertation) and ultimately to obtain a 




Materials and Methods 
Media, Reagents, Strains and Plasmids:   
Saccharomyces cerevisiae strain LM102 [MATa, bar1, leu2, trp1, ura3, FUS1-
lacZ::URA3, ste2∆ (3)] was used for Step2 growth arrest and binding assays; TM5117 [MATa, 
bar1, leu2, his3, ura3, FUS1-lacZ::URA3, ste2∆, gpa1∆ (3)] was used for Fus1-LacZ activities 
and the protease deficient strain BJS21 [MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 
ste2::KanR (36)] was used for protein isolation and immunoblot analysis.  GTPγS, GDP and 
BODIPY-GTPγS were obtained from Molecular Probes (Eugene, OR).  The STE2-GPA1 fusion 
plasmids were co-transformed by the method of Geitz (37) into LM102, TM5117 and BJS21.  
The plasmid pBKY1 containing STE2 with the cysteine residues and two known glycosylation 
sites replaced (Cys59Ser, Cys252Ser, Asn25Ser and Asn32Glu) and epitope tag comprising 
codons encoding a 9 amino acid sequence of rhodopsin (Rho-tag) introduced at the C-terminal 
end of the receptor sequence (4) was used in this study.   
 
Construction of fusion Ste2p-Gpa1p proteins: 
The following primers shown on table 1 were used for the constructions of the fusion 
proteins.  For that first fusion construct the open reading frame of GPA1 was PCR amplified 
from the plasmid YepGαβγ (38) and cloned into the plasmid pBKY1 using the BKG1 set of 
primers to yield the plasmid pBKG1 (refered to as wild type).  The pBKY1 was digested with 
EcoRI restriction enzyme and purified from an agarose gel for in vivo ligation with the GPA1 
PCR product using the transformation procedure described below.   
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Table 1: Names of plasmids constructed and used in this study. 
 
*The primers were used to amplify GPA1 from the plasmid YepGαβγ (38) and cloned into their templates by in vivo ligation. 
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The rhodopsin (TETSQVAPA) tag (Rho) was inserted between Ala5 and Pro6 of at the N-
terminal of STE2 in the fusion construct to produce the plasmid, pBKGR1.  This plasmid was 
used as the template for C-terminus truncated STE2 fusion plasmids, pBKG300, pBKG310, 
pBK320.  FactorXa restriction sites were incorporated between the STE2 and GPA1 using the 
pBKG1 as template to yield the plasmid pBKGX1.  Both FLAG (DYKDDDDK) and rhodopsin 
tags were inserted between residues Val457 and Thr458 of GPA1 in the pBUG1 and pBKGX1 
plasmids to generate the plasmids pBUGf1 /pBUGr1 and pBKXf1/pBKXr1 respectively.   All 
constructs except pBKG1 and pBUG1 were made by Dpn1 mediated site directed mutagenesis 
using the primers and templates listed on table 1.  The mutated plasmids were amplify in E. coli 
and isolated for DNA sequencing to verify the mutations.  The sequence of all constructs was 
verified by DNA sequence analysis completed by the molecular biology resource facility located 
on the campus of the University of Tennessee.  Three primers (F1424: [GTATATAAAGACG-
GTAGGTATTG]  (3), STE2B: [GGGATTGCTACAGTTACCATG] and GPA1B: [CTAGTGG-
ATCCATGGGGTGTACAGTGAG]) were used to sequence the fusion plasmids.  The GPA1 
plasmids were sequenced using two primers (F1424 and GPA1B).  DNA sequencing results were 
analyzed using the Megalign Lasergene V8.0.2 by DNASTAR Inc. (Madison, WI).  Mutagenic 
and sequencing primers were purchased from Invitrogen (Carlsbad, CA). 
 
Transformation and cell growth: 
For all transformation cells were cultured in selective media and grown to mid-log phase 
at 30oC with shaking (200 rpm) overnight. The cells were treated with LiAc (lithium acetate) as 
previously described.  Transformants were selected by growth on minimal medium (39) lacking 
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tryptophan (designated as MLT) to maintain selection for the plasmids.  All media components 
were obtained from BD (Franklin Lakes, NJ) and were of the highest quality available. 
 
Membrane extraction and Immunoblots: 
BJS21 cells expressing STE2 and GPA1 mutant constructs grown in their selective media 
were used to prepare total cell membranes isolated as previously described (40).  Cells were 
harvested and lysed by agitation with glass beads in 700 μL of HEPES buffer (50 mM HEPES 
(pH 7.5), 150 mM NaCl) and the following concentrations of protease inhibitors: 1.0 mM 
leupeptin, 10 μM pepstatin A, and 5.0 mM phenylmethanesulfonyl fluoride.  The lysate was 
cleared by centrifugation at 3000g for 2 minutes. The membrane fraction was harvested by 
centrifugation at 15000g for 30 minutes, and was then resuspended in the HEPES buffer with 
20% glycerol. Protein concentration was determined by BioRad (BioRad, Hercules, CA) protein 
assay (3).  For immunoblot analyses the membrane extract was solubilized in SDS sample buffer 
(BioRad, Hercules, CA) and 5 µg were fractioned by SDS-PAGE.  Blots were probed with 
antibody directed against the N-terminal 60 amino acids of Ste2p [generously provided by J. 
Konopka (32)], FLAG and rhodopsin antibodies (Sigma/Aldrich Chemical, St. Louis, MO) to 
detect Ste2p/Gpa1p or an antibody directed against Gpa1p (Santa Cruz Biotechnology, Inc., CA).  
The signals generated were analyzed using Quantity One software (BioRad, Hercules, CA). 
Growth Arrest Assays.  
 LM102 cells expressing the various fusion proteins or receptor alone were grown at 30 
ºC in MLT, harvested, washed three times with water and resuspended at a final concentration of 
5 x 106 cells/ml (36).  Cells (1 ml) were combined with 3.5 ml agar noble (1.1 %) and poured as 
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a top agar lawn onto MLT medium agar plate.  Filter disks (BD, Franklin Lakes, NJ) 
impregnated with α-factor pheromone (0.125 – 2.0 μg) were placed on the top agar.  The plates 
were incubated at 30 ºC for 18 hours and then observed for clear halos around the discs.  The 
diameter of halos around the discs were measured and analyzed by linear regression analysis 
using Prism software (GraphPad Software, San Diego, CA).  The experiment was repeated at 
least three times and reported values represent the mean of these tests. 
 
FUS1-LacZ Assays: 
LM102 and TM5117 cells expressing the various fusion proteins or Ste2p alone were 
grown at 30 ºC in selective media, harvested, washed three times with fresh media and 
resuspended at a final concentration of 5 x 107 cells/ml.  Cells (0.5 ml) were combined with α-
factor pheromone (final concentration of 1 μM) and incubated at 30 ºC for 90 minutes.  The cells 
were transferred to a 96-well flatbottom plate in triplicates, permeabilized with 0.5% Triton X-
100 in 25 mM PIPE buffer and then β-galactosidase assays were carried out using fluorescein di-
β-galactopyranoside (Molecular Probes, OR) as a substrate (41).  The reaction mixtures were 
incubated at 37oC for 60 minutes and 1.0 M Na2CO3 was added to stop the reaction.  The 
absorbance of the samples at excitation of485nm and an emission of 530 nMwas determined 
using a 96-well plate reader Synergy2 (BioTek Instruments, Inc., Winooski, VT).  The data were 
analyzed using Prism software (GraphPad Software, San Diego, CA).  The experiment was 





Whole cell saturation Binding Assay: 
This assay was performed using LM102 cells expressing expressing the fusion protein, 
BKG1 or receptor alone (BKY1).  The cells were grown at 30 ºC in MLT, harvested, washed 
three times with YM1 [ 0.5 M potassium phosphate (pH 6.24) containing 10 mM TAME, 10 mM 
sodium azide, 10 mM potassium fluoride,and 1% BSA] and resuspended at a final concentration 
of 4 × 107 cells/ml in YM1i (YM1 plus potassium fluoride (1 mg/ml), p-toluene-sulfonyl-l-
arginine methyl ester (3.8 mg/ml), NaN3 (0.6 mg/ml), bovine serum albumin (5 mg/ml) and 
tosyl-lysine chloromethyl ketone (1 mg/ml). (40)].  Cells (600 μl) were combined with 150 μl of 
ice-cold 5× binding medium (YM1i supplemented with 3H-labeled α-factor) and incubated on ice 
for 30 min. The final 1× concentrations of pheromone ranged from 0.8 to 100 nm. Upon 
completion of the incubation interval, 200-μl aliquots of the cell/pheromone mixture were 
collected in triplicate and washed over glass fiber filter mats using the Standard Cell Harvester 
(Skatron Instruments, Sterling, VA). Retained radioactivity on the filter was counted by liquid 
scintillation spectroscopy. LM102 cells lacking Ste2p, expressing only the empty vector (p424-
GPD), were used as a nonspecific binding control for the assays. Specific binding for each 
mutant receptor was calculated by subtracting the nonspecific values from those obtained for 
total binding. Specific binding data were analyzed by nonlinear regression analysis for single-site 
binding using Prism software (GraphPad Software, San Diego, CA) to determine the Bmax 






FactorXa cleavage of fusion proteins: 
The optimal conditions for factorXa activities were tested.  The initial conditions were to 
test factorXa activities at 4 oC and room temperature at different incubation time.  For the 
digestion, about 250 µg of membrane from BJS21 cells expressing fusion protein with factorXa 
cleavage sites (BKGXa) was resuspended in 250 µl 1X factorXa digesting buffer containing 
5units of factorXa enzyme in two separate tubes.  One of the tubes was incubated at 4 oC and the 
other at room temperature.  About 40 µl of the mixtures were aliquoted into fresh eppendorf 
tubes containing 20 µl of 3X SDS-PAGE sample buffer at 0 mins, 30 mins, 1 hour, 2 hours, 4 
hours and overnight (16 hours).  The extent of digestion of the fusion protein by factorXa was 
analyzed by Western blot using antibodies against Ste2p and Gpa1p.   To determine the optimum 
factorXa enzyme concentration, about 50 µg of membrane samples were resuspended in 40 µl 
1X factorXa digesting buffer containing different concentrations (0, 0.015, 0.03, 0.06, 0.12, 0.25 
and 0.50 Units) of factorXa enzyme.  The reaction mixtures were incubated at 4oC for 4 hours.  
About 20 µl of 3X SDS-PAGE sample buffer was added to each reaction mixture to stop the 
reaction and samples analyzed by immunoblot using antibodies against Ste2p and Gpa1p. 
 
BODIPY assay for GTPase activities of fusion proteins: 
BJS21 cells expressing Ste2p membranes were resuspended in MES buffer (20mM MES, 
10mM MgCl2, 2mM EDTA).  To determine the time course for fluorescence signal membranes 
samples (with or without 2.5 µM GTP) were mixed with 25 µM BODIPY-GTPγS in the 
presence or absence of 0.1 µM α-factor.  The fluorescence measurements was read every 5 
minutes with shaking before reading using a CytoFluor 4000 fluorescence plate reader 
243 
 
(Biosystems, Inc., Framingham, MA) at excitation of 485 nm and emission of  530 nm (33).  All 
experiments were done in opaque plastic 96-well plates at 25o C. Fluorescence signal in different 
BODIPY-GTPγS (0.25-2.0 µM) and α-factor (1.0 -1000 nM) concentrations were tested.  The 
effects of pH (6.0, 6.5, 7.0), NaCl (5.0-300mM), and GDP (0.5-400 µg/ml) were also 
investigated.  The data were analyzed using Prism software (GraphPad Software, San Diego, 
CA).  The experiments were done in triplicate and repeated at least three times and reported 
values represent the mean of these tests. 
 
The effects of GTP and GDP on Ste2p binding in fusion proteins: 
Membranes from BJS21 cells expressing the fusion proteins or Ste2p alone were 
extracted as described above.  Membranes (700 ml) were resuspended at a final concentration of 
0.25 mg/ml in YM1i containing 5.0 nM 3H-labelled α-factors and incubated for 60 minutes at 4o 
C in the presence of GTP-γ-S or GDP at different concentrations (1x10-4 – 1x10-10 M).  Upon 
completion of the incubation interval, 200-μl aliquots of the membrane mixture were collected in 
triplicate and washed over glass fiber filter mats using the Standard Cell Harvester (Skatron 
Instruments, Sterling, VA).  Retained radioactivity on the filter was counted by liquid 
scintillation spectroscopy.  Membrane from BJS21 cells lacking Ste2p, expressing only the 
empty vector (p424-GPD) was used as a nonspecific binding control for the assays.  Specific 
binding for each mutant receptor was calculated by subtracting the nonspecific values from those 
obtained for total binding. Specific binding data were analyzed by nonlinear regression analysis 






The plasmids encoding the STE2-GPA1 fusion and GPA1 constructed in this study are 
shown below.  These plasmids served as parental templates for site-directed mutagenesis which 
was used to generate the different constructs used in this study.  Site directed mutagenesis was 
undertaken using a primer mediated PCR based protocol. This approach involves using primers 
synthesized to contain specific site-directed mutations (see Table 1) to replicate the parental 
plasmids, thus incorporating the mutation into the newly synthesized plasmid. For selection of 
mutagenized plasmids, the PCR reaction mixture (containing a mixture of parental and 
mutagenized plasmids) was digested with the restriction endonuclease, DpnI (recognition target 
sequence: 5-Gm6ATC-3, where adenine residue is methylated) which selectively cuts the non-
methylated parental plasmid. The mutant plasmid generated in vitro is not methylated.  Thus, 
only the parental plasmid used as template in the mutagenesis reaction will be digested by DpnI, 
leaving the PCR mutagenized plasmid intact (43).  The BamHI and EcoRI digest of the plasmids 
showed the vector (~6.5 kb) in all plasmids (Figure 1).  The fusion STE2-GPA1 fragment (~2.9 
kb) comprising of STE2 (~1.35 kb) and GPA1 (~1.45 kb) and differences in sizes of truncated 








Figure 1: Agarose gel electrophoresis of the plasmids constructed in this study and maps of 
pBKG1 and pBUG1.  All plasmids were digested with BamH1 and EcoRI restriction enzymes 
from Biolabs Inc. (New England, Ipswich, MA).  The vector fragment (~6.5 kb) was observed in 
all plasmids.  The fusion STE2-GPA1 fragment (~2.9 kb) comprising of STE2 (~1.35 kb) and 
GPA1 (~1.45 kb).  Differences in sizes of truncated fusion plasmids were also observed.
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Expression of fusion protein: 
To create a Ste2p-Gpa1p fusion protein the C-terminus of Ste2p was linked directly to the 
N-terminus of Gpa1p. To verify that the fusion protein was expressed, total membranes were 
isolated from BJS2, a proteases deficient yeast strain, expressing either the fusion protein 
(BKG1) or Ste2p (BKY1).  Membranes from both strains were run on SDS-PAGE, 
immunoblotted, and probed with antibodies directed against Ste2p or Gpa1p.  The Ste2p (BKY1) 
used in this study to create the Ste2p-Gpa1p fusion protein is Cys-less (C59S and C252S), lacks 
glycosylation sites (N25G and N32G), and contains a 9 amino acid rhodopsin epitope tag (rho-
tag) introduced at the C-terminal end of the receptor.  This version of Ste2p was observed on 
blots at the 48 kDa position (4).  When membrane fractions containing Ste2p was resolved by 
SDS-PAGE a band corresponding to 48 kDa was observed on the anti-Ste2p blot, whereas a 
band of approximately 100 kDa was detected in samples containing the fusion protein (Figure 
2A).  The yeast Gpa1p was observed at the 52-54 kDa position (44).  On the anti-Gpa1p blot a 
band at 52-54 kDa, corresponding to endogenous Gpa1p expressed in the BJS21 strain, was 
observed in all the lanes.  A band of approximately 100 kDa was observed on an anti-Gpa1 
immunoblot of membrane fraction containing the fusion Ste2p-Gpa1p protein, indicating that the 
high molecular weight band observed in the anti-Ste2p blot is indeed a signal from the fusion 
protein.  The fusion protein was expressed at significantly reduced levels, ~50% compared to the 






A:  Expression of fusion (BKG1) & Ste2p (BKY1)  B:  Growth arrest activities 
   
 
C: Pheromone induced FUS1-LacZ transcription  D:  Pheromone binding activities 
     
 
Figure 2: Biological activities of Ste2p-Gpa1p fusion protein.   A: Images of blots showing 
the expression of the fusion protein (BKG1) and Ste2p (BKY1).  A band at the ~100 kDa 
position corresponding to the fusion protein is observed on both the anti-Ste2p and anti-Gpa1p 
blots.  About a 48 kDa band corresponding to Step was observed only in the anti-Ste2p blot, 
whereas a weak band corresponding to the endogenous Gpa1p expressed in the BJS21 cells was 
observed in all lanes on the anti-Gpa1p blot.  B: A plot of halo sizes (pheromone induced growth 
arrest) around discs on lawn of cells.  C:  Pheromone induced β-galactosidase activities.  D: The 
binding curves for fusion protein and Ste2p used to determine their binding affinity for α-factor. 
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Fusion protein complements Ste2p and Gpa1p deletion: 
The functional activities of the fusion protein were examined by pheromone binding 
assay, α-factor induced cell cycle arrest (halo assay) and FUS1-LacZ reporter gene activity.  
Comparison of halo (zone of growth arrest) size demonstrated that the fusing of Gpa1p to the C-
terminus of Ste2p did not compromise the fusion protein’s ability to mediate growth arrest in 
response to α-factor (Figure 2B).  The fusion protein showed about 90% of the control Ste2p 
growth arrest activities.  One of the earliest responses of the yeast cell to pheromone is the 
transcription of the gene FUS1.  The FUS1 gene product is involved in the fusion of cells during 
conjugation. The strains (LM102 and TM5117) used in this study contain a reporter gene 
construct consisting of a fusion between FUS1 promoter and the lacZ gene encoding the enzyme 
β-galactosidase (45).  This allows for rapid, sensitive detection of mating pathway activation by 
assessing β-galactosidase activity in response to mating pheromone (41).  The LM102 strain is 
Ste2p deficient but expresses endogenous Gpa1p, whereas the TM5117 strain is deficient in both 
Ste2p and Gpa1p.  The absence of Gpa1p in the TM5117 strain results in high basal FUS1-LacZ 
activities since the free Gβγ subunits are constitutively active.  Ordinarily, the Gα subunit (GDP-
bound, inactive state) binds Gβγ and renders the subunits inactive.  However in the presence an 
activated receptor, Gα exchanges bound GDP for GTP and the now active Gα-GTP subunit 
dissociates from Gβγ thus allowing these units to become active (9).  Assessment of β-
galactosidase (LacZ) activity in response to α-factor in LM102 cells indicated that the fusion 
protein induce the transcription of the FUS1 gene at levels similar to Ste2p (Figure 2C).  In the 
TM5177 strains the expression of the fusion protein was capable of reducing the Gβγ mediated 
β-galactosidase activity, and also responded to pheromone by increasing the activity.  The 
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reduction of basal β-galactosidase activity in TM5117 implies that the fusion protein also 
interacts with the Gβγ protein subunits in the cell.  Thus, the fusion protein was able to 
complement the deletion of both Ste2p and Gpa1p in the strains that were tested in this study. 
 
Fusion protein has similar affinity for α-factor to that of Ste2p: 
Although the immunoblot analysis (Figure 2A) showed that the fusion protein was 
expressed in the total membrane fraction, information about the cell surface expression could not 
be determined from this analysis.  Cell surface expression was examined using LM102 in a 
whole cell saturation binding assay to measure the Bmax (receptors/cell) and Kd (ligand binding 
affinity) values (Figure 2D).   Previous studies indicated that the control Ste2p used in this study 
has a binding affinity (~ 13 nM) similar to that of wild type Ste2p (4).  The Kd value measured 
for the fusion protein was 14.5 nM compared to 13.8 nM for the control Ste2p used in this study.  
The Bmax values that indicate the number of receptor molecules per cell was 37,600 for control 
Ste2p compared to 16,000 fusion protein receptors per cell.  Though the surface expression level 
of the fusion protein is about 50% that of Ste2p both proteins have similar affinity for the ligand, 
α-factor as determined by the Kd values. 
 
Expression and activities of Fusion protein containing factorXa: 
Some of the approaches that will be used in the fusion protein to determine the 
interactions between Ste2p and Gpa1p include cross-linking via disulfide bond formation or 
photoaffinity covalent linkage using Bpa.  In order to identify if a cross-link formed between 
Ste2p and Gpa1p in the fusion protein, two factorXa protease sites (IEGRIEGR) were inserted 
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between the two proteins to generate the BKGX1 construct.  This fusion protein is expressed and 
has functional activities similar (see Figure 3A-C) to the wild type fusion protein (BKG1).  Both 
proteins have a Kd value of about 15 nM.  Experiments were conducted to determine the 
optimum conditions for factorXa digestion of the Ste2p-Gpa1p fusion protein. The effects of 
temperature and incubation time were examined by treating membrane samples containing the 
fusion protein with 0.1 units of factorXa protease at 4 oC and at room temperature.  Aliquots of 
the reaction mixtures were transferred into fresh eppendorf tubes containing 3X SDS-PAGE 
sample buffer at 30 min, 1 hour, 2 hours, 4 hours and overnight (16 hours).  The extent of 
cleavage of the fusion protein by factorXa digestion was analyzed by immunoblotting using 
antibodies against Ste2p and Gpa1p (Figure 3D).  The appearance of a Ste2p band on the anti-
Step blot and a Gpa1p band on the anti-Gpa1p blot in fusion protein samples treated with 
factorXa indicate that the protease was capable of cutting the fusion protein into two separate 
proteins.  The results showed that treatment at 4 oC was better than at room temperature and that 
4 hours of incubation was sufficient enough to cleave most of the proteins.  Shorter periods of 
incubation (30 mins and 1 hour) were not sufficient for adequate cleavage, whereas longer 
periods (overnight, 16 hours) resulted in degradation of the proteins as a result of non-specific 
digestion.   
The enzyme concentration required for optimum cleavage was also examined.  The 
results showed that 0.5 unit of the factorXa enzyme was sufficient to digest most of the fusion 









Figure 3: Activities of fusion protein with factorXa site..  A: Images of blots showing the 
expression of the fusion protein with factorXa site (BKGX1).  B: A plot for growth arrest.  C: 
The binding curves for BKG1 (wild type) and BKGX1.  D-E: Blot images showing results for 
optimizing temperature, incubation time and enzyme concentrations for factorXa digest of fusion 
protein.  F:  Blot images showing example of results of digested fusion protein using the 
optimum conditions determined in this study for the factorXa. 
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Based on these results the protocol for factorXa digestion of the fusion protein in typical 
cross-linking studies was standardized to include 50 µg of membrane proteins suspended in 40 µl 
1X factorXa buffer containing 0.5 units of factorXa enzyme and then incubated at 4 oC for 4 
hours.  Approximately 20 µl of 3 X SDS-PAGE sample buffer is added to stop the reaction, and 
the resulting product is analyzed by immunoblotting using antibodies against both Ste2p and 
Gpa1p.  An example of the results of this protocol is shown in Figure 3F using a fusion protein 
without factorXa as a control.  Thus Ste2p and Gpa1p in the fusion protein can be separated by 
factorXa enzymatic cleavage. 
 
Phenotypes of N-terminal tagged and C-terminal truncated Ste2p fusion protein: 
One of the reasons for constructing the fusion protein is to obtain a Ste2p-G protein 
complex that will stable for X-ray crystallographic studies.  These studies require the use of a 
large quantity of purified protein.  The low level of Ste2p-Gpa1p fusion protein expression is a 
major concern if this protein will be used for such studies.  To improve on the expression levels 
we truncated part of the C-terminal region of Ste2p that has been identified to be essential for 
endocytosis of the receptor (46, 47).  The rhodopsin epitope tag (TETSQVAPA) was inserted 
between residues Ala5 and Pro6 of Ste2p for detection and affinity purification resulting in the 
creation of the BKGR1 protein.  This BKGR1 was used as the template for C-terminal truncation 
of Ste2p.  Three different truncations were constructed, BKGR-300 (last 131 residues of Ste2p 
deleted at position Asn300), BKGR-310 (last 121 residues deleted at position Ser310) and 
BKGR-320 (last 111 residues deleted at position Tyr320).  The N-terminal tagged fusion protein 




Figure 4:  Activities of truncated fusion proteins.  A:  Blots images of wild type (full length) 
and truncated fusion and Gpa1p as control.  The samples were probed with anti-Gpa1p antibody.  
B:  A plot of the sizes of halos formed as a result of cell cycle arrest in cells responds to 
pheromone, α-factor.  C:  The binding curves to measure the binding affinity of the Step N-
terminal tagged fusion protein (BKGR1). 
 
However, both growth arrest and ligand binding results indicated that the N-terminal tagged 
fusion protein was slightly less active than the wild type fusion protein.  The binding affinity of 
BKGR1 was determined to be 18 nM (Figure 4C).  These results imply that N-terminal tagging 
of Ste2p did not significantly affect the activities of the fusion protein.  The immunoblot analysis 
revealed three bands at about the 87, 88 and 89 kDa positions in lanes of membrane samples 
containing Ste2p-C-terminal truncated fusion proteins, BKGR-300, BKGR-310 and BKGR-320 
respectively (Figure 4A) verifying that the proteins were indeed truncated.  All of the truncated 
mutants had increased expression levels and growth arrest activities compared to the full-length 
fusion proteins.  The BKGR-310 protein was approximately 2-fold more active in the growth 
arrest assay than the non-truncated fusion proteins. 
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Activities of C-terminal tagged Gpa1p fusion proteins: 
The wild type fusion protein (BKG1) constructed in this study had only one epitope tag 
(rhodopsin tag) located at the extreme C-terminus of Ste2p.  Gpa1p fusion to Ste2p reduced 
accessibility of antibody to the epitope tag, making it difficult to detect the fusion protein on 
blots.  The Ste2p N-terminal Rho-tagged fusion protein (BKGR1 described above) is one of the 
alternative solutions to this problem.  Another alternative is to insert an epitope tag at the C-
terminal portion of Gpa1p for both detection and purification purposes.  Both Rho 
(TETSQVAPA) and FLAG (DYKDDDDK) epitope tags were inserted between residues Val457 
and Thr458 of Gpa1p using the wild type plasmids pBKG1 (fusion protein) and pBUG1 (Gpa1p) 
to generate the plasmids pBKGr1 (fusion-Rho)/pBKGf1 (fusion-Flag) and pBUGr1 (Gpa1p-
Rho)/pBUGf1 (Gpa1p-Flag) respectively (Figure 5). The proteins were expressed in BJS21 cells 
and membranes were extracted for immunoblot analyses.  The immunoblot analyses (Figure 5A) 
show that all proteins were expressed except for those with the Rho tag (BKGr1 and BUGr1).  
The DNA sequences of these plasmids were checked again.  The sequence results showed there 
was no other mutation apart from the Rho tag inserted.  To check if these proteins were 
expressed at very low levels, the amount of membrane protein loaded on the gel was increased 
by 10-fold, but a signal was not observed (data not shown).  In addition TM5117 cells expressing 
these proteins did not display any activity (Figure 5C) indicating that the inclusion of the Rho tag 
was not tolerated by these mutants.  In contrast the insertion of the FLAG epitope tag at the same 
position did not affect the activities of either the fusion protein (BKGf1) or Gpa1p alone 
(BUGf1).  The biological activities showed that BKGf1 had similar binding (Kd value of 16 nM) 








Figure 5:  Activities of C-terminal tagged Gpa1p in fusion protein.  A: Images of blots 
showing the expression of the fusion protein (BKG) and Gpa1p (BUG) with FLAG (f) or Rho (r) 
tags.  B: A plot of pheromone induced halo (growth arrest).  C:  Pheromone induced β-
galactosidase activities.  D: The binding curves for wild type fusion protein (BKG1) and fusion 
protein with FLAG tagged at the C-terminal of Gpa1p (BKGf1). 
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BODIPY assay for GTPase activities of Ste2p-Gpa1p Fusion protein: 
To determine whether the fusing of Gpa1p to Ste2p affects its ability to bind GTP, a 
GTPase fluorescence assay that depends on GTP binding (33-35) was adapted and modified for 
this study.  This method uses BODIPY guanosine 5 ′-O-thiotriphosphate (BODIPY-GTPγS, 
referred to as BODIPY in this study) as a probe for GTPase activity.  It has been shown that the 
interaction of GTPase with BODIPY results in increased fluorescence signal corresponding to 
GTP binding (35).  This property of BODIPY was exploited to design an assay for determining 
the GTPase activities of the fusion protein.  For preliminary studies membrane extracted from 
BJS21 expressing Ste2p and endogenous Gpa1p was used.  It was proposed that when Ste2p and 
Gpa1p are in the membrane, binding of α-factor to Ste2p will induce activation of Gpa1p leading 
to an increased affinity for GTP.  Thus in the presence of α-factor the binding of BODIPY to 
Gpa1p is expected to increase fluorescence signal.  However, initial studies showed that although 
GTP (1 μM) was able to reduce BODIPY (5 μM) signal, the presence of the α-factor pheromone 
(1 μM) caused reduction rather than enhancement of fluorescence signal (Figure 6A).  We tested 
whether α-factor had any quenching effects on fluorescence signal by mixing different 
concentrations of α-factor and BODIPY without membrane (Figure 6B).  The results indicated 
that fluorescence signal is reduced in the presence of α-factor (as low as 1 nM) even in the 
absence of membrane.  The most drastic reduction was seen in the presence of pheromone 
concentrations of more than 10 nM.  For subsequent studies 10 nM α-factor and 0.5 μM 
BODIPY was used.  The effect of pH was also determined by testing pH 6.0, 6.5 and 7.0 using 
BJS21 membranes containing Ste2p and Gpa1p.  The results suggest that ligand induced increase 







Figure 6: Optimizing condition for BODIPY-GTP assay.  A: Time course curves showing the 
effects of GTP.  B: a plot of different concentrations of α-factor showing the signal quenching 
effects of the pheromone.  C:  a graph of different pH conditions and BODIPY concentrations in 
the presence and absence of ligand.  D:  Curves showing the effects of different concentrations 
of GDP on fluorescence signal. 
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The concern of the BODIPY binding to any protein with GTPase activity other than Gpa1p was 
addressed by adding GDP to the mixture to occupy all guanine nucleotide binding sites in 
GTPase-like proteins.  The effects of GDP on fluorescence signal in the presence and absence of 
pheromone were examined (Figure 6D) by mixing membranes with GDP and incubating for 15 
minutes at 4oC before adding α-factor and BODIPY.   GDP at concentrations between 10 – 100 
μg/mL reduced non-specificity of the BODIPY binding and also displayed increased 
fluorescence signal upon α-factor binding to Ste2p.  Based on these results it was determined that 
a typical BODIPY assay should involve 20 mg membrane proteins resuspended in 90 μl of 
HEPES or MES buffer at pH 7.0 containing, 10 mM MgCl2, and 10 μg/mL of GDP.  The 
mixture is incubated for 15 minutes at 4oC before adding α-factor (10 nM) and BODIPY (1.0 
μM).  To eliminate background (non-specific) signals, a parallel set of reactions is carried out in 
membranes in the absence of Ste2p, Gpa1p, or fusion proteins.  The fluorescence signals of the 
background are subtracted from that of the test samples and the differences are plotted. 
 
GTP and GDP binding to Gpa1p in the fusion protein affect Ste2p affinity for α-factor: 
The GTPase activity of the wild type fusion protein (BKG1) expressed in BJS21 cells 
were examined using the BODIPY assay designed in this study.  The results shown in figure 7 
indicate that BJS21 (expressing endogenous Gpa1p) membranes containing the Ste2p-Gpa1p 
fusion protein displayed a higher increased in fluorescence signal compared to membranes 
containing control Ste2p.  The membrane sample containing the fusion protein also had high 
basal fluorescence due to the high level of Gpa1p (fusion) present compared to the low level of 




Figure 7: GTPase activities of fusion protein.  The fluorescence signal of membranes extracted 
from BJS21 cells expressing wild type fusion protein (BKG1), Ste2p (BKY1) or empty vector 
(p424) using the BODIPY assay optimum conditions determined in this study.  The fusion 
protein showed better response to α-factor than Ste2p. 
 
These results indicate that the BODIPY assay can be used to determine GTPase activity 
of the fusion protein, and it will be very useful for studies of GTPase activity in purified samples.  
Ligand binding to a GPCR results in reduction in the affinity of GDP bound to the Gα protein, 
and an increase in its affinity for binding to GTP.  It has been shown that increasing 
concentrations of GDP reduce the binding affinity of ligand for the GPCR (14).  The binding 
affinity of the wild type fusion protein in the presence of increasing concentrations of GDP was 
examined using BJS21 membranes containing Ste2p or the fusion proteins.  The membrane 
samples (also contain endogenous Gpa1p expressed by the BJS21 cells) were incubated with 
different concentrations of GDP for 20 minutes before adding 10 nM 3Hα-factor to each reaction 
mixture for another 30 minutes of incubation at 4oC.  The membranes were washed (see 
materials and methods for details) to get rid of unbound 3Hα-factor and then the amount of 3Hα-
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factor associated with the membrane were counted by counting 3H.  For background membranes 
transformed with empty plasmids were treated in similar manner.  The 3H count of the 
background was substrated from the counts of the control Ste2p and fusion protein samples to 
obtain specific binding counts.  The specific counts were plotted as percentage (using samples 
with no GDP as 100%) against the different concentrations of GDP.  The % 3Hα-factor binding 
results (Figure 8 A) suggest that increasing concentrations of GDP leads to a reduction in the 
affinity of Ste2p for α-factor in both the control Ste2p and the fusion protein.  However, the 
fusion was more sensitive to the GDP effects than the control Ste2p.  Thus, whereas 1x10-4 M of 
GDP reduced the binding affinity in the control Ste2p by 50% only 1x10-8M of GDP was 
required to cause similar effect in the fusion proteins.  When GDP was added to membranes after 
3Hα-factor binding no significant reduction in receptor affinity for α-factor was observed (Figure 
8A).   
The effect on the Ste2p-α-factor interaction caused by GTP binding to Gpa1p was also 
examined by conducting the fusion binding to 10 nM 3Hα-factor in the presence of increasing 
concentrations of GTPγS.  The results (Figure 8B) suggest that increasing the concentration of 
GTP led to decreased affinity of Ste2p for α-factor, and similar results were obtained whether the 
GTP was added before or after 3Hα-factor binding.  GTP treatement reduced α-factor binding 
was by about 65% in fusion protein. While only about a 40% reduction was observed in Ste2p 
membrane samples.  Again the fusion was observed to be more sensitive to GTP than the Ste2p 
as observed for the effects of GDP.  Thus, whereas 1x10-5 M of GTP reduced the binding affinity 





Figure 8: GDP/GTP effects on α-factor binding to fusion.  A: Binding curves of membranes 
extracted from BJS21 (expresses Gpa1p) cells expressing fusion (BKG1) or Ste2p (BKY1) 
proteins.  The binding affinities of the proteins were measured before or after GDP treatment at 
different concentrations.  B:  Binding curves of membranes from BJS21 and TM5117 expressing 




Since the BJS21 strained used for these assays also expresses Gpa1p, it was possible that 
the effect of GDP/GTP binding might be mediated by this endogenous Gpa1p, rather than the 
Gpa1p physically fused to Ste2p in the fusion protein.  To investigate this, the effect of GTP on 
receptor-ligand affinity was tested using membranes from the strain TM5117 (both Step and 
Gpa1p deleted) expressing either fusion or control Ste2p proteins.  While the fusion protein 
affinity for α-factor was reduced by the presence of increasing GTP concentration there was no 
significant changes in the Ste2p affinity (Figure 8B).  These results imply that the Gpa1p in the 
fusion protein binds to GDP or GTP and this affects the interactions of Ste2p with α-factor in a 









Although crystal structures for four GPCRs have been obtained, there are no structures 
for physiologically active GPCR-Gα complexes and details of the signal transduction 
mechanisms employed by GPCRs remains unclear (25). Signaling in the GPCR transduction 
cycle involve complexes of the receptors with other proteins including other GPCRs (dimer 
formation) and its cognate G proteins.  The use of GPCR fusions to understand the complex 
interactions between the receptor and its Gα subunit has become very popular since such fusion 
proteins provide a defined 1:1 stoichiometry of GPCR to Gα.  In this manner, bias in the analysis 
of ligand potencies and efficacies caused by varying ratios of receptor to G proteins can be 
eliminated.  This approach has been very useful in providing information about ligands and G 
protein interactions with GPCRs (5, 12, 14, 25).  Recently the crystal structure of opsin in its 
transducin C-terminus bound form and the various tricks used to obtained crystal structures of 
GPCRs indicate that GPCR complexes purified as conformationally homogeneous species may 
be more stable than monomeric receptors, hence more suitable for crystallization (23, 25, 48).  
Thus, the use of fusions proteins, such as GPCR-Gα, should enhance stability and prove very 
useful for crystallographic and other biophysical studies.  This part of the dissertation describes 
the expression and activities of different variants of the yeast GPCR Ste2p fused to its cognate 
Gα, Gpa1p.  Although, the Ste2p-Gpa1p fusion protein has been reported earlier (31), the authors 
did not carry out detailed characterization of this fusion protein.  The study only reported mating, 
growth arrest and FUS1-LacZ activities of the Ste2p-Gpa1p fusion protein that lacks the last 60 
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amino acids of Ste2p.  In this report detailed activities of full length and truncated Ste2p-Gpa1p 
fusion proteins are discussed. 
Analysis of the expression of the full length Ste2p-Gpa1p fusion indicates that the protein 
is expressed at 50% of the level of Ste2p.  This reduced expression may be due to a low rate of 
folding or trafficking of the large fusion protein to the membrane, compared to the trafficking of 
the smaller, separate proteins.  The ability of the Ste2p-Gpa1p fusion protein to function as a Gα 
subunit, and also as a receptor was addressed by expressing the protein in yeast cells devoid of 
Ste2p and/or Gpa1p.  The functionality of the fusion as a receptor was first examined by 
expressing the fusion protein in cells devoid of Ste2p.  Pheromone induced cell cycle arrest and 
FUS1-LacZ activities all indicated the fusion can complement the deletion of Ste2p.  Though the 
Bmax value indictaed that the fusion is expressed at the cell surface at only 50% of the Ste2p 
level, it has a binding affinity (~14 nM) similar to that of the WT receptor.  This implies that the 
direct attachment of Gpa1p to Ste2p did not alter its ability to function as a receptor and that it 
still maintains wild type activities as indicated by the biological assay..  The functionality of the 
fusion as a Gα protein was also examined by determining the activities in Ste2p and Gpa1p 
deleted strain (TM5117).  The deletion of Gpa1p results high basal FUS1-LacZ activities in 
TM5117 because the free Gβγ subunits are constitutively active.  When bound, the Gα subunit 
(GDP-state) renders the Gβγ subunits inactive.  However in the presence of an activated receptor, 
Gα-GDP exchanges GDP for GTP and the active Gα-GTP subunit dissociates from Gβγ thus 
allowing these units to become active.  The subsequent hydrolysis of GTP to GDP makes the 
Gα-GDP subunit available for another cycle (9).  Expression of the fusion protein in TM5117 
showed that this protein could interact with the endogenous Gβγ subunits leading to reduced 
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basal FUS1-LacZ activities (Figure 2C).  However, in the presence of ligand, the FUS1-LacZ 
activities increased, implying that Gpa1p in the fusion was able to couple with the Ste2p (directly 
attached) and the Gβγ subunits.   
Further analysis of Gpa1p in the fusion indicate that it still binds effectively to GTP and 
GDP, and that these interactions with GTP and GDP affect Ste2p binding with α-factor, as 
observed in other GPCRs (14, 49).  The high GTPase activities (BODIPY assay) of the fusion 
observed in response to α-factor also show that the coupling between Ste2p and Gpa1p proteins 
is not affected.  Although the BODIPY assay was able to measure the GTPase activities of the 
fusion protein, the assay still needs to be further refined.  For instance, the quenching effects of 
the pheromone may be a setback for fusion or Gpa1p mutants that require high pheromone 
concentration to trigger a detectable biological response.  Nevertheless, the results obtained from 
this assay indicate that it is very promising for determining the GTPase activities of purified 
proteins.  In the presence of GTP, a 65% reduction of binding was observed in the fusion protein 
compared to 40% when the two proteins were expressed independently.  The high sensitivity of 
the fusion protein to the effects of GDP or GTP can be attributed to the fact that the fusion 
provide 1:1 stoichiometry of Ste2p to Gpa1p; hence all ligand-bound-Ste2p in the fusion will be 
associated with a Gpa1p that will alter the binding affinity if the Gpa1p is bound to a GDP or 
GTP whereas not all ligand-bound-Ste2p is associated with Gpa1p in the control sample.    Thus, 
results from biochemical studies of GPCRs interactions with G proteins are most likely to be 
more precise using fusion proteins than the separate proteins. 
One of the reasons for constructing the Ste2p-Gpa1p fusion was to use the protein for 
cross-linking studies between the two proteins.  To do this, two factorXa protease sites 
266 
 
(IEGRIEGR) were inserted between the two proteins.  The fusion protein containing the 
factorXa site displayed functional activities identical to the wild type fusion.  A factorXa 
digestion protocol, developed for this study, was used to analyze both the wild type and the 
factorXa-mutant fusions.  The results indicated that the factorXa fusion mutant can be separated 
by enzymatic cleavage using the factorXa enzyme.  The disappearance of the fusion band and the 
appearance of bands of equivalent intensity at the Ste2p and Gpa1p positions on the 
immunoblots indicate that almost all the fusion were completely separated into Ste2p and Gpa1p.  
This enzymatic cleavage of the fusion protein proved to be very successful and reliable.  Thus, 
covalent interactions or cross-linking between Ste2p and Gpa1p in the fusion can be assessed 
using this methodology.  In this approach, when a covalent bond is formed by chemical cross-
linking between residues of Step and Gpa1p, the two proteins will still be attached via the 
covalent bond even after digestion of the complex with factorXa.  However, in the absence of a 
covalent bond the two proteins will run as separate entities on SDS-PAGE following factorXa 
digestion.  This technique will be very useful in identifying residue to residue interactions 
between the two proteins. 
 The Ste2p-Gpa1p fusion was also constructed for crystallographic and other biophysical 
studies that will provide structure-function information.  These studies require the use of a large 
quantity of purified protein.  The fusion protein in this study is expressed at levels about 50% of 
that observed for Ste2p.  To improve the expression level of the fusion protein, parts of the C-
terminal region of Ste2p that have been suggested to be essential for down-regulation by 
endocytosis were truncated.  Although, the N-terminus of Ste2p has been implicated to be 
essential for activity of the receptor (50, 51), a Rho (TETSQVAPA) epitope tag inserted between 
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Ala5 and Pro6 of Ste2p in the fusion protein (also in all truncated mutants) did not significantly 
affect its activity.  Three different truncations created by deleting the last 131 (Gpa1p attached to 
Asn300), 121 (Gpa1p attached to Ser310) or 111 (Gpa1p attached to Tyr320) residues of Ste2p 
displayed better expression and function (about 2-fold activities) than the wild type fusion.  The 
high functional activities of these truncated fusion mutants could be due to the increase in 
receptor number (as observed on the immunoblot, Figure 4A) and/or as a result of the reduced 
ability to down-regulate by endocytosis as observed for C-terminally truncated Ste2p mutants 
(32).  However, the expression level of these truncation mutants was about 70% of that for WT 
Ste2p.  Although truncation of the C-terminus increased the expression level of the fusion 
protein, this increase is still not enough for the production of large quantities of purified protein 
required for X-ray crystallographic studies.  It is therefore suggested that some further 
modifications be made to the protein, or alternately an expression system other than S. cerevisiae 
should be employed to improve expression levels.   
The insertion of the FLAG epitope tag (DYKDDDDK) between residues Val457 and 
Thr458 in Gpa1p of the fusion did not alter its activity to function as a Gpa1p protein.  This 
fusion protein displayed activities identical to wild type Gpa1p or similarly tagged Gpa1p 
mutant.  It also retained receptor functions similar to those of Ste2p.  Interestingly when the Rho 
tag was inserted at the same position, no detectable expression of either the fusion protein or free 
Gpa1p was observed on immunoblots using antibodies against Ste2p, Gpa1p and/or the Rho 
epitope.  Cells transformed with plasmids bearing these constructs did not display any observable 
activities.  The α5 helix (C-terminus) of the Gpa1p is known to play a critical role in mediating 
Ste2p coupling.  However, several studies have shown that the last five amino acids of Gpa1p are 
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critical for such activities (44, 52), therefore residue Val457 (16 residues away from the C-
terminus) was chosen as the site to insert the epitope tag.  It is not clear why the Rho tag affected 
protein expression of both the fusion and Gpa1p proteins, while the FLAG tag did not.  One 
possible explanation is that the FLAG epitope tag is more hydrophilic than the Rho tag.  Thus, 
that region of Gpa1p can tolerate the very hydrophilic FLAG tag but not the moderately 
hydrophilic Rho epitope tag.  Since N-terminal Rho tagging of Ste2p in the fusion protein 
displayed expression and activities similar to those of the the wild type fusion, it will not be 
necessary to put the Rho tag on Gpa1p. 
This study is the first to report detailed activities of a full length Ste2p-Gpa1p fusion 
protein that retains the function (both in vivo and in vitro) of each individual protein, and can 
complement the deletion of both proteins.  The fusion protein functions as a receptor (Ste2p) 
with near wild type affinity for α-factor and as a tethered Gα protein (Gpa1p) with affinity for 
GTP/GDP similar to that for the native Gα.  The fusion protein could be separated by cleaving a 
protease site that was engineered between the two proteins.  Truncation of the C-terminus of 
Ste2p in the fusion increased both expression and activities of the construct.  This fusion protein 
will be a very useful tool to study the structure-function relationship between the receptor and 
Gα proteins, and should help to develop an understanding of the critical interactions required for 
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General Conclusions and Discussion 
This dissertation details how three different cross-linking approaches have been used to 
understand the interactions between the Saccharomyces cerevisiae pheromone receptor, Ste2p, 
its ligand, α-factor, and its cognate Gα protein, Gpa1p.  Chemical cross-linking using DOPA-α-
factor analogs have provided insights into the interactions of the C-terminus of α-factor with 
specific residues in Ste2p.  The incorporation of benzoyl-L-phenylalanine (Bpa) into Ste2p for 
photoaffinity cross-linking to identify specific residues that contact or are in close proximity with 
α-factor is also reported.  The use of cysteine disulfide cross-linking to determine specific 
residue-to-residue interactions in the Ste2p-Ste2p homo-dimer and the Ste2p-Gpa1p hetero-
dimer revealed conformational changes in Ste2p and Gpa1p that occur during signal 
transduction.  Finally different variants of Ste2p-Gpa1p fusion proteins that displayed biological 
activities similar to Ste2p and Gpa1p proteins are also discussed.  In this final part of the 
dissertation, the major findings of these studies are summarized, including how these results 
contribute to current knowledge of GPCRs interactions with their ligands and G proteins, and an 
outline for future experiments that will provide further details on the mechanism(s) of signal 
transduction through GPCRs upon ligand binding.  
 
Interactions of α-factor with Ste2p: 
Though there have been several reports on the interactions of α-factor with Ste2p (1-3), 
specific residue-to-residue interactions have not been reported.   Previously it was reported that 
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α-factor analogs containing Bpa at positions 1 and 13 cross-linked into portions of Ste2p 
comprising residues Ser251-M294 and Phe55 – Arg58, respectively (1, 2, 4).  The studies with 
Bpa analogs did not identify the exact residue of Ste2p that interacted with position 1 or 13 of α-
factor.  Although Bpa-α-factor analogs have been useful for photoaffinity labeling of Ste2p the 
diphenylketone side chain in Bpa is considerably larger than the side chain of any natural amino 
acid.  Because of the structural similarity of DOPA to Tyr and Trp, DOPA should be a better 
replacement than Bpa.  In this study the periodate-mediated chemical cross-linking of [DOPA1 
Lys7(BioACA),Nle12]α-factor (Bio-DOPA1) and [Lys7(BioACA),Nle12, DOPA13]α-factor (Bio-
DOPA13) into Ste2p were investigated.  These α-factor analogs were potent agonists, and 
comparison to the α-factor control indicated that the replacement of Trp at postion 1 or Tyr at 13 
with DOPA did not significantly affect the ability of the peptide ability to bind and activate 
Ste2p.  Thus, the reduction in the activities of Bio-DOPA1 and Bio-DOPA13 were mainly due to 
tagging with biotin (for detection) and not the DOPA replacement.  Matrix-assisted laser-
desorption ionization-time-of-flight (MALDI-TOF) analysis revealed that Bio-DOPA1  and Bio-
DOPA13 α-factor  analogs cross-linked to fragments of Ste2p comprising residues Leu264-
Thr284 and Phe55 – Met69, respectively, similar to previous report using the Bpa analogs (1, 2, 
4).  Cross-linking of the Bio-DOPA13 α-factor analog into a Ste2p mutant (Cys59Ser) devoid of 
cysteine was greatly diminished suggesting that DOPA13 of the α-factor analog interacted 
directly with Cys59 of Ste2p.  These results indicate that the N-terminus of α-factor interacts 
with residues near the extracellular surface of TM5-TM6-TM7 whereas the C-terminus interacts 
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with residues near the TM1 region.   The precise mechanism of α-factor binding to Ste2p is not 
well defined. 
Despite variations in ligand specificity of the GPCRs, there are some similarities in the 
ligand interactions among the GPCR families. GPCRs ligands are classified as full agonist, 
partial agonists, inverse agonists, antagonist, synergist and allosteric regulators.  These ligands 
induce different conformational changes in GPCRs, which can result in the production of 
different intracellular signals (6-10).  The development of drugs targeting GPCRs are mostly 
based on the mechanisms of full, partial and inverse agonists, antagonist, and allosteric 
modulators.  Thus, understanding the activities of these ligands will facilitate the design of drugs 
that target GPCRs (9, 11, 12).  Although several studies have reported on the activities of partial 
and inverse agonists, antagonists and allosteric modulators, not much has been reported on 
synergist activities.   The proposed mechanism by which the α-factor synergist enhances the 
activities of α-factor is critical for designing drugs that are required to selectively increase the 
activities of GPCRs only in their ligand-bound state.  In this approach if the signaling pocket of 
the ligand in the GPCR is known, a specific molecule or peptide can be generated that will only 
interact within the signaling pocket without inhibiting the activities of the agonist.  Such drugs 
will be very selective since they will target only agonist bound receptors so that a mutant agonist 
that can not fully activate its receptor can, through interaction with the synergist, induce full 
activation. 
 The cross-linking of the Bio-DOPA α-factor analogs to Ste2p was prevented in the 
presence of a 100-fold molar excess native α-factor (WHWLQLKPGQPNleY) and an α-factor 
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antagonist (WLQLKPGQPNleY) but it was not influenced by the presence of BSA.  However, 
an α-factor synergist (WHWLQLKPGQP) reduced cross-linking of Bio-DOPA1 by 70% but had 
no significant effect on Bio-DOPA13 cross-linking.  This α-factor synergist lacking the last two 
residues of α-factor has been shown to have significantly reduced binding affinity for Ste2p, 
however it enhances the activity of the wild-type α-factor (5).  The interaction sites of the 
synergist is unknown. The data collected in this dissertation suggest that the synergist is most 
likely to interact within the signaling pocket. The differential inhibition of cross-linking by the 
α-factor synergist suggests that the synergist interacts within a similar site as the N-terminus of 
α-factor in Ste2p.  Though the synergist does not bind to Ste2p, the results of this dissertation 
suggest that the binding of α-factor to Ste2p induce conformational changes at the extracellular 
surface of the receptor that opens the signaling pocket, allowing the synergist to interact with the 
receptor.  Thus, in the absence of a potent agonist that binds Ste2p the synergist does not interact 
within this pocket since this pocket is only exposed upon binding of a potent agonist.  This 
scenario explains why the synergist can not activate receptor by itself, but in the presence of α-
factor it increases the activities of the receptor to greater than wild type level.   
Non-naturally occurring amino acids can be synthesized to contain a variety of chemical 
moieties for use as photoaffinity labels.  To incorporate unnatural amino acids into proteins in 
living cells, a novel method has been developed that uses orthogonal pairs of tRNA/ aminoacyl-
tRNA synthetases evolved and expressed in the target cell (13).  In S. cerevisiae orthologous 
tRNA/aminoacyl-tRNA synthetase pairs have been used to incorporate a variety of unnatural 
amino acids, including the photoactivatable amino acid analog p-benzoyl-L-phenylalanine [Bpa] 
281 
 
(14).  This dissertation reports the site-specific incorporation of Bpa into Ste2p using an 
orthologous tRNA/aminoacyl tRNA synthetase pair.   
In this system, the amber TAG stop codon was engineered into specific sites within the 
STE2 coding region.  The results showed that the mutant receptors were expressed at the 
membrane at levels from 5 to 10% of the wild-type receptor.  Whereas some mutants displayed 
defects in activities others have activities similar to wild type receptor as determined by growth 
arrest and binding assays.  Mass spectrometry proved that Bpa was incorporated at the expected 
position for the G188TAG receptor.  Ste2p-Bpa mutant expression increased when the unnatural 
amino acid was delivered as a dipeptide via the peptide transport system of S. cerevisiae.  
Bpa-Ste2p receptors were used to selectively photocapture biotinylated α-factor.  These 
cross-linking results indicate that Ste2p residues Phe55 and Tyr193, but not Gly188, are in close 
proximity to α-factor in the ligand bound conformation of Ste2p.  The close proximity of Ste2p 
residue Tyr193 to α-factor suggests that this aromatic residue may interact with the highly 
aromatic and hydrophobic N-terminus (W1H2W3L4) of α-factor.  This idea is very speculative 
and therefore Tyr193 remains a target for future studies.  The cross-linking of Phe55Bpa Ste2p 
mutant with α-factor was not surprising since this the TM1 region of Ste2p has been suggested 
to be the site of interaction for the C-terminus of the ligand.  The exact residues in α-factor that 






Binding mechanism of α-factor to Ste2p: 
The multi-step processes in which peptides bind to their receptors are thought to provide 
the basis for understanding ligand interactions with GPCRs (9, 15).  Understanding the 
mechanism of α-factor binding to Ste2p will be critical for elucidating other GPCRs-peptide 
ligand interactions.  A two-step model for the binding of α-factor to Ste2p, described in part II of 
this dissertation, should provide more information on how pheromone and other peptides bind to 
their cognate GPCRs.  In this model it is suggested that the C-terminus of α-factor first interacts 
with Ste2p within a binding pocket that includes residues (Phe55-Met69) in TM1.  These 
interactions induce conformational changes at the extracellular surface of the receptor allowing 
the N-terminus to bind and penetrate, thus activating the receptor.  The interactions with the N-
terminus also induce additional conformational changes that are propagated to the cytoplasmic 
ends of the receptor leading to G protein activation.  This model is consistent with a report that 
suggested that α-factor associates with Ste2p via a two-step process involving an initial 
interaction that places the ligand in a hydrophobic environment, followed by a conversion to a 
state in which the ligand moves to a more polar environment (16). 
 
N-terminus of α-factor required for conformational changes at TM5-TM6 in Ste2p: 
 Cysteine disulfide bonds formed by the third intracellular loop (IL3) Cys mutants suggest 
that IL3 is a dimer contact surface in Ste2p homo-dimer.  The observed presence of higher order 
oligomers of Ste2p indicates that multiple contacts interact in the oligomer. The reduction of 
dimer formation through residues at the cytoplasmic ends of TM5 and TM6 in presence of α-
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factor, but not the α-factor antagonist, also suggests that the interactions of the pheromone N-
terminus with Ste2p induce conformational changes in these regions of TM5 and TM6, similar to 
what has been reported for other GPCRs (17-19).  These conformational changes at the 
cytoplasmic ends of TM5 and TM6 were shown to be affected by Gpa1p expression.  Thus the 
binding of α-factor and Gpa1p to Ste2p coordinated to stabilize the active conformation of the 
receptor.  The Bio-DOPA cross-linking studies revealed that the N-terminus of α-factor interacts 
with residues Ser251-Met294 (TM6-TM7) consistent with the results that the α-factor antagonist 
(lacking the first 2 N-terminal residues) does not induce proper conformational changes in 
residues at the cytoplasmic ends of TM5-TM6.  Conformational changes in TM5, TM6 and TM7 
have been observed to be critical for GPCRs activation (17-19).  It is therefore suggested that the 
N-terminus of α-factor is responsible for inducing activation of Ste2p required for 
conformational changes in TM5 and TM6.  However, agonist binding did not effect the high 
level of dimer formation mediated by residues located in the middle of IL3, suggesting that these 
residues may play a role in stabilizing Ste2p homo-dimers during receptor activation.  
 
TM5 and TM6 in Ste2p interact with Gpa1p: 
 Ste2p residues L228 (at TM5 boundary), L247, L248 and L249 (all at TM6 boundary) 
were observed to interact with Gpa1p.  The close proximity of these residues with the C-terminus 
of Gpa1p indicates that they provide a hydrophobic environment that favors the Gpa1p C-
terminus interactions, similar to the reported interactions of opsin with transducin (20).  The 
reaction of S243 (Ste2p) with Q463 and K467 (Gpa1p) suggests that these residues are involved 
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in a hydrogen bonding network, with hydrogen bridges between these three residues.  These 
hydrogen bridges may be required for receptor activation, since this was only observed in the 
ligand-bound form of the receptor.  The interactions of Gpa1p residues with different Ste2p 
residues in the active and inactive states suggest that the C-terminus of Gpa1p undergoes 
conformational changes during activation.  These changes involve two movements; the first is an 
anti-clockwise 90o rotational movement similar to the helix mechanism model of transducin (21), 
and the second, termed “withdrawal” movement, involves both vertical and horizontal 
displacement that result in about a 5.0 Å shift from the inner bundle of the receptor to the 
cytoplasmic surface (see part 5, Figure 6).  These conformational changes bring TM5 and TM6 
closer to each other, positioning L228 (TM5) and I248 (junction between IL3 and TM6) in close 
proximity to contact I469 and G470 of Gpa1p. It also generates new contacts between IL3 of 
Ste2p and C-terminal helix of Gpa1p; S243 interacts with Q463 and K467 with multiple 
hydrogen bonds, and L247 is located in close proximity with K467, probably mediated by 
hydrophobic interaction.  The information obtained from this study will be critical for 
understanding the mechanism by which Gα proteins are activated by GPCRs to transduce signal 
to effector molecules. 
 
Ste2p and Gpa1p fusion: 
The Ste2p-Gpa1p fusion proteins displayed biological activities similar to wild type 
Ste2p or Gpa1p, and are capable of complementing the deletion of Ste2p and/or Gpa1p.  The 
analyses of the functionality of the fusion as a receptor (Ste2p) and/or Gα protein (Gpa1p) 
indicate that the protein has affinity for α-factor and GTP/GDP similar to the wild type of the 
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separate proteins.  The fusion construct could be separated by cleaving a protease site that was 
placed between the two proteins.  Truncation of the C-terminus of Ste2p in the fusion increased 
both expression and activities.  This fusion protein will be a very useful tool to study the 
structure-function relationship of both proteins and also the critical interactions that are required 
for GPCRs coupling with G proteins.  
 
Working model for α-factor and Gpa1p binding to Ste2p and receptor activation: 
The results presented in this dissertation, combined with the work of others including 
receptor mutagenesis analyses and structure-activity relationships of α-factor analogs, allowed 
the proposal of a binding model for the peptide ligand. The model (Figure 1) suggests a bend in 
the α-factor around the Pro8-Gly9 (22), with the Lys7 side chain facing away from the TMs 
domains and interacting with a binding pocket formed by the extracellular loops (23). Studies of 
the N-terminus of α-factor indicated a strong preference for a large hydrophobic residue at the 
amino-terminal position of the pheromone (4, 24, 25). Analyses of α-factor Trp3 activities 
indicated that the side chain of this residue is in a hydrophobic pocket (1, 2, 16).  Based on data 
obtained from part II in this dissertation and other cross-linking studies (1, 2, 4) it is likely that 
the N-terminus of α-factor interacts with a pocket consisting of aromatic residues from the 
extracellular ends of TM5, TM6, and TM7 and the loops EL2 and EL3 attached to these TMs.  In 
addition, the C-terminus of the pheromone interacts with TM1, where Gln10 of α-factor is in 
close proximity to residues 47 and 48 of Ste2p (3) and Tyr13 is in close proximity to Arg58 and 




Figure 1: Working model for α-factor and Gpa1p binding to Ste2p.  The transmembrane 
domains (TM) of Ste2p are labeled in different colors, α-factor is shown as a pink ribbon and 
Gpa1p C-terminus is colored in pale blue (positioned between TM5-TM6). The α-factor is 
suggested to bind with the Lys7 side chain facing away from the transmembrane domains and 
interacting with a binding pocket formed by the extracellular loops.  The C-terminus (Tyr13) of 
α-factor interacts with TM1 residues Arg58 and Cys59.  The N-terminus (Trp1) interacts with a 
pocket consisting of aromatic residues from the extracellular ends of TM5, TM6, and TM7 
where it is in close proximity to Lys269 of Ste2p.  The C-terminus of Gpa1p (pale blue) is shown 
to be in close proximity to TM5 and TM6.   
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The data obtained from part IV and V suggest that the binding and interactions of the N-
terminus of α-factor to the TM5-TM6 regions of Ste2p induce conformational changes at the 
cytoplasmic ends of these TMs.  This in turn leads to activation of the receptor and ultimately 
interactions with Gpa1p.    
In the inactive form of Ste2p, the C-terminus of Gpa1p is suggested to be close to TM6 
where residues L247 and L248 in TM6 are in close proximity to N465 and I469 in Gpa1p, 
respectively.  Upon α-factor binding to Ste2p conformational changes (most likely rotational 
movements) at the ends of TM5 and TM6 occur that also induce conformational changes at the 
C-terminus of the Gpa1p.  The changes at the C-terminus of Gpa1p are suggested in this study to 
involve a ~90o anti-clockwise rotation, and at the same time a withdrawal from the inner core of 
the receptor which involves a vertical shift of about 5.0 Å.  These changes cause the C-terminus 
of Gpa1p to move closer to TM5 and be withdrawn into the cytoplasmic surface of TM5-TM6.  
The conformational changes at the TM5 and TM6 regions did not affect the strong dimer 
formation of the IL3 region (connects the two TMs), suggesting that Ste2p dimers are not 
affected by receptor activation.  The data in part 4 also suggest that residues in IL3 may be 
involved in stabilizing the Ste2p homo-dimers during the receptor activation.  Overall, the results 
indicate that the binding of α-factor and Gpa1p are coordinated to stabilize the active 
conformation of Ste2p.  This coordination was also reported in part 6 of the dissertation where 
the binding of GTP or GDP to Gpa1p in a Ste2p-Gpa1p fusion protein affected the binding of α-





Although great progress has been made in understanding the structure-function 
relationships of GPCRs and their G proteins, the mechanism underlying the interactions between 
these proteins still remains unclear, and only partial information is available concerning the 
binding sites for most molecules, including peptides, within the GPCR.  The data obtained 
during the course of research for this dissertation will be important in understanding the 
complexity of GPCR signal transduction.  However, in order to fully understand the activation 
mechanism of GPCRs upon agonist binding and their interactions with G proteins further studies 
are necessary to reveal additional details. This final part of the dissertation outlines a few 
suggestions to elucidate the interactions between the Ste2p with α-factor and Gpa1p. 
 
Cross-linking studies: 
 The results obtained in part 2 indicate that DOPA α-factor analogs are indeed very useful 
to study Ste2p regions that interact with specific residues in α-factor.  Although cross-linked 
fragments were identified by MALDI-TOF analysis based on the fragment size observed 
compared to predicted sizes of Ste2p fragments, the sequencing of this fragment to obtain the 
amino acid sequence will be more substantial.  However, the data analyses from this dissertation 
were limited due to relatively low sensitivity of the instruments used, lack of proper algorithms 
to analyze complex fragmentation patterns, and difficult-to-interpret fragmentation of branched 
peptides.  It is therefore recommended that analysis of DOPA1 and DOPA13 cross-linked 
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fragments should be carried out using instruments that will provide more information, such as 
the amino acid sequencing of the fragments to determine specific residues that interact with 
DOPA.  The incorporation of DOPA at different positions of α-factor will be very helpful to 
determine the exact binding site and receptor residues involve in the binding.  
This dissertation work revealed that L228 (at TM5 boundary) S243, L247, L248 and I249 
(all at TM6 boundary) are in close proximity to C-terminus of Gpa1p.  The crystal structure of 
opsin in its G protein-interacting conformation shows that TM5, TM6, TM3 and IL2 all 
interaction with the C-terminus of transducin Gα (20).  Since this dissertation only tested a 
limited number of Ste2p residues (L228-I249) it is most likely that some residues N-terminal to 
L228 in TM5 and/or C-terminal to I249 in TM6 and also some TM3 residues may interact with 
Gpa1p in Ste2p in the inactive state.  The cross-linking studies should be expanded to include 
residues in IL2.  The incorporation of Bpa in these target regions of Ste2p (as described in part 
III of the dissertation) is also recommended. 
 The Ste2p and Gpa1p fusion constructs generated in this study displayed activity similar 
to that of non-fused Ste2p and Gpa1p.  The separation of fused Ste2p and Gpa1p using factorXa 
indicated that this fusion is a useful tool for studying the interactions between Ste2p with Gap1p.  
The 1:1 stoichiometry of Ste2p to Gpa1p provides an ideal condition to capture any interactions 
between the two proteins.  An outline of how this fusion protein can be used for cross-linking 
studies using either cysteine disulfide bond formation or Bpa photoaffinity labeling is shown in 





Figure 2: Ste2p and Gpa1p fusion cross-linking studies.  The membrane extract containing 
the fusion protein is subjected to either UV-cross-linking (1. using Bpa-Fusion mutants) or 
chemical oxidation (2. using cysteine-Fusion mutants) in the presence or absence of α-factor 
binding.  The fusion protein is then digested with factorXa to separate the two proteins.  The 
samples are then resolved on SDS-PAGE to determine their sizes on the immunoblots using 
antibodies against Ste2p and Gapa1p (Figure 3 only shows the blots for anti-Ste2p).  If Ste2p and 
Gpa1p are cross-linked then whether with ligand binding (product B) or without ligand binding 
(product C) a band similar to the size of the fusion should be observed even after the factorXa 
treatment.  On the other hand if Ste2p and Gpa1p are not cross-linked then whether with ligand 
binding (product D) or without ligand binding (product A) a band similar to the size of the Ste2p 
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